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Résumé 
Contexte : L’anémie falciforme ou drépanocytose est un problème de santé 
important, particulièrement pour les patients d’origine africaine. La variation 
phénotypique de l’anémie falciforme est problématique pour le suivi et le 
traitement des patients. L’architecture génomique responsable de cette variabilité 
est peu connue.  
Principe : Mieux saisir la contribution génétique de la variation clinique de cette 
maladie facilitera l’identification des patients à risque de développer des 
phénotypes sévères, ainsi que l’adaptation des soins.  
Objectifs : L’objectif général de cette thèse est de combler les lacunes relatives 
aux connaissances sur l’épidémiologie génomique de l’anémie falciforme à l’aide 
d’une cohorte issue au Bénin. Les objectifs spécifiques sont les suivants : 1) 
caractériser les profils d’expressions génomiques associés à la sévérité de 
l’anémie falciforme ; 2) identifier des biomarqueurs de la sévérité de l’anémie 
falciforme ; 3) identifier la  régulation génétique des variations transcriptionelles ; 
4) identifier des interactions statistiques entre le génotype et le niveau de sévérité 
associé à l’expression ; 5) identifier des cibles de médicaments pour améliorer 
l’état des patients atteints d’anémie falciforme. 
Méthode : Une étude cas-témoins de 250 patients et 61 frères et soeurs non-
atteints a été menée au Centre de Prise en charge Médical Intégré du Nourrisson 
et de la Femme Enceinte atteints de Drépanocytose, au Bénin entre février et 
décembre 2010.    
 ii 
Résultats : Notre analyse a montré que des profils d’expressions sont associés 
avec la sévérité de l’anémie falciforme. Ces profils sont enrichis de génes des 
voies biologiques qui contribuent à la progression de la maladie : l’activation 
plaquettaire, les lymphocytes B, le stress, l’inflammation et la prolifération 
cellulaire. Des biomarqueurs transcriptionnels ont permis de distinguer les patients 
ayant des niveaux de sévérité clinique différents. La régulation génétique de la 
variation de l’expression des gènes a été démontrée et des interactions ont été 
identifiées. Sur la base de ces résultats génétiques, des cibles de médicaments 
sont proposées.  
Conclusion: Ce travail de thèse permet de mieux comprendre l’impact de la 
génomique sur la sévérité de l’anémie falciforme et ouvre des perspectives de 
développement de traitements ciblés pour améliorer les soins offerts aux patients.  
 Mots clés : Drépanocytose, anémie falciforme, génomique, eSNP, expression, 
interactions, biomarqueurs, pharmacogénetique, Afrique Sub-Saharienne 
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Abstract 
Background: Sickle Cell Disease (SCD) is an important public health issue, 
particularly in Africa. Phenotypic heterogeneity of SCD is problematic for follow-up 
and treatment of patients. Little is known about the underlying genomic 
architecture responsible for this variation.  
Rationale: Understanding the genetic contribution to the inter-patient variability 
will help in identifying patients at risk of developing more severe clinical outcomes, 
as well as help guide future developments for treatment options. 
Objectives: To characterize genome-wide gene expression patterns associated 
with SCD clinical severities and to identify genetic regulators of this variation. More 
specifically, our objectives were to associate gene expression profiles with SCD 
severity, identify transciptional biomarkers, characterise the genetic control of 
gene expression variation, and propose drug targets.  
Methods: A case-control population of 250 SCD patients and 61 unaffected 
siblings from the National SCD Center in Benin were recruited. Genome-wide 
gene expression profiles and genotypic data were generated. 
Results: Genome-wide gene expression patterns associated with SCD clinical 
variation were enriched in B-lymphocyte development, platelet activation, stress, 
inflammation and cell proliferation pathways. Transcriptional biomarkers that can 
discriminate SCD patients with respect to clinical severities were identified. 
Hundreds of genetic regulators were significantly associated with gene expression 
variation and potential drug targets are suggested. 
 iv 
Conclusion: This work improves our understanding of the biological basis of SCD 
clinical variation and has the potential to guide development of targeted treatments 
for SCD patients.   
Keywords: Sickle cell disease, genomics, eSNP, transcriptomics, interactions, 
biomarkers, drug repurposing, Sub-Saharan Africa. 
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A. INTRODUCTION 
A.1 Research problem 
Sickle Cell Disease (SCD) is an important public health issue [1] affecting 
millions throughout the world, especially pediatric patients of African ancestry. 
SCD is the single most important genetic cause of childhood mortality world-wide. 
An estimated 2.28 per 1000 of all conceptions worldwide are affected by SCD, 
with higher estimates among populations whose ancestors originate from Sub-
Saharan Africa. Among these populations, estimates of SCD prevalence increases 
to 1 in 500 in African American populations, and 1 in 100 in populations from 
Nigeria, Benin, and other West African countries [2].  
In 2006, the World Health Organisation issued a report that specifically 
addressed SCD as a prevalent medical condition that contributed to the under-5 
death rate on the African continent. An urgent need to provide care and research 
was emphasized in this report [2]. In 2008, the United Nations recognized SCD as 
a global health priority and urged all African countries to have a plan to reduce 
under-5 mortality rates [3]. In order to accomplish this, active North-South and 
South-South partnerships that prioritize research are required to help sub-Saharan 
African countries develop robust sickle cell strategies that can provide diagnosis, 
management, and treatment of SCD.   
A major problem in managing SCD is that the underlying phenotypic 
heterogeneity observed in patients is not understood. Little is known about the 
underlying genomic architecture responsible for this phenotypic diversity of SCD, 
which is most likely the result of a combination of host genetic and environmental 
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factors [1,4]. Understanding the genetic contribution to the inter-patient variability 
would help identify patients at risk of developing more severe clinical outcomes, as 
well as help guide future developments in treatment options [5,6].  
 There is a lack of disease specific treatments available for SCD patients. 
Drugs used to treat SCD related phenotypes are either non-specific or have a 
number of side effects and/or contraindications. The FDA has approved only one 
drug, hydroxyurea (HU), for the specific treatment of SCD related events. 
However, because of the number of contraindications associated with this 
medication, the drug’s usefulness is limited. Also, HU is not used in developing 
countries, where comorbidities including malaria and nutritional deficiencies may 
affect the toxicity profile [7]. New drugs are therefore urgently needed for the 
treatment of this disease.  
In this study, we hypothesized that, in addition to environmental factors, 
genetic factors impact SCD clinical phenotypes. We aimed to identify genetic 
factors influencing the disease by integrating the joint analysis of genotyping and 
gene expression data. The work in this thesis was performed to conduct an in 
depth study to characterize genome-wide gene expression patterns that are 
associated with SCD clinical variation in pediatric patients from Benin, West Africa. 
Using gene expression variation data, we assessed the presence of transcriptional 
biomarkers that discriminate SCD patients with different clinical severities. 
Through genome-wide association studies, genetic determinants were tested for 
association with gene expression levels. This enabled us to better characterize the 
biological basis of genetic variation as it relates to clinical variation. In a final 
approach, we evaluated our genetic findings for the presence of known or novel 
 2 
drug targets, with an emphasis on therapeutic interventions. This work has 
provided important information which can be used in the development of novel 
therapeutics, or in repurposing existing ones, and provided guidance for targeted 
therapies. 
A.2 Overview 
 
The research presented in this thesis explored the genetic contribution to 
gene expression variation in Sickle Cell Disease (SCD) patients with different 
clinical severities. The results from this work have helped advance the 
identification of patients at risk of developing more severe clinical outcomes, as 
well as helped in guiding future developments for treatment options. 
The thesis begins with an introduction on Sickle Cell Disease and genomic 
approaches in public health. The methods and results sections are presented in 
order to address the four main objectives: to associate gene expression profiles 
with SCD severity, identify transcriptional biomarkers, characterise the genetic 
control of gene expression variation, and propose drug targets. In the discussion 
and conclusion chapters, the implications of the results and examples of how they 
improve our understanding of the biological basis of SCD clinical variation is 
explained, as well as how they help guide future research on SCD.   
A.3 Sickle Cell Disease (SCD) 
 Sickle cell disease (SCD) is a congenital, life-long blood disorder 
characterized by the presence of sickled haemoglobin. It is inherited in an 
autosomal recessive manner from a single point mutation in the hemoglobin beta 
gene, either as a homozygote (eg. Hb SS) or as compound heterozygotes (eg. 
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Hb SC). Sickled hemoglobin affects the globin chain structure, which polymerizes 
upon deoxygenation, distorting red blood cells (RBCs) into elongated "sickled" 
cells and consequently leading to their inability to transport oxygen and function 
effectively.  
A.3.1 Epidemiology of SCD 
 
Epidemiologic studies show that the incidence and prevalence of SCD 
varies significantly depending on geographic location and ethnic background. 
About 7% of the world’s population carries genes responsible for 
hemoglobinopathies. Each year approximately 300,000-400,000 infants are born 
with major haemoglobin disorders [1]. More than 200,000 sickle-cell incidents arise 
yearly in Africa alone [2]. The prevalence of the sickle-cell trait (in which carriers 
have inherited only one copy of the mutant gene) ranges between 10% and 40% 
across equatorial Africa and decreases to between 1% and 2% on the North 
African coast and <1% in South Africa [2]. This distribution is a reflection of the 
fact that the sickle-cell trait confers a survival advantage against malaria infection 
among the carriers of a single copy of the SCD mutation, a well-known 
evolutionary phenomenon referred to as “heterozygote advantage”. The selection 
pressure due to malaria has resulted in an increase in the frequency of the SCD 
mutant gene in areas of high malarial transmission. In West African countries, the 
prevalence of SCD is between 15% and 30%, whereas in East Africa, the 
prevalence of the SCD trait shows marked tribal variations, reaching as much as 
45% among the Baamba tribe who live in the west of Uganda. [2].  
Table A.1 below shows conservative estimates of prevalence by region as 
established by the World Health Organisation [8]. At least 5.2% of the world’s 
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population carries a sickle cell variant. Over 70% of all conceptions that have the 
SCD mutation occur in Africa. Around 2.28 per 1000 conceptions worldwide are 
affected [8]. Most children born with SCD in high-income countries survive the 
disease into adulthood but suffer from a chronic disorder, while most children with 
SCD born in low-income countries die before the age of 5 years. Haemoglobin 
disorders account for 3.4% of child mortality in children aged under 5 years 
worldwide and 6.4% of children who die before the age of 5 in Africa [2]. 
 5 
 Table A.1.  World Health Estimates of SCD prevalence. 
 
 
* Source: Adapted from Table 1 of World Health Report [8]
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A.3.2 Phenotypic variation and clinical heterogeneity of SCD 
 
As early as 1976, researchers were aware of the phenotypic variability of 
SCD. At the time, the causal mutation was not known. A quote from Norman 
Davidson captures the irony of this simple Mendelian disease with a complex 
phenotype, that even today, we don’t understand: 
 "I remember asking a new graduate student, Harvey Itano, what his research 
problem was. He said he was going to test your (Linus Pauling’s) hunch that there 
was a difference in hemoglobin molecules between normal people and those with 
sickle cell anemia. I thought that was a crazy idea; a complicated human disease 
could not have any such simple cause”  [9].  
Patients with SCD suffer a wide variety of disease complications [10]. Some 
individuals have mild manifestations of the disease, which can be clinically 
unapparent; while others have severe complications [11] that recur frequently, 
affecting the entire body. Death can occur suddenly and unexpectedly even in 
apparently stable SCD patients. The underlying cause of this clinical variation 
remains unknown, but is most likely influenced by a combination of genetic and 
environmental factors. While some SCD patients have only one crises event every 
few years, others have several severe and painful crises events every year, often 
requiring hospitalisation. Figure A.1 below shows the main SCD related clinical 
phenotypes. 
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Figure A.1. Main clinical manifestations observed in SCD patients.  
 
 
* Figure taken from : http://adkteamtalk.wordpress.com/author/adkteamtalk/ 
 
Complications of SCD are often from obstructed circulation. Red blood cells 
often become trapped in the spleen of children with SCD, leading to a serious risk of 
death from a sudden profound anaemia associated with rapid enlargement of the 
spleen. Reduced spleen function associated with the condition causes children with 
SCD to be susceptible to bacterial invasions, bone infections (osteomyelitis), 
gallbladder infections (cholecystitis), lung infections (pneumonia), and urinary tract 
infections.  
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Vaso-occlusive (VOC) events are also common in SCD and occur when tissue 
damage results from obstructed blood flow. They can be recurrent and are 
unpredictable, lasting from hours to days. Many affected children present with painful 
swelling of the hands and/or feet (hand-foot syndrome) when blood flow is blocked to 
the extremities due to VOC events. Vaso-occlusion can also cause “acute chest 
syndrome” (pneumonia or pulmonary infarction), bone or joint necrosis (tissues 
damage caused by insufficient oxygenation of the bone), priapism (painful and 
prolonged erection), renal failure, and cardiac problems. Poor eyesight or blindness, 
and ulcers on the lower legs (in affected adolescents and adults) are some other 
symptoms that may occur as a result of blockage in small blood vessels due to the 
disease. Cerebrovascular complications from VOC include confusion due to transient 
ischemic attacks, ischemic strokes, and hemorrhagic strokes, sometimes associated 
with seizures.  
SCD patients experience severe anemia which causes fatigue, paleness, rapid 
heart rate, shortness of breath, and, or jaundice. Other complications include delayed 
growth, delayed puberty, and painful joints. SCD patients commonly experience 
chronic pain in the back bones, the long bones, and in the chest.  
Although boys and girls are equally at risk to inherit the mutation that causes 
SCD, previous studies found that men with sickle cell disease experience more sickle 
cell crises after puberty than do women. It has also been noted that the median age 
of death from SCD for men is 42 compared to 48 years for women. Recently, this 
gender difference for SCD severity was attributed to nitric oxide being significantly 
higher in woman than in men [12]. Nitric oxide, which is stimulated by estrogen 
production in women, helps blood vessels to dilate, reducing obstruction. 
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A.3.3 Genetics of hemoglobin in unaffected and SCD patients 
 In SCD, the causal mutation is known and is inherited in an autosomal 
recessive manner [13]. The most common form of SCD is associated with patients 
homozygous for a single base mutation in codon 6 of the β-globin gene (HbSS) 
causing a single amino acid substitution in position β6 (glutamic acid to valine) and 
results in βs. The second most common abnormal Hb mutation in West Africa, βc, is 
also caused by a single mutation/amino acid change at the same position in the β-
globin gene, but with lysine replacing glutamic acid. See Table A.2 below.  
Table A.2 Adult hemoglobin variants and their corresponding genotypes. 
 
 In unaffected individuals, β-globin is encoded by a structural gene found in a 
cluster with four other β-like genes on chromosome 11. The cluster contains five 
functional genes, ε, Gγ, Aγ, δ, β, which are arranged in the order of their 
developmental expression [14]. ε is an embryonic globin gene expressed primarily in 
yolk sac-derived cells from 3 to 8 weeks of gestation; Gγ and Aγ are fetal globin genes 
expressed primarily in fetal liver-derived cells from 6 weeks of gestation to 6 months 
after birth; and δ and β are adult globin genes expressed primarily in bone marrow-
derived cells starting shortly before birth and persisting throughout adult life. The β 
gene is responsible for 97-98% of adult β-globin, and the δ gene is responsible for -2-
3% [15]. Upstream of the entire β-globin complex is the locus control region, a 
regulatory element essential for the expression of all the genes in the complex [14].  
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 β-globin gene products pair up with α-globin gene products to form hemoglobin  
tetramers that surround a heme core that binds oxygen. α-globin genes are found on 
chromosome 16, including ζ chain expressed in the embryonic stage, and α chain 
expressed in the fetal and post-natal stages. β-like chains pair with the α-like globin ζ 
chain in the embryonic life, and with α-chain in fetal and post-natal life to form the 
developmentally regulated hemoglobin molecules [16]. The change in globin 
production from embryonic to fetal and from fetal to adult is called hemoglobin 
switching [17]. Homozygous HbSS patients have (α2βs2) hemoglobin tetramers, 
whereas HbSC compound heterozygotes have (α2βsβc) tetramers. See Figure A.2.  
 
 
 11 
Figure A.2 Chromosomal arrangements of globin genes.  
The α-hemoglobin genes are located on chromosome 16 and the β-hemoglobin 
genes are located on chromosome 11. Both α-hemoglobin and β-hemoglobin genes 
are ordered by their developmental expression along the chromosome. The tetramer 
proteins that are formed from the hemoglobin genes are shown in the center.  
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A.3.4 Historical perspective of SCD 
The first documented report of SCD was by Dr. James Herrick and Dr. Ernest 
Irons in a dental student from Grenada in 1904 [18]. They identified irreversibly 
sickled red blood cells, which they described as “very irregular and with many 
elongated forms.” The autosomal recessive inheritance of the disease was described 
by Neel and Beet in 1947. In 1949, Pauling et al. demonstrated that the HbS chain in 
SCD patients had an abnormal electrophoretic mobility which led to the proposal that 
this was a molecular disease of Hb [13]. This was the first time a genetic disease was 
linked to a mutation of a specific protein. Ingram et al. demonstrated that the SCD 
mutation caused a single amino acid change. This was followed by analysing the 
structure and physical properties of HbS, which formed intracellular polymers upon 
deoxygenation. These studies put SCD at the leading edge of investigations to 
elucidate the molecular basis of human diseases. It was at this time that it was noted 
[19] that infants with SCD rarely have clinical manifestations in the first year of life.  
A.3.5 Natural history of SCD 
Based on the observations made on SCD infants described above, it was 
proposed that the high levels of fetal Hb in the red blood cells, which persists during 
the first year of life, somehow protects SCD infants from clinical manifestations. 
Childhood clinical manifestations of SCD are seen when the switch from fetal Hb to 
adult Hb occurs.      
It is interesting to note that in a small proportion of individuals (0-0.8% 
prevalence [20]), hereditary persistence of fetal hemoglobin (HPFH) occurs. HPFH 
alleviates the severity of SCD since HbF can bind to oxygen with greater affinity than 
with adult hemoglobin, thus reducing the aggregation of mutated hemoglobin and the 
sickling of red blood cells. Persistence of fetal hemoglobin provides a hallmark 
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example of a genetic modifier that results in a decrease in the number of painful 
episodes in patients with SCD who have a hereditary persistence of fetal Hb.  
Once the switch to adult Hb has occurred, the average life expectancy of SCD 
patients varies, with SCD patients in North America having significantly longer life 
expectancies than African patients, most likely due to newborn screening, superior 
health care and follow-up programs, and access to medication. The peak incidence 
of death among those affected with sickle cell disease is between 1-3 years of age in 
the USA and in Jamaica; and the median survival of patients with sickle cell disease 
has been estimated to be 42 years for men and 48 years for women in a Jamaican 
cohort; and 53 years for men and 58.5 years for women in an American cohort [2].  
Survival of patients with SCD on the African continent is dismal [1]. 
Historically, the life expectancy of sickle cell patients in Africa has been assessed 
against the yardstick of infant under-five mortality. Using this yardstick, sickle-cell 
disease contributes the equivalent of 5% of under-five deaths on the African 
continent, more than 9% in West Africa, and up to 16% of under-five deaths in 
individual West African countries [2]. In Benin, West Africa, no reliable estimate of 
mortality rate for SCD children is presently available, however, a rough estimate has 
been documented that more than 50% of the untreated affected children do not reach 
their fifth birthday [21]. A recent estimate of between 50-90% of affected children 
born in Africa with SCD will die before age 5 years, due either to complications of 
SCD itself or more commonly from complications from pneumococcal disease, 
malaria, or diarrheal disease [22]. 
 14 
A.3.6 Pathophysiology of SCD 
The primary pathophysiological event in the erythrocytes of individuals with 
SCD is thought to be polymerization of sickle haemoglobin (HbS) [23]. HbS 
polymerization causes structural damage to the red blood cell membrane, which 
alters the properties of the erythrocyte, impairs blood flow through the 
microvasculature, and leads to hemolysis, vaso-occlusive episodes, tissue ischemia 
and organ dysfunction. The extent of polymerization is determined by the intracellular 
haemoglobin composition (% HbS, % HbA, and % HbF), total Hb concentration,  
oxygen saturation, and intracellular pH. Intracellular HbS polymerization leads to a 
marked decrease in the flexibility of the sickle erythrocytes and obstruction in various 
microcirculatory beds, as well as chronic anaemia.  
Other abnormalities in the properties of the sickled erythrocytes include 
membrane abnormalities, adhesion between red blood cells, changes in ion fluxes 
and volume, and endothelial adhesion [24]. These properties result from 
polymerization events and may in turn increase polymerization. The adhesive 
interactions between sickled red blood cells and the endothelium is due to the 
inflammatory reaction of the disease and leads to the microvascular pathogenesis 
[25]. Decreased flexibility and permeability of the red cell membrane may be equally 
important pathophysiological events for the onset and frequency of SCD crisis [26]. In 
Figure A.3, the pathophysiology of SCD is described. Through polymerisation of the 
hemoglobin molecules, ensuing erythrocyte membrane damage and hemolysis 
occurs. Intravascular hemolysis of erythrocytes leads to nitric oxide scavenging by 
plasma hemoglobin and provokes hemolysis-related complications [27].  
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Figure A.3 Pathophysiology of SCD.  
Normal red blood cells that contain homozygous HbAA are quite elastic which 
enables them to maneuver so that they can pass through small capillaries. The red 
blood cells of a person with sickle cell disease (homozygous HbSS) lose this 
elasticity due to the polymerisation of deoxygenated HbS, which form long stiff rods. 
These stiff rods exert pressure on the walls of the red blood cell membrane causing it 
to collapse and distort into a variety of shapes including the classic shape of a 
farmer’s sickle, from which SCD derives its name. When re-oxygenated in the lungs, 
the red blood cells regain their original round shape. However with repeated sickling 
(deoxygenation) and unsickling (oxygenation) there is increasing crystallization and 
formation of stiff rods within the red blood cells, causing them to become increasingly 
hard, brittle and consequently irreversibly sickled. Sickled red blood cells are fragile 
and break easily. The damaged cells are rapidly destroyed by the reticulo-endothelial 
cells in the spleen, whereby their lifespan is reduced from the normal 120 days to 
about 5 to 20 days. This rapid break down of red blood cells in the host leads to the 
anemia associated with the disease.  
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* Figure taken from : http://sgugenetics.pbworks.com/w/page/61172304/Pathophysiology%20of%20Sickle%20Cell%20Anemia 
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A.4 Risk factors of SCD severity  
 
A.4.1 Genetic risk factors of SCD clinical variation  
 
Although SCD is a monogenic disease, the clinical variation manifested in 
SCD is polygenic, with multiple known genes contributing to its phenotypic variation 
[28]. Mapping the genetic variants associated with SCD clinical sub-phenotypes have 
largely been limited to candidate gene approaches and genome-wide association 
studies.  
A.4.1.i SCD causative genotype 
The primary genetic determinant of SCD severity is the causative genotype. 
Individuals who are homozygous for the βs mutation (HbSS) tend to have the most 
severe disease followed by those who are compound heterozygous HbSC. HbSS 
individuals have higher rates of acute chest syndrome and pain crises than 
individuals with HbSC [29]. However, HbSC individuals have increased risk for 
thromboembolic complications, retinopathy, and renal papillary necrosis than those 
with HbSS [29]. While the causative genotype is a key determinant of disease 
severity, the frequency and severity of complications still vary considerably within 
each genotypic group. 
A.4.1.ii SCD haplotypes 
Genetic variation linked to the beta-globin mutation may influence the clinical 
manifestations of SCD. When these genetic variants that are linked to beta-globin 
mutations are located on the same genetic background of non-coding DNA, they 
form a “haplotype” that is specific for each SCD mutation. Five major beta globin 
haplotypes exist, named according to the country or region of where they were 
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initially identified: Senegal (SEN), Benin (BEN), Central African Republic (CAR), 
Arab-Indian (AI) and Cameroon (CAM) (See table A.3), as well as non-canonical 
atypical haplotypes (ATYP). The four African haplotypes show broad trends in 
disease severity. The Central African Republic haplotype tends to have the least 
favourable clinical course, followed by the Benin and Senegal haplotypes [30]. The 
ranking of the Cameroon haplotype is uncertain. The Arab-Indian haplotype seems 
to, on average, produce fewer complications than its African counterparts. No clear 
explanation exists for the differences in severity between haplotypes; however, one 
hypothesis states that the haplotypes influence baseline HbF levels [31]. The 
patterns of severity apply only at the population level. Broad overlap in the clinical 
manifestations prevents the use of haplotypes to predict the clinical course of SCD in 
a particular individual. Usually, people with SCD outside Africa (e.g., African-
Americans) have mixed haplotypes for their sickle cell genes. Analysis of haplotypes 
in this setting is even less likely to provide clinically useful information.  
The HbC mutation is restricted to individuals of West African descent. This 
mutation is associated with less severe clinical manifestations than the HbS mutation 
and lies on a different haplotypic background.   
Table A.3 Classic HbS haplotypes 
 
*CAR=Central African Republic 
Four restriction fragment length polymorphism (RFLP) sites that differentiate the classic 
HbS haplotypes.  The RFLP sites are located in a 70kb region upstream (5') of the HbS 
mutation. *Ref: Hanchard et al. BMC Genetics 2007 8:52   doi:10.1186/1471-2156-8-52 
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A.4.1.iii HbF 
 Fetal hemoglobin (HbF: α2γ2) is a major genetic modulator of the hematologic 
and clinical features of SCD, an effect mediated by its exclusion from the sickle 
hemoglobin polymer. Among the majority of individuals with SCD who do not have 
hereditary persistence of fetal hemoglobin (HPFH), the residual levels of fetal 
hemoglobin vary considerably (1-25%). Approximately 40% of this variation is 
accounted for by the X-linked F-cell production locus (Xp22.3-22.2); β-S cluster 
haplotypes account for an additional 14% [32]; and common SNPs at the BCL11A 
(2p16), HBS1L-MYB intergenic region (6q23), and beta-globin loci account for an 
additional 20% of the variation in HbF levels [33]. The mechanism of action of fetal 
Hb is through disruption of the polymerization of deoxy-HbS and through diluting the 
intracellular concentration of HbS [34]. Together, these HbF mechanisms effectively 
prevent many clinical manifestations of SCD.  
The distribution of HbF among red blood cells (RBCs) is important. In HPFH, 
HbF exists at high levels homogenously in all red cells which protects them from 
sickling. In the absence of HPFH, patients with high levels of HbF have a 
heterogeneous distribution of fetal hemoglobin among RBCs. For example, a patient 
in whom half the cells have 30% Hb F and half have 0%. The patient would have 
15% HbF overall. However, half the cells would sickle and occlude blood flow 
through the microcirculation. These deformed cells would block the flow of the 
normally shaped high HbF cells. Thus, even though this patient has relatively high 
overall HbF levels, he would still experience SCD clinical manifestations.   
Higher HbF levels were associated with reduced rates of acute painful 
episodes, leg ulcers, and less frequent acute chest syndromes [35]. Genetic factors 
that explain a large proportion of HbF variation in SCD have been mapped [36]. 
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However, HbF levels have no clear association with other important SCD clinical 
manifestations such as stroke and silent cerebral infarction, priapism, urine albumin 
excretion, and systemic blood pressure [35]. Thus, other factors likely contribute to 
the remaining variation in SCD clinical phenotypes and are most probably controlled 
by a complex interplay between both genetic and environmental factors [34,37]. 
A.4.1.iv α-Thalassemia 
Thalasemias are inherited hemoglobinopathies that result from quantitative 
reductions in globin chain synthesis and lead to imbalanced alpha and beta chain 
tetramers. Thalassemias are different from SCD, since they don’t necessarily 
produce a mutant form of β globin. However, co-inheritance of thalasemias with SCD 
affects severity of SCD. Those with diminished β-globin chains are termed β-
thalassemias, whereas those with decreased α-chain production are called α-
thalassemias. More than 30% of most populations with HbSS SCD carry one or more 
determinants for α thalasemmia. In people of East African descent, this is usually the 
α-globin gene deletion (-α3.7/). The co-existence of the α-thal (-α3.7/) deletion with 
SCD has a quantitative effect on intracellular Hb S concentration, reducing the 
frequency of Hb S polymerisation and number of irreversibly sickled cells [34]. Thus, 
co-existing α-thal (-α3.7/) has a protective effect against complications related to 
severe hemolysis in SCD patients. In parts of West Africa, and in Benin in particular, 
the estimated prevalence of α thalassemia is small [38].  
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A.4.1.v Genetic factors of SCD phenotypes identified through candidate 
gene studies 
A number of candidate gene studies have associated genetic variants with 
various SCD phenotypes. Genetic factors that could potentially affect the 
pathogenesis and modulate the phenotype downstream of the HbS polymorphism 
event include those involved in pathways mediating inflammation, oxidant injury, 
blood coagulation and hemolysis, and vascular remodeling. Based on their 
pathophysiology, candidate genes and SNPs that could plausibly affect the different 
sickle-related complications have been selected and tested for association in 
candidate gene studies. However, most candidate gene association studies were 
characterised by small sample sizes and most of them do not present with a 
replication of the findings in another study population. Lack of replication is one of the 
hallmarks of false positive signals in genetics, typically obtained from underpowered 
studies. This can  lead to contradictory results when studies are compared [28]. The 
most rigorously studied SCD subphenotypes and associated polymorphisms are 
shown in Table A.2. 
It has been proposed that the TGF-β/Smad/BMP pathway play an important 
role in multiple subphenotypes of SCD based on consistent associations in candidate 
gene studies [28]. The TGF-β/Smad/BMP pathway regulates diverse cellular 
processes and plays roles in inflammation, fibrosis, cell proliferation, hematopoiesis, 
osteogenesis, angiogenesis, nephropathy, wound healing, and the immune 
response. The many complications of SCD are affected by most of these processes 
so it is reasonable to suspect that perturbations of this pathway would modulate a 
SCD patient’s development, progression, and resolution.  
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Table A.4. Candidate gene studies in SCD sub-phenotypes. 
Results from the most rigorously studied SCD sub-phenotypes and associated 
polymorphisms from candidate gene studies.  
 
* Source adapted from Steinberg et al [28]. 
A.4.1.vi Genetic factors identified by genome-wide association studies 
(GWAS)  
 
Seven genome-wide association studies have been performed with SCD 
related phenotypes [39]. The most recent GWAS was performed to identify genetic 
factors associated with hemolysis in SCD [40]. The authors used principal 
component analysis of reticulocyte count, lactate dehydrogenase, aspartate 
aminotransferase and bilirubin levels, measurements of hemolysis, to compute a 
haemolytic score that was used as a subphenotype in a genome-wide association 
study. They identified in one cohort (1,117 patients) and replicated in two additional 
cohorts (n= 549 and 296 patients) the association of a single nucleotide 
polymorphism in NPRL3. The HBA1/HBA2 regulatory elements are located in introns 
of NPRL3. Perhaps by independently down-regulating expression of the HBA1/HBA2 
genes, NPRL3 reduces haemolysis in SCD. 
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 Another recent GWAS examined total bilirubin and choletithiasis (gallstones) 
risk in SCD [41]. When hemolysis occurs, circulating heme increases, leading to 
elevated unconjugated bilirubin levels and increased incidence of cholelithiasis. In a 
discovery cohort of 1,117 SCD patients, 15 SNPs were significantly associated with 
total bilirubin levels. SNPs in UGT1A1, UGT1A3, UGT1A6, UGT1A8, and UGT1A10 
were identified. All of these associations were validated in four independent sets of 
more than 3000 SCD patients.  
In a GWAS that identified genetic factors associated with mortality in SCD 
patients [42], the authors used a Bayesian network model to construct disease 
severity with 24 clinical events and laboratory tests and obtained a score that 
predicted mortality. The analysis was performed in two independent patient groups. 
The first patient group consisted of 1,265 patients with either “severe” or “mild” SCD 
disease based on the network model of disease severity, and discovered 40 SNPs 
that were strongly associated with SCD severity. Thirty-two of the 40 SNPs were 
analysed in an independent set of 163 patients. Five of these SNPs were significantly 
replicated, 8 showed consistent effects, although did not reach statistical 
significance, and 19 did not show any convincing significance. Among the replicated 
associations are SNPs in KCNK6, a potassium channel gene. Using an analytical 
method that examined genetic regions, 27 genes with a strong enrichment of 
significant SNPs were present and 20 were replicated with varying degrees of 
confidence. Among the novel genes identified by this analysis as being associated to 
SCD was the telomere length regulator gene TNKS.  
These studies were the first to use GWAS to understand the genetic diversity 
that accounts for phenotypic heterogeneity of SCD. Nonetheless, a large part of the 
clinical variation in SCD remains to be explained. The genetic factors associated with 
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SCD clinical phenotypes listed in Table A.3 and in Appendix I, include 111 genes 
overall [39]. These genes were identified through candidate genes association 
studies, GWAS, or gene expression studies.  
 
Table A.5 Genetic factors associated with SCD. 
Genetic factors associated with clinical phenotypes observed in SCD that are 
reported in Human genome epidemiology (HUGE) [39] are shown below.  A total of 
143 publications on SCD are reported in HUGE, 68 of which are studies that 
identified genetic factors associated with SCD clinical phenotypes. These 68 
publications are grouped by SCD clinical phenotype, study type (candidate gene 
study, GWAS, or gene expression study), sample size, significant genes, replication 
cohort size (if done), significant genes replicated, significance (either p-value or Odds 
Ratio and confidence intervals), first author and year of the publication.  
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A.4.1.vii Gene expression studies and SCD 
 
Few studies have performed global gene expression profiling on SCD 
patients. Perhaps the most interesting was by Jison et al. [43] who reported that 112 
genes are differentially expressed between 27 African-American patients with SCD 
in steady-state and 13 controls using data generated from peripheral blood 
mononuclear cells (PBMCs). These genes were involved in heme metabolism, cell-
cycle regulation, antioxidant and stress responses, inflammation, and angiogenesis. 
Less pertinent studies include one whose goal was to validate a globin 
reduction protocol and did not characterise differential gene expression as it 
pertained to SCD [44]. Another study, examined differential miRNA expression 
between healthy and SCD affected erythrocytes [45]. Recently, miRNAs isolated 
from platelets from SCD patients and controls were analysed and significant 
differences were identified in functionally active platelet miRNAs [46].  
A.4.2 Environmental risk factors of SCD clinical variation  
Observations of clinical variability between identical twins with SCD and also 
within the same individual affected with SCD at different periods in his/her lifetime, 
highlight the important contribution of environmental factors to the phenotypic 
variation in SCD [47]. Environmental factors, such as physical activity, diet, and 
toxins, can elicit changes in gene expression, altering the epigenome, without 
changing the DNA code [34]. Such epigenetic changes may be the reason for the 
discordance of clinical phenotypes in identical twins with SCD [34]. 
Other environmental factors that affect SCD phenotypes are infections: 
malarial infections, viral infections, HIV infections, and bacterial infections. The HbSS 
mutation is a risk factor for death from malaria [48], as well as a potent comorbid 
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factor for death from bacterial infections, particularly invasive pneumococcal disease 
[48].  
Malnutrition and dehydration are also major determinants of sickle cell disease 
severity. Furthermore, seasonal affects influence SCD severity. Cultural background 
(some African tribes believe that SCD is a curse, ostracising the individual rather 
than treating him or her), and lack of medical education and resources contribute to 
disease severity and clinical variation in parts of Africa, such as in Benin [21].  
A.5 Measuring SCD severity  
 
In order to study factors associated with SCD severity, a method to measure 
disease severity is required. Many methods have been proposed to measure the 
severity of SCD clinical manifestations. Some methods use categorical 
classifications, others are quantitative; however, no method has been universally 
accepted. Below is a description of the most commonly used methods of classifying 
SCD patients according to category and severity. 
A.5.1 Traditional case-control  
 
Most studies recruit SCD patients in steady-state condition. In these studies, 
the patient is not experiencing a crisis event and has stable hematological values. 
Steady-state SCD patients are compared to controls and evaluated for differences in 
the exposure of interest. This method of classification does not measure intra-
individual variation observed in SCD patients.  
A.5.2 Clinical Categories  
 
  In parts of Africa, where only basic clinical lab tests are available, clinical 
categories are used as a proxy to severity indices. At the National Sickle Cell 
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Disease Center (NSCDC) in Cotonou, Benin, West Africa, patients are seen on a 
regular basis and four clinical categories are assigned to them based on their 
disease course [21]. Upon enrolment into the program and when in steady state, 
patients are labeled “entry” (E). After at least one year of follow-up, distinction is 
made between patients with obvious positive changes, including improvement of their 
general status, increased velocity of linear physical growth and marked reduction in 
the frequency and severity of SCD-related acute events (group 1) and those with no 
such improvements (group 2). Both of the groups include patients sampled while in 
steady state. They are labeled “steady state satisfactory” (SSS) and “steady state 
unsatisfactory” (SSU), respectively. Finally, all patients followed and who are 
experiencing a SCD-related crises event are labeled “acute” (A). These clinical 
categories serve as proxies to a severity gradient of the clinical phenotypes observed 
in SCD patients. 
 
A.5.3 Severity index 
 
One attempt to establish a severity index of SCD [49,50] was based on the 
frequency of vaso-occlusive crisis events. This method of ranking severity among 
individuals with SCD has been proven insufficient because the intra- and inter-patient 
variability of SCD cannot be measured using this parameter alone.  
Miller and colleagues (2000) examined the records of nearly 400 children who 
were followed at comprehensive sickle cell centers in North America [51]. They 
performed a multivariate analysis of the clinical courses of these children between 
infancy and 10 years of age and determined that several factors, including an 
episode of dactylitis (inflammation of a digit, finger, or toe) prior to one year of age, 
low hemoglobin levels before 2 years of age, and persistent leucocytosis (elevated 
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white blood cell counts) in the absence of infection, were associated with severe 
complications, such as recurrent severe pain episodes, stroke and acute chest 
syndrome.  
A smaller study [52] which tracked the course of adult and pediatric patients 
over a 7-year period confirmed the factors identified by Miller et al. [51] to be 
associated with SCD severity in adults. However, the smaller study also identified 
that adults with an elevated white blood cell count experienced more frequent 
hospital admissions for painful vaso-occlusive crises than did those with lower white 
blood cell counts [52]. Interestingly, none of the assessed variables were found to be 
correlated with severity of SCD in children. The smaller size of the study and the 
greater age range of the children evaluated however most likely account for the 
difference between the results in this study and the report by Miller and colleagues 
[51]. 
Other investigators, such as Hebbel [53] used a scoring system to assess 
disease severity. One such severity index was proposed by El Hazmi [54,55] which 
takes into account many clinical manifestations observed in SCD. This severity index 
allows classification of patients in mild as well as severe forms of sickle cell disease. 
In Table A.4 below, the parameters that comprise this index are detailed.  
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Table A.6. SCD Severity Index. 
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A.5.4 Network model to predict risk of death 
 
Using data from 3380 patients and accounting for all common genotypes of 
sickle cell disease, a Bayesian network model, which includes 25 SCD clinical events 
and laboratory test results, was used to predict the risk of death within 5 years for 
SCD patients [42]. The reliability of the model was supported by its use in the 
analysis of two independent patient groups. In one group, the severity score was 
related to disease severity based on the opinion of expert clinicians. In the other 
group, the severity score was related to the presence and severity of pulmonary 
hypertension and the risk of death. Along with previously known risk factors for 
mortality, such as renal insufficiency and leukocytosis, the network identified 
laboratory markers for severity of hemolytic anemia and its associated clinical events, 
as contributing risk factors. The authors report that this model can be used to 
compute a personalized disease severity score for therapeutic decisions to be made 
according to the prognosis. Also, the severity score could serve as an estimate of 
overall disease severity in genotype-phenotype association studies, and provides an 
additional method for studying the complex pathophysiology of sickle cell disease. An 
online severity calculator based on their model has been made publically available 
[56].  
A.5.5 Fetal hemoglobin levels or F cell distribution as a marker of severity 
 
HbF levels have been used in association studies to identify genetic factors 
influencing SCD severity. Higher HbF levels were associated with reduced rates of 
acute painful episodes, leg ulcers, and less frequent acute chest syndromes [35]. 
However, HbF levels had no clear association with other SCD clinical manifestations 
such as stroke and silent cerebral infarction, priapism, urine albumin excretion, or 
systemic blood pressure [35].    
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A.6 Biomarkers of SCD 
 
The incidence of most clinical complications in SCD varies markedly both with 
time in the same individual and between different individuals. Meaningful biomarkers, 
indicators of a biological state that can objectively be measured and evaluated as 
either an indicator of a normal or a pathogenic biological process, could be useful in 
the management of SCD. Biomarkers can be used in early diagnosis of 
complications, detection of chronic organ damage, identification of individuals at risk 
of a severe clinical course, and monitoring response to treatment. 
More than 100 different blood and urine protein biomarkers have been 
described in SCD [57]. Nearly all of these biomarkers are abnormal in the steady 
state of SCD, and become more abnormal during complications. Some biomarkers 
indicate damage to specific organs, whereas others indicate damage to more 
systemic processes. Unfortunately, however, none of these biomarkers provide 
specific prognostic or clinical information beyond that which can be provided by the 
simple measurement of heamoglobin concentration. To date, no prognostically 
validated biomarker has been identified to predict which SCD patients will develop 
severe outcomes.  
Recently, blood transcriptional profiling has been successfully used to predict 
disease pathogenesis in tuberculosis, infections, and tumour progression [58,59,60]. 
Through the identification of aberrant gene expression, it is possible to identify 
individuals who are susceptible to disease and to predict their outcome. Biomarkers 
that identify SCD sub-phenotypes exist [57,61,62,63,64], but none have been 
validated in longitudinal studies. Furthermore, no transcriptional biomarkers of clinical 
progression have been identified for SCD patients.  
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A.7 Management of SCD  
 
The vast majority of the therapies offered to patients with SCD are supportive 
and do not modify or change the underlying pathophysiology of the disease. These 
therapies include analgesics to relieve acute pain and curb or manage vaso-
occlusive crisis events [65,66,67], as well as antipyretics to relieve fever and anti-
inflammatories to reduce inflammation associated with the events. Blood transfusions 
are administered to compensate for RBC death and dehydration. Dehydration is also 
treated with I-V Saline solution (normal or 5% dextrose in saline). Chronic pain is 
managed with the use of oral morphine in addition to acetaminophen, NSAIDs (used 
for deep bone pain), and opiates. Antibiotics are administered when an infection is 
suspected.  
SCD patients are also treated using standard procedures to treat chronic 
hemolytic anemia, pulmonary hypertension and various organ damage syndromes 
associated with the disease. Dialysis or kidney transplant for kidney disease, 
gallbladder removal in patients with gallstone disease, hip replacement for avascular 
necrosis, wound care for leg ulcers and surgery for patients who have eye problems 
are all examples of treatments required by some SCD patients. 
Prevention of complications is also an important aspect of SCD treatment. To 
prevent stroke, regular blood transfusions followed by iron chelation for the treatment 
of hemochromatosis are performed [68]. Blood transfusions are also done in order to 
reduce HbS percentages to below 30%, thereby reducing the risk of polymerization 
and blood clot formation. Bypass surgery to restore adequate blood supply may also 
be required to prevent myocardial infarction. 
Neonatal screening for SCD allows for prophylaxis immunization to pediatric 
patients who are susceptible to infectious diseases. Preventative treatments include 
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penicillin prophylaxis and immunization against streptococcus pneumonia. Parental 
teaching about SCD susceptibility to infections and the importance of preventative 
treatments and vaccinations can also help to increase adherence and thus alleviate 
the infection morbidity and mortality rate in SCD patients.  
Non pharmacological approaches, such as support groups, physical therapy, 
acupuncture and acupressure can also have an impact in the treatment of SCD by 
improving quality of life for the SCD patient.  
Bone marrow transplantation is a possible cure for SCD patients, however, 
this difficult and risky procedure is strongly dependent on the availability of a suitable 
donor. It is only used in cases of severe SCD children who have minimal organ 
damage to the disease. Bone marrow transplantation is still considered an 
experimental procedure [26]. 
A.7.1 Lack of SCD specific drugs 
The only FDA approved disease-modifying therapy for SCD is hydroxyurea (HU), 
but it has variable outcomes and is potentially toxic [69,70]. 
HU was first approved for use in SCD in February 1998. It was approved for use 
in reducing the frequency of painful crises and the need for blood transfusions in 
adult patients with recurrent moderate-to-severe painful crises (generally at least 
three crises during the preceding 12 months). 
HU was shown to promote the production of fetal hemoglobin [71,72] by 
stimulating development of erythroid cells [73,74], increasing RBC mean corpuscular 
volume, and reducing the number of dense cells and irreversibly sickled cells in the 
circulation [75]. HU inhibits ribonucleotide reductase, blocking DNA synthesis and 
cell division.  
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Unfortunately, less than half of SCD patients treated with HU benefit from its use 
[76]. Even when HU is administered, the exact dose of HU needed to prevent painful 
crises is unknown. Thus, patients receive the maximum tolerated dose, often 
resulting in the development of macrocytosis (a blood condition of insufficient and 
unusually large RBCs that leads to oxygen deficiency throughout the body and can 
result in organ damage). HU administration is not recommended to patients who are 
pregnant because hydroxyurea has been shown to be teratogenic in mice, although 
no human studies have been conducted to support this finding for obvious ethical 
reasons. Administration of HU in children is controversial. A number of concerns 
have been identified in the treatment of pediatric SCD patients with HU. Among these 
concerns are the possibility of impaired neurocognitive development and impaired 
bone maturation. As well, the carcinogenic potential with long-term use of HU is 
unknown and recent studies of 15 years of follow-up have identified the risk of 
developing myeloid leukemia. In cultured human cells, it was observed that following 
HU administration, regions of the cell’s genome were duplicated and/or deleted. 
The data on hydroxyurea applies only to patients who are homozygous HbSS 
living in developed counties. Patients with compound heterozygous conditions (e.g., 
HbSC disease) were excluded from the studies in order to eliminate possible 
response variability in the data. As a result, compound heterozygous HbSC patients 
are not eligible to receive HU for their treatment. Also, HU has not been tested on 
patients living in developing countries where comorbidities, including malaria and 
nutritional deficiencies, may affect the toxicity profile [7].  Finally, HU remains too 
expensive for SCD patients in resource poor areas, especially in Africa, where the 
largest burden of the disease is located.  
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A.8 Public Health Genomics and SCD  
Public health genomics can offer an unbiased, global approach that integrates 
genome-based knowledge and information to improve the health of SCD populations. 
It is through recent technological advances that public health genomics has evolved 
[77] as an extension of genetic epidemiology, which focuses on the role of genetic 
factors and their interaction with environmental factors in the occurrence of disease 
in human populations [78]. Public health genomics applies systematic, evidence-
based assessments of genomics applications in health practice and works to ensure 
the delivery of validated, useful genomic tools in medicine. Examples of emerging 
applications of human genome discoveries for clinical practice and disease 
prevention are given in Table A.5 below.  
 
Table A.7 Application of Human Genome Discoveries in Public Health.  
*Source adapted from Khoury et al. [77]  
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A.8.1 Genome-wide association studies (GWAS) 
An important development in genetic epidemiology has been the emergence 
of genome-wide association studies (GWAS). The integration of genome-wide 
association studies (GWAS) in epidemiology has lead to large collaborative case-
control, cross-sectional, and cohort studies that have identified novel genetic variants 
associated with disease. This prominent genomic approach [79,80,81] uses dense 
genotyping chips to ascertain the genotype at hundreds of thousands of common 
single nucleotide polymorphisms (SNPs) in several thousand individuals with and 
without disease, and significant association between these two variables is assessed 
without a priori hypotheses.  
Most GWAS-discovered variants are relatively “weak” risk factors (most with 
relative risk of 1.05 to 1.50 per allele). Nonetheless, a considerable number of 
associations have been reported for many disease phenotypes pinpointing to genes 
and pathways involved in the etiology of the diseases in question.  
 Although GWAS provide valuable clues to the pathogenesis of complex traits, 
such as the capacity to provide a relatively unbiased examination of the entire 
genome for common risk variants, there are certain aspects related to GWAS for 
which considerable challenges remain. For example, in identifying common risk 
alleles, GWA studies cannot clearly distinguish between the signal from true risk 
variants and the statistical noise from the vast numbers of markers that aren't 
associated with disease. To separate true signals from noise, researchers have to 
set a high threshold which a marker needs to exceed before it is accepted as a likely 
disease-causing candidate. This reduces the incidence of false positive results, but it 
also means that many true disease markers with small effects are lost in the 
background noise. Furthermore, most efforts at replication have concentrated on the 
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signals for which the statistical evidence is strongest; whereas, some susceptibility 
loci with modest effect sizes might also benefit from further exploration in the context 
of their biological plausibility. By increasing the numbers of samples in disease and 
control groups, researchers are trying to lower the statistical noise from non- 
associated markers so that disease genes with even small effects stand out above 
this noise. As the cost of genotyping has decreased steadily, this approach has 
become more and more feasible. However, the logistical challenge of collecting large 
numbers of carefully ascertained patients will always be a serious obstacle. This is 
because most published GWAS feature case-control designs and thus concerns 
inherent to this type of design, i.e. selection bias, misclassification bias, and 
population stratification, remain. Population stratification occurs when there is a 
systematic difference in allele frequencies in cases and controls due to different 
ancestries. Past GWAS have been dominated by subjects of Western European 
ancestry, and only now are we beginning to understand the genetic risk variants in 
non-European populations [82]. In African populations standard SNP-disease 
genome-wide mapping has been challenging [82] because of decreased linkage 
disequilibrium (LD) in these populations [83,84,85]. LD is the non-random association 
of alleles at two or more loci, usually on the same chromosome. LD is a phenomenon 
derived from linkage, which is the presence of two or more loci on a chromosome 
with limited recombination between them.  
 GWAS relie heavily on the "common disease, common variant" (CDCV) 
assumption, which states that the genetic risk for common disease is mostly 
attributable to a relatively small number of common genetic variants [86]. However, 
the vast majority of the reported associations account for a minor fraction of the 
disease variance. The missing heritability has been suggested to result from larger 
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numbers of variants of smaller effects; rarer variants (possibly with larger effects); 
structural variants poorly captured by existing arrays; and gene–gene and/or gene-
environment interactions [87,88,89].  
 
A.8.2 Genome-wide gene expression studies– transcriptomics 
Transcriptomics, or genome-wide gene expression profiling, is another 
important development in public health genomics. Microarray-based transcription 
profiling is a genomic approach used to quantify gene expression variation for 
thousands of genes at once [90,91].  
The expression of DNA follows the rules of a central dogma which occurs in 
two stages: (i) Transcription, during which DNA is transcribed into messenger RNA 
(mRNA) and (ii) Translation, during which mRNA serves as a template for protein 
synthesis. Regulation of gene expression is the first stage in a multi-step process 
toward the production of phenotypes and is arguably the most important component 
in the genetic basis of phenotypic variation [92,93]. Transcript abundance sums the 
effects of various sources of variation in gene expression including genetic variation, 
spontaneous inherited epigenetic marks, and environmental factors. These causes of 
variation in gene expression can be variable at the cell, tissue, organism, or 
population level [94] and act together at various magnitudes on multiple modulators 
that include promoters, activators, enhancers, repressors, trans effectors, chromatin, 
and environment- or genotype-dependent methylation states [93].  
Microarrays are used to interrogate total RNA with the relative fluorescence 
intensity proportional to transcript abundance. This powerful technology shows high 
repeatability and is cost-effective. Recently, even deeper transcription profiling based 
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on NextGen sequencing of RNA has become available. However, this technology 
remains expensive for most population-based studies.  
A large number of studies have shown strong correlations between exposures 
and transcriptomic signatures in blood. The seminal Emilsson et al. study [95] on a 
sample of 1,002 individuals from the Icelandic Family Blood cohort demonstrated the 
pertinence of using gene expression profiles to explain and predict obesity-related 
traits even in blood. For example, 2,172 (9.2%) gene expression traits in blood are 
correlated with Body Mass Index, 1,098 (4.6%) with Percentage Body Fat, and 
711 (3.0%) with Waist-to-Hip ratio.  
 
A.8.3 Data Integration in Genetics and Genomics: Functional genomics and 
systems biology approaches to study disease 
As a consequence of the rapid progress and accumulation of new methods 
and discoveries in genomic technologies, other “omics” related research fields are 
becoming available, such as transcriptomics (described above), proteomics, and 
metabolomics. New methods [96] of integrating these “omic” scans has led to the 
fields of functional genomics and systems biology. Functional genomics approaches 
study the relationship between an organism’s entire genome and its phenotype. 
Systems biology focuses on complex interactions between genetic and 
environmental factors within biological systems. Both of these approaches use a 
more holistic perspective rather than the traditional reductionist approach. As a 
consequence, integration and analysis of complex data sets from multiple 
experimental sources, including genomics, transciptomics, and proteomics, are used 
in order to obtain a global understanding of an organism’s health. Using unbiased 
approaches, that take into account the entirety of the genome and its gene products, 
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allows for an understanding of the dynamic properties of an organism at the cellular 
level. This provides a more complete picture of how biological function arises from 
the information encoded in an organism’s genome and in understanding how a 
particular mutation(s) leads to a given phenotype.  
 
A.8.4 GWAS of gene expression (eQTL/eSNP analysis) 
The integration of genome-wide gene expression with genotyping data is a 
functional genomics and systems biology approach to study disease that jointly 
explores the environmental and genetic influences on disease phenotypes. Through 
the joint analysis of gene expression and genotyping data, greater insight is gained 
than can be provided by either type of data alone [92,97,98,99,100]. This line of 
research was motivated by the basic idea that transcript abundance is a quantitative 
trait with a heritable component. Consequently, quantitative linkage mapping (QTL) 
methods were used to map sources of expression variation and were named 
expression QTLs (eQTLs). The term expression single nucleotide polymorphism 
(eSNP) denotes SNPs associated with variation in transcript abundance in a 
population [101].  
The original studies of this nature employed cell lines and clearly established 
not only that the majority of transcripts are highly heritable, but also that they are 
often associated with regulatory polymorphisms that account for 15 to 70% of the 
variance in gene expression in a sampled population [102,103,104]. Sample sizes of 
less than a hundred individuals are sufficient to obtain genome-wide significance 
levels [105,106], in stark contrast with sample sizes required to reach this 
significance level using standard GWA study designs [107], and many of the 
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associations are consistent across three major human ethnic groups (Africans, 
Europeans, and Asians) [102,103]. 
Subsequent studies of peripheral blood isolates confirmed the genetic 
contribution in gene expression variation somewhat surprisingly since the 
environmental component of variance should be much higher in leukocyte mixtures 
isolated from individual people (rather than homogeneous cell lines grown in uniform 
culture conditions). Large samples of Icelanders [95] have further shown that 
associations involving so-called cis-acting expression SNPs, namely eSNPs located 
in the same gene as the transcript they regulate, sometimes highlight genes that 
have been associated with complex disease in other GWAS – even where that 
disease is manifest in a different tissue. Distal-regulatory eSNPs (where a 
polymorphism in one gene acts on an unlinked target gene) are less common, in 
part because the threshold of evidence for genome-wide significance is several 
orders of magnitude higher owing to the additional multiple comparisons, but also 
because it seems that cross-correlation is weaker between loci [107].  
A.8.5 Transcriptional gene-environment interactions 
 The meaning of the term “interaction’ can be a cause of confusion. Often, 
distinction is made between statistical interactions, public health interactions, and 
biological or causal interactions [108]. Statistical gene-environment (GxE) 
interactions are described as the differential effect of a given genotype exposed to 
different environmental conditions [92]. These interactions can be qualitative, where 
the effect is present in one condition, or going in opposite directions in different 
strata. However, if the effects go in the same direction, but differ in magnitude, than 
they are “quantitative interactions” and are scale dependent (e.g. raw or log-
transformed for continuous traits; additive or multiplicative for binary traits) [109]. 
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Statistical interactions should be distinguished from public health interactions, which 
are based on the concept of synergy as a joint effect that is greater than the sum of 
the excess risks from each factor alone, or biological interaction, which occur when 
an effect of one factor at the cellular or molecular level is dependent on the presence 
or absence of the other.  
Identifying gene-environment interaction effects has been challenging 
[92,110]. Using the joint analysis of gene expression and genotyping data, gene-
environment interactions are more likely to be significant since they are less likely to 
suffer from the power and multiple testing issues that conventional GWA studies 
have had. This is because transcript abundance is a continuous trait, hence 
potentially more informative than binary outcome data, and thus provides more 
mapping power. Also transcription is closer to the genetic effect and/or the causal 
mechanisms of exposure, with genotypes having an effect on transcript abundance 
on average one order of magnitude stronger than on disease phenotypes, reflecting 
the tight link between genetic regulatory elements and gene expression traits [92].  
Most transcriptional gene-environment interactions have been reported in 
model organisms [111,112,113,114], and in humans, most of the documented 
studies report genotype-treatment interactions that are performed in vitro [92]. Only a 
few genome-wide surveys of transcriptional gene-environment interaction in vivo 
have been conducted in humans [115].  
In SCD, gene-environment (GxE) interactions may explain part of the 
phenotypic variation observed in patients. By identifying GxE interaction, an 
improved understanding of why certain patients do not ameliorate in clinical status 
even after following a rigorous clinical care program may be possible. Identifying GxE 
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interactions may also provide a basis for targeting interventions for individuals at high 
risk of developing a worse outcome. 
A.8.6 Pharmacogenomics 
Pharmacogenomics is the study of how the entire genetic makeup of an 
individual affects their response to drugs. A functional genomics or systems biology 
approach to pharmacogenomics integrates genetic variation on drug response in 
patients by correlating gene expression with a drug’s efficacy or toxicity. There are 
multiple, highly effective drugs in widespread use whose primary mechanism of 
action is to affect gene transcription [116]. Understanding gene transcription variation 
in disease can help in drug discovery. Identifying genes whose expression variation 
is under genetic control could lead to candidate transcription-modulating drugs which 
should be investigated as candidates for potential novel treatments.  
By applying a genomic approach to study genetic factors that influence SCD 
clinical variation, it is hoped that an improved understanding of the pathobiology will 
lead to better care and treatment for this disease.  
A.8.7 Drug rescue and repurposing 
 
Genomics discoveries about the molecular basis of disease provide 
opportunities to translate research into clinically useful products. However, the 
translation process is long, costly, and has a low success rate. More than 95% of 
drugs fail the required therapeutic development process [117]. The average time 
form target selection to approval is ~13 years, and the cost of bringing a new drug to 
market exceeds US$1 billion [117]. Thus, strategies to reduce the time frame, 
decrease costs, and improve success rates are urgently needed.  
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Drug rescue and repurposing offer the advantage of harnessing previous 
research and development efforts [117]. Drug repurposing takes approved drugs or 
compounds that have already been tested on humans, and that have detailed 
information on their pharmacology, formulation, dosing, and potential toxicity, and 
tests their application for use in alternative diseases. This can enable the rapid 
testing of new clinical hypotheses, leading to improved health outcomes. By applying 
drug repurposing to SCD, new therapies might be discovered by identifying 
regulatory genes involved in the disease that are also drug targets.  
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B. RATIONALE AND HYPOTHESIS  
B.1 Rationale 
The underlying causes of the clinical heterogeneity in SCD remain unknown. 
Thus far, almost all attempts at finding genetic factors associated with SCD severity 
have used classical candidate gene or genome-wide association approaches, but 
these efforts have had limited success. Important genetic advances in recent years 
have enabled the investigation of entire human genomes. For African populations, 
where standard SNP-disease genome-wide mapping has been challenging [82], 
functional genomics and systems biology approaches offer an attractive analytically-
powerful and cost-effective alternative. Since disease in general involves differential 
expression, a systems genetics approach to map genetic variation associated with 
gene expression traits that are correlated with SCD clinical phenotypes is likely to 
reveal regulatory variation modulating SCD and the clinical heterogeneity.  
B.2 Conceptual model 
Khoury et al. [78] used a conceptual model to illustrate the scope of genetic 
epidemiology as the interface of genetic and environmental interactions in disease. In 
this model, mutations are the basis for genetic variation in populations. The 
frequency of specific genotypes, the survival of mutations in subsequent generations, 
and the frequency of a new mutation in a particular generation are determined by the 
balance between the occurrence and recurrence of such mutations (possibly 
influenced by environmental factors) and other dynamic population processes, such 
as selection, chance fluctuations, and mating patterns. See Figure B.1. 
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Figure B.1 Scope of genetic epidemiology.  
 
 
 
 
Here, we apply this conceptual model to the case of SCD, a monogenic 
disease with phenotypic variation that is believed to be caused by the interaction 
between genetic and environmental factors through gene expression variation. 
The genomics revolution has added powerful new potentialities and renewed 
impetus for understanding how biological and environmental processes act together 
in health and illness. This revolution has driven a paradigm shift from reductionist 
approaches that focus on single genetic elements in isolation to systems and 
functional approaches that focus on the interconnectedness of networks of elements 
acting as a whole. Using the genetic epidemiology conceptual model proposed by 
Khoury et al. [78], we propose that a SCD patient’s clinical outcome is a complex 
result of their genome, gene products (transcriptome), and environment, all 
interacting together to modify the phenotypic expression of the Hb mutation. See 
Figure B.2 below.  
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Figure B.2 SCD Conceptual Model. 
 
 
 
In order to evaluate the genetic determinants that modify SCD clinical 
outcome, we recruited patients with the two most common SCD mutations, HbS and 
HbC, as well as unaffected (HbA) participants used as controls. In order to identify 
genome-wide genetic factors that influence SCD, we genotyped over 733, 000 single 
nucleotide polymorphisms (SNPs) and measured expression levels of over 48,000 
gene-specific probes genome-wide. We had access to environmental factors, 
including sex, age, and hematological blood counts (which are influenced by 
infection, diet, treatment, ect.). The two main SCD phenotypes that we used were 
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discrete categorical variables: clinical status and clinical categories. These variables 
are used at the National SCD Center in Benin as a proxy to severity.  
B.3 Hypothesis 
We hypothesize that both genetic and environmental factors contribute to 
gene expression variation, which in turn accounts for the phenotypic variation 
observed in SCD patients.  
We hypothesize that gene expression differences will be enriched in biological 
pathways that impact the disease course to account for different clinical severities.  
We also hypothesize that transcriptional biomarkers can be identified for the 
purpose of classifying patients in groups with different SCD severities.  
Furthermore, we hypothesize that the genetic factors controlling gene 
expression can be detected and that interactions between genotype and clinical 
severity may further explain part of the inter-individual variation of this disease.  
Finally, we hypothesize that differentially expressed genes that are under 
genetic control can be used to identify potential drug targets.  
By identifying the underlying genomic architecture of the clinical heterogeneity 
in SCD, gene expression profiles and the genetic control of the variation associated 
with SCD severity, we can provide important biologic knowledge which will guide the 
future development of novel therapeutics and targeted treatments, as well as 
improved follow-up programs for SCD patients.  
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B.4 Objectives 
The present work proposes the following objectives:  
1. Identify gene expression variation associated with SCD clinical severity  
a. Identify biological pathways that impact the course of the disease;  
2. Identify transcriptional biomarkers that can classify SCD patients by clinical 
severity; 
3. Identify genetic regulators of gene expression variation in SCD 
a. Test for interaction between genotype and disease severity that may 
further explain the variation in SCD; 
4. Identify known drug targets, using the results of our genomic eSNP analyses, 
which could be candidates to test in future studies as novel therapies for SCD 
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C. METHODS 
In order to address the main objectives of this study, we implemented a 2-
phase approach. In the first phase (Discovery phase, n=157), we explored clinical 
factors that were associated with gene expression variation and quantified their 
effects. In the second phase (Replication phase, n=154), we attempted to replicate 
these findings. Utilising this 2-phase approach allowed us to identify and confirm 
transcriptional biomarkers of SCD severity. In order to have sufficient power to 
identify genetic regulators of gene expression variation, interactions effects, and drug 
targets, we combined the data sets (combined data set I = 263, combined data set 
II=173).  
C.1 Ethics approval 
Ethics approval for the study was granted by Sainte-Justine Research Center 
Ethics Committee and by the Faculté des Sciences de la Santé of the University of 
Abomey-Calavi in Benin, West Africa. Written informed consent (Appendix II) was 
obtained by a parent or guardian on behalf of all participants in the study.  
C.2 Study design 
 Case-control-studies, where sampling is conditional to the presence or absence 
of disease, are widely used in epidemiology for studying associations between 
disease and potential risk factors. In the current context, the risk factors are 
represented by genetic data: alleles/genotypes and/or expression profiles. Some of 
the advantages in using this type of design include that it is relatively quick and 
inexpensive and that the assessment of the “exposure” variable (i.e. 
genotypes/expression) is quite straightforward. Yet, in the context of genetic studies, 
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using a case-control approach raises a few concerns that need to be addressed in 
order to guarantee the validity of the study. More specifically, study participants, who 
typically provide data on exposures and other covariates, must also provide 
biological material – usually blood, for genotyping or gene expression purposes. 
Such samples are difficult to obtain, inventory and process. In addition, concerns 
about potential abuses of genetic data as well as the procedure itself (i.e. 
venopuncture to collect blood) makes using healthy subjects, especially children 
used as controls, hard to justify and to recruit. The resulting low level of control 
subject participation can invalidate a study. Furthermore, self-selected controls may 
not accurately represent the base-population studied.  
 An important concern regarding the use of unrelated cases and controls in 
association studies is that it is difficult to distinguish valid association due to linkage 
from spurious association due to confounding effects. One of the major confounders 
of importance in genetic association studies is population stratification which occurs if 
the population from which the cases and controls were sampled consists of latent 
subpopulations, each with different variant allele frequencies and risks of disease. A 
spurious association due to this confounding effect will occur for any variant allele that 
is at an elevated frequency in the subpopulation with the greatest disease prevalence.  
Several approaches exist to account for population stratification in genomic studies, 
including methods based on Genomic Control [118] and Principal Component 
Analysis (PCA) [119]. Genomic Control aims at correcting the Trend test statistic 
inflated null distribution by estimating an inflation factor, usually called , using many 
markers. The main assumption of this method is that the inflation factor is the same 
for all markers. PCA-based methods use markers to define continuous axes of 
variation, called principal components, which reduce the data to few variables 
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containing most of the information about the genetic variability. These axes often 
relate the spatial distribution of the ancestries of the samples. Using PCA methods, 
Price et al. propose an association test to account for stratification. It is implemented 
in the software Eigenstrat [119,120]. In practice, it is common to use principal 
components to adjust the results of the classical association test and correct for 
stratification.  
 
C.2.1 Case-control study design  
For the present study, we used the case-control study design and recruited 
SCD patients from the pre-existing National SCD cohort in Benin, West Africa at the 
Centre de Prise en charge Médicale Intégrée du Nourrisson et de la Femme 
Enceinte atteints de Drépanocytose (CPMI-NFED). Siblings, unaffected by SCD, of 
patients seen at the Center were invited to take part as controls. Using this study 
design both case-control and case-only analyses were performed. A two-phase 
sampling design was implemented to replicate our gene expression findings. An 
initial recruitment of patients was performed in the discovery phase (n=126 SCD), 
followed by recruitment in a replication phase (n=124 SCD). The distribution of SCD 
clinical severities, Hb genotypes, and sexes were equally proportionate in both 
phases. The comparison of interest was between SCD patients with different disease 
severities classified as a quantitative severity index or as discrete categorical 
classes. Of equal interest was a comparison of SCD patients and controls. 
Unaffected siblings of SCD were recruited at the CPMI-NFED in 2010 by 
approaching families who were already at the clinic for a scheduled visit for their 
affected SCD child. In the discovery phase, 31 controls were recruited. In the 
replication phase, 30 controls were recruited. The control sample had similar 
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distributions for age and sex to the SCD patient sample. Genetic ethnicity and 
relatedness were assessed for the cases and controls.  
C.3 Setting  
 
C.3.1 Location 
The study was performed at the CPMI-NFED located in Cotonou, the largest 
city (population of 678 874 inhabitants based on the 2013 census [121]) and the 
financial capital of the Republic of Benin. Benin (population of 9 983 884 inhabitants 
based on the 2013 census [121]) is a country in Sub-Saharan West Africa, with one 
of the highest death rates worldwide for children under the age of five. The CPMI-
NFED is the only established SCD Center in the country and follows the majority of 
the SCD population of Benin. Established SCD centers are rare in West Africa and 
the CPMI-NFED is a model for SCD clinical care and management for other African 
countries. See Figure C.1 below for a map showing the location of the recruitment 
site in Cotonou relative to West Africa. 
 
Figure C.1 Location of recruitment site. 
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C.3.2 Recruitment dates  
 
Recruitment was performed from February 2010 until April 2010 in the 
discovery phase, and from April 2010 until December 2010 in the replication phase. 
The main difference between the two cohorts is time of sampling. An important 
feature of gene expression variation is that it might vary with time and between 
seasons. Therefore, a discovery/replication design based on time of sampling when 
gene expression variation is surveyed seems appropriate to capture the 
environmental/seasonal component of variation. 
C.4 Participants: method of selection and eligibility criteria 
 
C.4.1 SCD patients 
All (100%) of the SCD patients recruited for this study were part of a large 
cohort of SCD children longitudinally followed at the CPMI-NFED. This cohort was 
initiated as a SCD screening program in 1993 [21]. In 2003, the program was 
extended to evaluate clinical improvement and to study the disease course of SCD 
children who were enrolled in this comprehensive follow-up program [21]. Affected 
infants were and are evaluated at monthly intervals for the first 12 months of life and 
thereafter every 3 months. At the center, basic management of the disease and its 
symptoms consists in anti-pneumococcal and anti-malarial prophylactic medication, 
supplementation with folic and ascorbic acids, and specific vaccinations (Hepatitis B 
and Hemophilus influenxae B vaccines, and anti-pneumococcal and anti-Salmonella 
typhi vaccines) in addition to the six vaccines for children recommended by the World 
Health Organization. During scheduled medical visits, parents of these children are 
educated about SCD and the importance of nutrition, emphasising the importance of 
keeping clinic appointments and scheduling regular follow-up visits. In 2003, it was 
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demonstrated [21] that the children followed by this program showed a marked 
reduction in frequency and severity of SCD-related acute events, with improvement 
in general status and physical growth after follow-up. Today, over 2000 infants are 
enrolled at the CPMI-NFED.  
Recruitment of SCD cases was performed by approaching patients who 
arrived at the Center for their scheduled visit. Recruitment of SCD cases who were 
referred to the CPMI-NFED as newly diagnosed, first time patients was also 
performed by approaching patients who arrived at the Center for their scheduled visit.  
For non-genetic studies, selecting incident cases is ideal in order to avoid 
biases inherent when using prevalent cases (such as reverse causality, which is a 
problem when the cause and effect are sampled at the same time and reversed; 
survival bias, where survivors of a lethal disease are more likely to enter a study than 
other cases; migration bias, which can occur when the disease risk factors are 
related to migration from the area, ect.). For genetic studies, however, since the 
exposure of interest is fixed (genotype) and established prior to the outcome, 
including both incident and prevalent cases is not a concern. SCD patients who were 
admitted to the center or already enrolled in the CPMI-NFED programme from 
February 2010 to December 2010 were invited to participate in the study.  
Inclusion criteria included being a patient at the CPMI-NFED and having one 
of the major forms of SCD (HbSS or HbSC) and providing signed informed consent. 
All patients seen at the Center were eligible to be included in the study since all had 
HbSS or HbSC and since sampling the entire spectrum of clinical severity observed 
in the SCD population was desired. Approximately equal numbers of boys and girls 
were sampled. No other exclusion or inclusion criteria were imposed.  
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C.4.2 Controls 
 
Controls (n=61) were also sampled in 2010 from the city of Cotonou at the 
CPMI-NFED and were children unaffected by SCD and siblings of patients followed 
at the Center. Only children without clinical signs or symptoms of malaria, who tested 
negative for the commercially available rapid malaria detection test and the thick 
smear analysis for parasetemia quantification, and who were confirmed not to have 
SCD (not HbSS or HbSC) with at least one normal hemoglobin allele (HbA), were 
eligible to be included as a control. No other exclusion or inclusion criteria were 
imposed. 
 
Figure C.2 Flow diagram for participant selection.  
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C.4.3 Similarities in cases and controls  
 
In case-control studies, potential biases can occur if differences exist between 
cases and controls in the manipulation, timing or processing of samples during the 
collection procedure. With this in mind, we attempted to minimize the differences by 
following similar, pre-established protocols for cases and controls. All cases and 
controls were invited to participate in the study by a trained recruitment officer who 
approached potential participants at the same site (CPMI-NFED) in the morning 
(between 9am and noon). No difference in timing of recruitment existed based on 
case-control status of the participant. After consent, cases and controls had blood 
drawn in the same manner for all analyses that followed. A trained phlebotomist 
collected the required samples for cases and controls in a similar manner and stored 
the samples until the required analysis was performed (complete blood counts and 
HPLC). Shipment to Montreal was done in a similar manner and not based on case 
control status. Nucleic acids isolation and genomic experiments were performed in 
Montreal using identical protocols for cases and controls. All experiments were 
performed in a similar manner for cases and controls. 
 61 
C.5 Data sources and measurements 
C.5.1 Protection of privacy  
 
All study material (i.e. biological samples and SCD clinical data, ect.) was 
coded to maintain the anonymity of the participants.  
C.5.2 Nucleic acid extractions from whole blood 
 
The same collection procedure was followed for all samples in order to reduce 
technical heterogeneity (Appendix III). A total of 10 ml of peripheral whole blood was 
collected from each patient between 9:00 am and 12:00 pm during their visit to the 
SCD Center and stored at -30oC. Approximately 3 ml of this blood was collected for 
RNA work in TEMPUS blood RNA Tubes (Life Technologies). TEMPUS tubes 
contain a stabilizing reagent that immediately lyses whole blood cells and stabilizes 
RNA by inactivating cellular RNases and selectively precipitates RNA; genomic DNA 
and proteins remain in solution. Blood drawn in TEMPUS blood RNA Tubes are 
stable for up to 5 days at room temperature and for several months at -20oC. 
Approximately 5ml of this blood was collected in EDTA tubes for DNA work. 
Shipment of the samples to Montreal was done at -20oC. Total RNA was isolated 
using the TEMPUS RNA extraction kit (Life Technologies) following the 
manufacturer’s recommendations. Since globin mRNA influences the signal quality in 
gene expression analyses, and since it is heavily expressed in total mRNA isolated 
from blood, a globin mRNA reduction step was performed using GLOBINclear-
Human kit (Life Technologies). Total RNA extractions were quantified and quality 
was checked using the RNA 6000 Nano LabChip kit and 2100 Bioanalyzer (Agilent 
Technologies). Only samples of high RNA quality (Agilent’s RNA Integrity Number > 
7.5) were retained for expression profiling. Whole blood was collected in EDTA tubes 
 62 
for DNA isolation. DNA samples were extracted using QIAamp DNA Kit (Qiagen). 
Quantity and quality was checked using Agilent’s DNA 6000 Nano LabChip kit and 
the 2100 Bioanalyzer (Agilent Technologies).  
 
C.5.3 Gene expression profiling 
For each participant, total RNA was reverse transcribed, and labeled by 
incorporating fluorescent oligonucleotides to obtain cRNA. Using 500ng of this 
labeled cRNA, expression profiles of more than 48,000 probes were generated with 
Illumina’s HumanHT-12 v4 BeadArrays. The manufacturer’s recommended protocols 
were followed. To summarise, for each sample, the labeled cRNAs were hybridised 
to oligonucleotides which were immobilized to beads held in microwells on the 
surface of an array. Twelve samples were hybridized to each array. After performing 
washing and staining steps, the array was scanned and measured for relative 
fluorescence. The level of fluorescence that is measured for each probe represents 
the relative expression level for that individual’s gene-specific probe. See Figure C.3 
below. The raw intensities were extracted using the Gene Expression Module in 
Illumina’s BeadStudio software. Expression intensities were log2 transformed and 
quantile normalized (QNM) using JMP Genomics v5.0 (SAS) after an outlier filtering 
procedure was applied. Levene’s test of normality of log2 expression data for each 
probe was performed and probes departing from normality (p< 0.001) were removed. 
QNM is the most aggressive method of normalization [122,123,124], and 
remove’s technical variability by assigning each measure the mean value across 
samples for each rank, which creates an identical distribution for all samples. QNM 
has become the standard method in most gene expression studies [123], and is  
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Figure C.3 Experimental procedure used for cDNA microarray chips.  
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appropriate under the assumption that only a small number of measures differ among 
samples and that variation in the distributions is mostly technical noise that should be 
removed.  
After applying QNM, 28,595 probes with expression at or above background 
levels averaged across all the arrays were retained for further analysis. These 
represent probes remaining after removal of 18,404 probe measurements that were 
considered to lie below background detection levels indicated by the inflection point 
in a plot of rank-ordered normalized intensities (see Figure C.4 below). Also, 427 
probes overlaying known SNPs included in the Illumina’s OmniExpress BeadChip 
were removed from the analysis.  
Illumina’s HumanHT-12 BeadArrays were the arrays of choice because of their 
genome-wide coverage that targets more than 25,000 annotated genes using more 
than 48,000 probes that have a high reproducibility (concordance between replicates 
shown to be r2=0.996 [125]).  
 Gene expression profiling was performed using the high-throughput facilities at 
the McGill University Genome Quebec Innovation Center in Montreal. 
(http://www.genomequebecplatforms.com/mcgill/home/index.aspx). 
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Figure C.4 Transformation and quality control of gene expression data. 
A) Distribution of the log2 transformed data for the 48,000 probes before quantile 
normalisation. The graph shows overlayed kernel density measures for the 48,000 
probes for 324 samples. Two outliers shown in this plot were removed. B) The 
distribution is shown after removal of the outliers. C) The average expression level of 
each normalized probe for all samples was calculated. Using the mean values, the 
48,000 probes were ordered from least expressed to most expressed. Using the 
inflection point of the plot of rank-ordered log2 transformed, quantile normalized 
probe intensities, 28,595 expressed probes were chosen since they were above 
background detection levels and were retained for further analysis. Below is the plot 
of the average values of all 48,000 probes, with the 28,595 expressed probes 
highlighted (dark line).  
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C.5.4 Quality control of gene expression data  
To minimize chip and batch effects, a randomized design was used during 
hybridization. Hybridization was performed on two different dates. In order to test for 
a potential batch effect, four samples from the first hybridization batch were re-
hybridized with the second batch as a means of quality control. These four technical 
replicates clustered adjacent to one another in hierarchical analysis, indicating a 
negligible batch effect on the data. This was confirmed by testing for batch effect in 
the probe-by-probe analysis of variance.  
C.5.5 Genome-wide genotyping 
Genome-wide genotyping data was generated for each participant for over 
733,200 single nucleotide polymorphisms (SNPs) using Illumina’s HumanOmni 
Express BeadChip arrays following the manufacturer’s protocols. In simplified terms, 
detection of thousands of polymorphism genotypes for each individual is performed 
through labeling the isolated DNA with allele-specific oligonucleotides, hybridization 
of the labeled DNA to an array that contains immobilized nucleic acid sequences of 
target, washing, and detection using fluorescence. Interpretation of the signal was 
performed by extracting the fluorescent signal of each allele at each target using the 
Genotyping Module in Illumina’s BeadStudio software. 
 Illumina’s HumanOmni Express BeadChip arrays offer multiple advantages over 
other genotyping methods including high sample-throughput, comprehensive 
genomic content with a mean SNP spacing of 4.0 kb, optimized tag SNPs from all 
three HapMap phases that selects the greatest amount of common SNP variation 
possible, and high reproducibility (>99.9%). Of particular interest is that the SNP 
variation in African samples was evaluated by including the Yoruban sample, an 
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African ethnic group from Nigeria. Although the percent of the genetic variation that is 
captured in the Yorubans by using the HumanOmni Express is relatively low (0.4), 
this was the best available technology at the time that this study was performed.  
 
 Genotyping was performed using the high-throughput facilities at the McGill 
University Genome Quebec Innovation Center in Montreal. 
(http://www.genomequebecplatforms.com/mcgill/home/index.aspx). 
 
C.5.6 Quality control of genotyping and evaluation of genotyping errors 
 The genotyping process involved a stringent protocol for maintaining the 
quality of the results acquired. Evaluation of genotyping errors was carried by 
calculating marker properties for each data set using PLINK [126]. Only SNPs with 
minor allelic frequency >5%, a call rate >99% and an exact Hardy-Weinberg (HWE) 
P value >0.001 were included. This resulted in sets of SNPs for each data set that 
were retained for further analyses (see Section C.6.1).  
C.5.7 Hematological variables 
 
The remainder of the 10 ml blood sample of whole blood that was collected 
from each participant (approximately 3 ml) was analysed in Cotonou at the CPMI-
NFED and used for complete blood counts using an automated KX-21 blood analyser 
(Sysmex Corporation, Japan), for identification of the hemoglobin phenotype by high-
performance liquid chromatography (HPLC) and Capillary Electrophoresis [127], and 
for quantitative falciparum malaria parasites determination (thick smear blood 
analysis). The complete blood count (CBC) hematological variables analysed were 
red blood cell counts (RBC cells/pL), white blood cell counts (WBC cells/pL), and 
parasetemia counts. The automatic blood analyser is an accurate and reliable 
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method of obtaining CBC. HPLC and Capillary Electrophoresis is a standard 
diagnostic method for SCD and has a high accuracy and reliability [127]. Quantitative 
falciparum malaria parasites determination was performed by trained laboratory 
technicians.    
C.5.8 Diagnosis of SCD patients  
 Patients were diagnosed with SCD at the SCD Center in Cotonou after the 
HbSS or SC proteins were detected by High Performance Liquid Chromatography 
(HPLC) and Capillary Electrophoresis [127]. This method of SCD diagnosis is a 
standard, reliable procedure with high accuracy.  
C.5.9 Sequenom genotyping of SNPs in β-globin region on chromosome 11 
 
 Identification of the rs334 genotype (the SNP that causes the HbS mutation) 
and characterization of haplotype structure in the Hb locus was performed using 
Sequenom MassARRAY technology. This method uses a primer extension assay to 
perform multiplexed genotyping of single nucleotide polymorphisms (SNPs) present 
in genomic DNA amplified by a multiplex PCR. Matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry accurately measures the mass of short 
oligonucleotide primers extended by a single dideoxynucleotide. The multiplexed 
genotyping assays rely on the natural molecular weight differences of DNA bases. By 
careful analysis of the genotyping primers, mass spectra of genotyping products can 
be generated with no ambiguity in allele assignment [128].  
Twenty-one SNPs spanning a 61,345 bp region on chromosome 11 were 
genotyped. Figure C.5 details the chromosomal location of the 21 genotyped SNPs, 
including those that were used to construct the SCD haplotypes based on SNPs 
located at the classical RFLP sites used for SCD haplotyping [129]. See Table C.1.  
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Figure C.5 Chromosomal location of SNPs in globin region.  
Twenty-one SNPs spanning a 61,345 bp region on chromosome 11 that includes the β-globin gene. The SNPs located at the four 
RFLP sites (Xmn1, HindIII, Hinc2, and HbS) were used to construct the SCD haplotypes.  
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Table C.1 Classic sickle beta-globin haplotypes.  
Construction of the classic sickle beta-globin haplotypes was performed based on genotypes of 3 SNPs that mark RFLP sites  
[129]. 
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Assays were designed using SpectroDESIGNER software. The Sequenom 
Genotyping System offers flexible and efficient assay design (i.e. 96% success rate), 
improved call rates (i.e. 85%) and accuracy (i.e. error rate is less than 0.5%). Six 
hundred (600) ng of genomic DNA for each participant was used and the 
manufacturer’s recommended protocols were followed at the high-throughput 
facilities at the McGill University Genome Quebec Innovation Center in Montreal 
(http://www.genomequebecplatforms.com/mcgill/home/index.aspx). SNPS with 
greater than 20% missing data were excluded and individuals with less than 75% call 
rate were excluded.  
 
C.5.10 Measures of SCD clinical severity 
In order to test for association between gene expression and clinical severity 
in SCD, all analyses were performed using two main categorical variables:  
SCD clinical status: examines the effect of being followed at the 
comprehensive clinical care program (2 groups + controls). 
SCD clinical categories: captures the clinical heterogeneity in SCD patients 
and is used as a proxy to SCD clinical severity (4 categories + controls). 
C.5.10.1 SCD Clinical status 
 
In order to evaluate the effect of the CPMI-NFED’s comprehensive clinical 
care program, each patient was assigned a discrete categorical variable for clinical 
status: patients sampled at enrolment into the program and in steady-state were 
labeled as entry (E), and patients already being followed at the SCD Center were 
labeled as follow-up (FU). At the Center, most patients that are followed obtain a 
steady-state condition with general clinical improvement, which involves increased 
 73 
velocity of linear physical growth and marked reduction in the frequency and severity 
of SCD-related acute events. However, some followed patients experience no such 
improvement and remain in an unsatisfactory state. Thus, both environmental and 
genetic factors influence a patients SCD clinical status.  
C.5.10.2 SCD Clinical categories 
 
In order to evaluate the clinical heterogeneity observed in SCD patients, we 
also assigned each patient a discrete categorical variable for Clinical Category based 
on their observed evolution in clinical condition that was evaluated at the SCD center 
over a period of 12-24 months. Patients were labeled as: Steady-State Satisfactory 
(SSS) if they had obvious positive changes including improvement of their general 
status, increased velocity of linear physical growth and marked reduction in the 
frequency and severity of SCD-related crises events. If no such improvement was 
observed during the followed period in the program, SCD patients were labelled as 
Steady-State Unsatisfactory (SSU). If patients were experiencing a crisis event 
related to SCD, they were labeled Acute (A). Finally, all newly enrolled patients into 
the program and who were in steady state were labelled Entry (E).  
C.5.10.3 SCD Severity index 
A quantitative SCD severity score (SV) was calculated according to a modified 
version of the method described by Sabastiani et al. [56] using an online sickle cell 
disease severity calculator (http://www.bu.edu/sicklecell/projects/) [56]. Each patient 
was assigned a score based on their sex, Hb genotype, mean corpuscular volume 
(MCV), and white blood cell (WBC) counts. Controls were assigned a score of 0.  
C.5.11 Confirmation of control status 
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The unaffected siblings were confirmed not to have SCD by performing High 
Performance Liquid Chromatography (HPLC) and Capillary Electrophoresis [128] at 
the SCD Center in Benin. Individuals with at least one normal (HbA) allele were 
assigned as controls.  
C.6 Variables 
 
C.6.1 Data Sets 
Depending on the analysis performed, different subsets of the data were used. 
See Table C.2 below. For the study that evaluated gene expression profiles 
implicated in SCD, case-control and case-only analyses were performed using the 
discovery, replication and combined data sets. For the study that tested for 
transcriptional biomarkers, analyses were performed to discriminate clinical 
categories and controls, and to discriminate SSS from SSU, were performed using 
the discovery and replication data sets. For the study that identified the genetic 
control of gene expression variation, combined data sets that included cases and 
controls was performed, or that only included cases for identification of the SNP-by-
Clinical category interaction effects. For the study that identified potential SCD drug 
targets, case-controls analysis was performed using the combined data set, and a 
case only (SSS and SSU SCD patients) subset of the combined data set.  
With combined data set I, we were interested in characterising the entire 
spectrum of SCD severity (measured by clinical categories) and thus kept all 
categories and Hb genotypes. In combined data set II, we focused on a sub-set of 
this sample that included HbSS patients and controls in order to characterize SCD 
clinical status and follow-up. HbSC individuals were excluded from combined data 
set II given their small sample size relative to the HbSS group. SCD patients 
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undergoing an acute event also were excluded from combined data set II to focus on 
the steady state of the disease. 
C.6.2 Variables in the “Gene expression profiles and biological pathways 
implicated in SCD” project 
 
Our first objective was to identify variables that influence gene expression 
variation in SCD and to quantify their impact. In order to address this question, the 
outcome variable of interest was genome-wide gene expression traits using the 
28,595 expressed probes. In unsupervised analyses that evaluated the impact of 
variables on gene expression variation, SCD clinical severity (SCD Clinical Status, 
SCD Clinical categories, and SCD Severity Index), Hb genotypes (HbSS, HbSC, HbA 
controls), sex, blood cell counts (WBC and RBC), genetic ethnicity (gPCs), date of 
sampling, phase, and age were included. Interaction between Hb genotype, Clinical 
severity, and sex was also evaluated for their impact on gene expression variation.  
In order to quantify the effects of SCD clinical severity (Clinical status and 
Clinical category) and Hb genotypes (exposure variables) on gene expression 
variation (outcome variable), an ANCOVA was performed that accounted for sex, cell 
counts, and genetic ethnicity (gPCs) as potential confounders.  
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Table C.2 Data sets. 
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*For each study indicated, a particular data set was used: Combined I = combined data set I; Combined II = combined data set II; 
SSS= steady-state satisfactory; SSU= steady-state unsatisfactory. The number of participants in each data set is indicated (n). The 
tested number of probes and SNPs are listed, as well as the corresponding method of adjusting for multiple testing (Mult.testing 
adj.). The analyses performed are abreviated: HC= hierarchical clustering; PCA= principal component analysis; VCA= variance 
component analysis; ANCOVA= analysis of covariance; GSEA= gene set enrichment analysis. The variable of interest in each 
analysis (end point) is listed, as well as the tested variable and covariates: RBC= red blood cells; WBC= white blood cells.  
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In order to identify biological pathways that impact the course of SCD through 
gene expression, the outcome variable of interest was gene expression profiles, and 
these were produced for patients grouped according to their SCD clinical severity 
(Clinical Status and Clinical categories). In this analysis, we accounted for Hb 
genotype, blood cell counts, and sex as potential confounder variables.  
 
C.6.3 Variables in the “Transcriptional biomarkers of SCD clinical severity” 
project   
 
  In order to identify transcriptional biomarkers that discriminate SCD patients by 
clinical category, the exposure variables were the gene expression levels from the 
28,595 expressed probes, which were used to discriminate SCD patients based on 
their Clinical category (outcome variable).  
C.6.4 Variables in the “Genetic control of gene expression variation in SCD 
patients” project 
 
In order to identify the genetic regulation of gene expression in SCD, linear 
regression models were run. Gene expression was the outcome variables of interest, 
and genome-wide genotyped SNPs were exposure variables that were tested for 
association with gene expression traits. We accounted for Hb genotype, clinical 
severity (Clinical Status and Clinical Category), cell counts (WBC and RBC), and sex.  
In order to determine if there was modification of the association between an 
individual’s genotype (exposure) and their gene expression level (outcome) based on 
their clinical severity (interaction effect), we used the same variables as explained 
above, and included an interaction term: SNP-by-Clinical severity (SNP-by-Clinical 
Status and SNP-by-Clinical Category). For this analysis, we also accounted for 
relatedness (potential confounder). 
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C.6.5 Variables in the “Potential SCD drug targets” project 
 
In order to identify known drug targets that could be used in SCD, 2 eSNP 
analyses were run. In the first eSNP analysis, genes that controlled gene expression 
in SCD patients and controls were identified. In the second eSNP analysis, genes 
that controlled gene expression in steady-state satisfactory and unsatisfactory SCD 
patients were identified. These genes (dependent variable) were then examined to 
determine if there were drug targets (outcome variable) described in public 
pharmacogenetic databases.  
C.7 Statistical methods 
 
C.7.1 General results methods 
C.7.1.i Relatedness 
In order for the assumption of independent observations to hold, it is important 
to account for relatedness in GWAS. We tested for relatedness by estimating 
genome-wide identity-by-descent (IBD) using Jmp Genomics/SAS and PLINK [126]. 
IBD is a measure of how many alleles at any marker in two samples come from the 
same ancestral chromosomes. The probability that zero, one, or two alleles are 
identical by descent (“shared IBD”) is denoted by the notations P(Z=0), P(Z=1), and 
P(Z=2), respectively. These probabilities may either refer to given markers or be 
thought of as sample-wide. Pi-hat is a measure of IBD estimated using PLINK, and is 
equal to P(Z=2) plus one-half of P(Z=1). This is the probable number of shared 
alleles at any given marker. Although there are other methods to estimate 
relatedness that may be more accurate [130,131,132], IBD and Pi-hat can achieve 
reasonable estimates of relatedness among pairs of subjects that is sufficiently 
appropriate for quality assurance purposes.  
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In order to avoid biases from groups of correlated markers, SNPs were pruned 
using PLINK based on marker properties and LD (SNPs with any missing data were 
removed and only autosomal SNPs were included, all SNPs that were in LD (r2<0.3) 
were removed). This left 193,652 SNPs for further analyses. In order to decrease 
computational time in future analyses that included the relatedness matrix, a random 
sample of SNPs was chosen, with a per-SNP probability of being kept equal to 0.01. 
This left a final number of genome-wide SNPs equal to 1,986 SNPs for the 
relatedness analyses [123]. The relatedness matrix that was generated using 1,986 
SNPs was compared to the matrix that was created using 327,554 SNPs. Similar 
levels of relatedness were obtained (correlation of 0.98; see Appendix IV).   
C.7.1.ii Ancestry analysis  
Global genotypic variation and ancestry was inferred based on principal 
component analysis using Eigenstrat proposed by Price et al. [119,120]. This method 
is commonly used to adjust the results of GWAS and correct for stratification. 
Ancestry analyses of 119, 104 and 235 unrelated individuals from the discovery, 
replication and combined I data sets were performed using 485,000 genotypes. 
Significance of genotypic principal components (gPCs) was tested using the Tracy-
Widom test and the percent of variance in the data that was explained by each gPC 
was calculated.  
 
C.7.2 Gene expression profiles and biological pathways implicated in SCD 
analyses 
All statistical analyses of the gene expression data were performed using JMP 
Genomics v5.0 (SAS), and SAS 9.3 (SAS). 
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C.7.2.i Unsupervised statistical analyses 
The unsupervised statistical analyses performed below, are an attempt to find 
hidden structure in the data without any a priori hypothesis.   
C.7.2.i.1 Hierarchical clustering 
The CLUSTER procedure in SAS was used to perform one-way and two-way 
hierarchical clustering using Ward’s minimum-variance method [133]. This analysis 
allows an illustration of how the data clusters without any a priori hypothesis. One-
way clustering (clustering based on each participants’ gene expression level or 
clustering based on samples), identifies co-regulated and functionally related genes 
or sub-types of related samples. Two-way clustering (clustering of gene expression 
levels with samples), identifies which genes are the most important for sample 
clustering. The method is based on an agglomerative hierarchical clustering 
procedure. Each observation begins in a cluster by itself. The two closest clusters are 
merged to form a new cluster that replaces the two old clusters. Merging of the two 
closest clusters is repeated until only one cluster remains. One-way clustering has 
been widely performed in current biological research for discovering and 
understanding gene functional relationships [134], or used in biomedical research 
where clustering disease samples to diagnose disease types or disease progress 
[135,136].  
C.7.2.i.2 Principal and Variance component analysis 
Principal Component analysis (PCA) finds low dimensional linear 
combinations of data with maximal variability. Variance Component analysis (VCA) 
attributes and partitions variability into known sources via a classical random effects 
model. Both PCA and VCA of the gene expression data were performed such that 
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the first three expression PCs (ePC) are modeled either simultaneously or 
individually as a function of various effects in the data: Hemoglobin genotype, SCD 
severity (Clinical status or Clinical category), Sex, and pair-wise combination of fixed 
effects. 
C.7.2.ii Supervised statistical analyses 
The supervised statistical analyses that were performed are described below.  
C.7.2.ii.1 ANCOVA 
SAS GLM was used to evaluate the magnitude and significance of 
differentially expressed probes. Probe-level differential expression analyses were 
performed using analysis of covariance. Variance was partitioned among the 
hemoglobin genotype (Hb), clinical severity (clinical status effect or the clinical 
category effect), sex, and total blood cell counts (red (RBC) and white blood cells 
(WBC)) as covariates. The effects of date of sampling, phase (discovery vs 
replication), age (in years), and gPCs were tested. Pairwise contrasts (Hb 
genotype*Sex, Hb genotype*ClinStatus/Clinical category and ClinStatus/Clinical 
Category*Sex) also were evaluated. The following ANCOVA models were of interest:  
Expression = μ + Hb genotype + SCD Clinical Status + Sex + WBC + RBC + ε 
Expression = μ + Hb genotype + SCD Clinical Category + Sex + WBC + RBC + ε 
 
The error ε was assumed to be normally distributed with mean equal to zero. 
The number of probes that were differentially expressed between the 3-way SCD 
Clinical status effect (EvsFUvsCtls) and the 6-way SCD clinical category effect 
(AvsSSSvsSSUvsE) were also evaluated. Since multiple comparisons were 
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performed, the p-value was corrected using the method of False Discovery Rate 
(FDR=1%) and was applied separately to each term in the analysis of covariance.    
C.7.2.ii.2 Enrichment analysis 
Enrichment analysis for the differentially expressed genes in the SCD Clinical 
status contrasts and the SCD Clinical category contrasts were performed using Gene 
set enrichment analysis (GSEA) [137] on the C2 collections of MsigDB database 
(http://www.broad.mit.edu/gsea/msigdb). Merged to C2 are 28 gene sets collected 
from transcriptional analyses of PBMC samples in an immunological context, and are 
named M x.x (eg. M 1.3). Their descriptions can be found in Chaussabel et al. [138]. 
Also included are 10 gene sets generated from profiling major immune cell subsets 
found in the human blood [139], prefixed with “Bali”. The resulting p values from the 
GSEA were adjusted for multiple testing by using Benjamini and Hochberg method 
[140] to control the false discovery rate. Results were considered to be significant if 
the adjusted p values are <0.05. A Normalized Enrichment Scores (NES) greater 
than 0.25 in a SCD patient group relative to the controls was used.  
 
C.7.3 Identification of transcriptional biomarkers analyses 
C.7.3.i Discriminant analysis  
Using the entire gene expression data (28,595 expressed probes), 
discriminant analysis was performed to identify biomarkers for each clinical category. 
Discriminant analysis is a classical statistical method for predicting a classification 
variable (SCD clinical category) from a set of continuous responses (probes). SAS K-
means clustering was used to select one representative predictor from each cluster. 
The default settings were applied, which included a maximum number of K-means 
clusters per predictors set to 500. T-tests were performed to filter the predictors 
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(using FDR 1%). A linear metric was used to compute distances between groups with 
a forward stepwise variable selection method. Each clinical category’s proportion was 
calculated in the sample and used as a prior. The best model was chosen based on 
likelihood ratio test.  
Using the selected probes identified in the discovery phase to predict clinical 
category, each individual’s clinical category was predicted in the replication sample 
and accuracy was measured.  
For the analysis that predicted SSS from SSU patients, a receiver operating 
curve (ROC) was generated. A ROC curve is a graphical plot which illustrates the 
performance of a binary system as its discrimination threshold is varied. It is created 
by plotting the fraction of true positives out of the positives (TPR= true positive rate) 
versus the fraction of false positives out of the negatives (FPR = false positive rate), 
at various threshold settings. TPR is also known as sensitivity, and FPR is one minus 
the specificity or true negative rate. The diagonal divides the ROC space. Points 
above the diagonal represent good classification results (better than random), points 
below the line poor results (worse than random). The ROC can be used to generate 
summary statistics. When using normalized units, the area under the curve (AUC) is 
equal to the probability that a classifier will rank a randomly chosen positive instance 
higher than a randomly chosen negative one (assuming “positive” ranks higher than 
“negative”).  
C.7.3.ii Leave-one-out cross validation 
In order to assess the accuracy of the results of the discriminant analysis, 
leave-one-out cross-validation was performed. This technique involves using a single 
observation from the original sample as the validation data, and the remaining 
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observations as the training data. This is repeated such that each observation in the 
sample is used once as the validation data.  
Leave-one-out cross validation was performed on combined data set I (n=311, 
K=311), and on the SSS and SSU data set (n=80) using the cv.glm function [141] in  
the package boot in R [142]. This method refits the generalized linear model with a 
subset of data (training set: n-1) and calculates the accuracy of the prediction on the 
remaining data. The SCD severity index was the response variable that was 
predicted. For the clinical category analysis, a prediction was made for each 
participant based on the 310 remaining participants’ biomarker’s gene expression 
levels. For the SSS and SSU analysis, a prediction was made for each participant 
based on the 79 remaining participants’ biomarker’s gene expression levels. R2 and 
p-values were calculated for the linear regression analysis between predicted and 
actual values.  
C.7.4 Genetic control of Gene Expression analyses 
 
C.7.4.i GWAS of gene expression  
 
GWAS of gene expression analysis, a method that integrates genome-wide 
genotying data with genome-wide gene expression data [92,97,98,99,100], was 
performed using JMP Genomics v5.0 (SAS), SAS 9.3 (SAS), and PLINK [126]. 
Linear regression analyses were modeled assuming a co-dominance mode of 
inheritance, where each allele has an additive effect on the level of gene expression 
that is transcribed.   
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C.7.4.i.1 Multiple linear regression 
Multiple linear regression analyses were performed using PLINK to test for 
significant associations between gene expression levels and SNP genotype. In these 
analyses, we tested for association between probe expression levels and SNP 
genotype while accounting for clinical severity (Clinical Status or Clinical Category), 
sex and blood cell counts (white and red blood cell counts, WBC and RBC), 
assuming that the error ε is normally distributed with a mean of zero, where:  
 Model 1: Expression = μ + SNP+ Clinical Status + WBC + RBC + Sex+ ε  
Model 2: Expression = μ + SNP+ Clinical Category + WBC + RBC + Sex+ ε 
Only well-annotated, autosomal probes with validated chromosomal location 
and gene function based on the most recent annotation in NCBI and UCSC as of 
October 2011 were included for the association tests. In the process, all probes were 
aligned to the reference genome (hg19), ambiguous probes and all non-RefSeq 
probes were excluded, and probes overlaying known SNPs (427 of them) were 
removed from the analysis. SNPs that had a minor allelic frequency <5 %, an exact 
Hardy-Weinberg (HWE) test P value <0.001 and > 1% missing data, calculated 
seperately for each data set, were excluded. This resulted in a total of 19,431 
expressed probes that were tested for association with 560,675 SNPs in model 1, 
and 18,890 expressed probes that were tested for association with 568,921 SNPs in 
model 2.  
We distinguish between eSNP associations based on the chromosomal 
location of the probe-SNP pair and the distance between them (see Figure C.6). A 
local association implicates a probe and a SNP located on the same chromosome 
that is 1 Megabase pairs (Mb) or less apart from each other (it is assumed that a 1 
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Mb region has on average 200 SNPs); while a distal cis association is an association 
between a SNP and probe located on the same chromosome but further than 1 Mb 
apart. A distal association implicates a probe and a SNP located on different 
chromosomes. We applied Bonferroni correction for all eSNP associations by 
accounting for both the number of SNPs and probes tested.  
Figure C.6 Representation of local and distal eSNP associations.  
Cis associations are eSNP associations between a SNP and a gene located on the 
same chromosome no more than 1Mb apart between the SNP-probe pair. Distal 
eSNP associations are on different chromosomes.  
 
 
Since 560,675 SNPs were tested for association with 19,431 probes in model 
1, a genome-wide Bonferroni threshold for distal-associations corresponds to 
0.05/(19,431 probes x 560,675 SNP) = 4.59 × 10-12 and for local associations to a 
Bonferroni threshold of 0.05/(19,431 probes x 200 SNPs) = 1.28 x 10-8 considering 
an average number of 200 SNPs tested against each probe.  
Since 568,921 SNPs were tested for association with 18,890 probes in model 
2, a genome-wide Bonferroni threshold for distal-associations corresponds to 
0.05/(18,890 probes x 568,921  SNP) = 4.65 × 10-12 and for local associations to a 
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Bonferroni threshold of 0.05/(18,890 probes x 200 SNPs) = 1.32 x 10-8 considering 
an average number of 200 SNPs tested against each probe.  
C.7.4.ii Detection of Interaction effects  
 Here we test for statistical transcriptional interactions using the method of 
Idaghdour et al. [92], where an interaction is described as the differential effect of a 
given genotype exposed to different clinical outcomes (Clinical status or clinical 
category) associated with gene expression. In model 3, we test for SNP-by-Clinical 
Status interaction effects using 7,002 differentially expressed probes for the 3-way 
Clinical Status effect and using combined data set II. In model 4, we test for SNP-by-
Clinical Category effects using 4,220 differentially expressed probes for the 6-way 
Clinical Category effect using a subset of combined data set I that contains only SCD 
patients.  
Model 3: Expression = μ + SNP+ Clinical Status + WBC + RBC + Sex + 
SNPxClinStatus + ε  
Model 4: Expression = μ + SNP+ Clinical Category + WBC + RBC + Sex+ 
SNPxClinCat + ε 
where ε is assumed to be normally distributed with a mean of zero. 
For these analyses, we reduced the effect of outlier expression values by 
further filtering the set of genotypes for each sub-group. We calculated marker 
properties in each of the sub-groups of patients separately and included only SNPs 
that had a minor allelic frequency <5 %, an exact Hardy-Weinberg (HWE) test P 
value <0.001 and > 1% missing data for each sub-groups of patients. A final number 
of 455,750 SNPs in combined set II, and 399,821 SNPs in combined set I were used.  
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This resulted in 7,002 differentially expressed probes for the 3-way Clinical 
Status effect that were tested for association with 455,750 SNPs in model 3; and  
4,220 differentially expressed probes for the 6-way clinical category effect that were 
tested for association with 399,821 SNPs in model 4. 
 A genome-wide Bonferroni correction was applied by accounting for both the 
number of SNPs and probes tested in these analyses. Since 455,750 SNPs were 
tested for association with 7,002 probes in model 3, a genome-wide Bonferroni 
threshold for distal-associations corresponds to 0.05/(7,002 probes x 455,750 SNP) 
= 1.57 × 10-11 and for local associations to a Bonferroni threshold of 0.05/(7,002 
probes x 200 SNPs) = 3.57 x 10-08 considering an average number of 200 SNPs 
tested against each probe.  
Since 399,821 SNPs were tested for association with 4,220 probes in model 4, 
a genome-wide Bonferroni threshold for distal-associations corresponds to 
0.05/(4,220 probes x 399,821 SNP) = 2.96 × 10-11 and for local associations to a 
Bonferroni threshold of 0.05/(4,220 probes x 200 SNPs) = 5.92 x 10-8 considering an 
average number of 200 SNPs tested against each probe.  
C.7.4.ii.1 Q-K mixed model that includes relatedness matrix 
Because cases and controls were potentially related, we included the pairwise 
relatedness estimates (IBD) calculated for each of the SCD individuals and controls 
and used this matrix to estimate the random effect of shared genetic and 
environmental components in a Q-K mixed model [143]. Only autosomal SNPs with a 
MAF>0.1, missingness=0, and that were not in linkage disequilibrium (r2<0.3) were 
included in estimating relatedness (final number of SNPs = 1,992 SNPs). Using the 
GLIMMIX procedure in SAS and including this relatedness matrix in a mixed model, 
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we reran the analyses to identify interaction effects that remained significant after 
accounting for the random effects of shared genetic and environmental components. 
C.7.4.iii Comparison of significant eQTL results in SCD with published eQTL 
results  
The significant SNP-expression (eSNP) associations identified in SCD in this 
study were compared to the associations reported in 12 published eQTL studies of 
peripheral blood or its derivatives at nominal P-values < 10-7. These published 
associations were accessed using the eQTL Browser (http://eqtl.uchicago.edu/cgi-
bin/gbrowser/eqtl/) and compared to our study results. 
C.7.5 Identification of potential drug targets in SCD analyses 
 
In order to identify drug target genes in SCD, 2 basic eSNP analyses were run 
for SCD patients (n=205) and controls (n=58), separately (model 5).  
Model 5: Expression = μ + SNP + ε 
The genes that were significantly associated with SNPs were evaluated to 
identify if they were drug targets. A drug target is described as a gene that is affected 
by a chemical or drug in the Comparative Toxicogenomics Database (CTD database: 
http://ctdbase.org/). The CTD is a public website and research tool that curates 
scientific data describing relationships between chemicals, genes and human 
diseases [144]. In Figure C.7, a flow diagram of the approach is shown.  
In a second analysis, candidate drug target genes for SCD patients in 
unsatisfactory conditions (SSU) were identified by examining the overlap between 
eSNP genes that were differentially expressed between SSS (steady-state 
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satisfactory) and SSU (steady-state unsatisfactory) patients and the CTD database. 
See Figure C.8 for the flow diagram for these analyses.  
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Figure C.7 Flow diagram for SCD drug targets 
Steps used in identifying drug targets for SCD patients. 
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Figure C.8 Flow diagram for drug targets of SCD progression. 
Steps used in identifying drug targets for genes differentially expressed between SSS 
and SSU SCD patients that were under genetic control. 
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D. RESULTS 
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D.1 GENERAL RESULTS  
 
D.1.1 Flow diagram of participant selection  
As previously mentioned, participants were recruited from the SCD cohort in 
Benin during 2010. For the purpose of this study, a total of 452 participants with 
clinical data and blood samples for nucleic acids isolation were recruited. Three 
hundred twenty four (324) of these participants were gene expression profiled. We 
excluded 128 participants due either to small sample sizes in some categories 
(HbCC and Post-Acute (PA) patients), or because of over-representation of the Entry 
(E) patients, or because of poor RNA quality in some samples.  
After gene expression profiling, three hundred eleven (311) samples were 
retained for further analysis based on quality control checks during the hybridisation, 
normalisation and standardisation steps. This made a final sample size of 126 in the 
Discovery phase, 124 in the Replication phase, and 311 in combined data set I for 
gene expression analyses.  
We genotyped 263 of the 311 patients. Forty seven participants were excluded 
due to quality control checks, relatedness, or re-sampling. This made a final sample 
size of 142 in the Discovery phase, 129 in the Replication, and 263 in combined data 
set I for joint gene expression and genotyping analyses (eSNP analyses).  
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Figure D.1.1 Flow diagram of participant selection. 
 
 
 
 
D.1.2 Participant characteristics: demographic and clinical data 
Demographic and clinical characteristics for the 311 recruited participants are 
shown in Table D.1.1 below. Approximately three quarters of the SCD sample had 
the HbSS genotype (n=190; 76%) and one quarter were compound heterozygotes 
(HbSC; n= 60; 24%). Sixty one participants had at least one HbA allele and were 
used as controls. The odds ratio of a SCD patient having an HbSS genotype (HbSS 
vs HbSC) and having a particular SCD clinical category was calculated, but was not 
significant (Chi Square p value= 0.2783). See Table D.1.2 A and D.1.2.C below. 
Roughly, equal numbers of boys and girls were recruited. One hundred and thirty five 
SCD patients were male (54%), and one hundred fifteen were female (46%). More 
boys were Acute (67%) or SSU (61%) than girls, but this was not significant (OR and 
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95% confidence intervals, as well as Chi Square p-values are shown in Table D.1.2 B 
and D.1.2.C below). The distribution of the main variables is similar for each dataset 
(Figure D.1.2).  
Three quarters of our controls were heterozygous HbAS and one quarter were 
homozygous HbAA. Only 14 probes were differentially expressed between HbAA and 
HbAS individuals at FDR 1%.  Furthermore, none of the variance in the controls was 
explained by this effect as evidenced by variance component analysis and by the 
lack of clustering based on Hb genotype in the PCA analysis (Figure D.1.3). For 
these reasons, we grouped HbAA and HbAS individuals and used them as a control 
sample.
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Table D.1.1 Participant (n=311) characteristics.  
 
* Characteristics of participants in Combined dataset I (C), Discovery phase (D) and in Replication phase (R)  Hb genotype, Sex (M=males, F=females), Cell 
counts (RBC=red blood cells, WBC = white blood cell, the number of indivdiuals infected with malaria parasetemia (# of infec), age (years), and self-declared 
Ethnicity are measured by clinical category: Entry, Acute, steady-state satisfactory (SSS), steady-state- unsatisfactory (SSU) controls. Significant differences 
are indicated for combined dataset I. ** p<0.0001 Nonparametric comparisons for each pair using the Wilcoxon Method. *p<0.05 Nonparametric comparisons 
for each pair using the Wilcoxon Method.  
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Table D.1.2 SCD clinical categories.  
Clinical categories for Combined dataset I (C), Discovery (D), and Replication (R) phases are stratified by A) Hb genotype or by B) 
sex.  C) The odds ratios for a SCD patient having a particular genotype and having a particular clinical category was not significant. 
Neither was the odds ratios for a SCD patient being a boy or girl and having a particular clinical category.  
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Figure D.1.2 Pie charts.  
Pie charts of patient characteristics in the discovery, replication, and combined I and II datasets for genome-wide gene expression 
analysis (Exp) and genome-wide genotyping analysis (Geno). Each main variable (Clinical status: Entry (E), Follow-up (FU), and 
Controls (C); Hb Genotype: HbSS, HbSC, Controls (Ctls, C); and Sex: Female (F), Male (M)) was sampled in equal proportions in 
the datasets. 
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Figure D.1.3 VCA in the controls.  
Variance component analysis for the Hb genotype effect (HbAS vs HbAA) in the controls on the first three expression principal 
components (ePC1-3) explains zero percent of the total variance in the combined dataset (A), and PC analysis identified a lack of 
clustering based on Hb genotype (B).  
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D.1.3 Hematological variables 
Complete blood counts (CBC) were obtained for each participant. The CBC 
hematological variables that were analysed were red blood cell counts (RBC 
cells/pL), white blood cell counts (WBC cells/pL), and malaria parasetemia levels. 
The hematological variables were evaluated for correlation with each other. RBC 
were negatively correlated with WBC (r2= -0.4892). Nonparametric tests were 
evaluated using the Wilcoxon method for significant differences between the 
hematological variables and SCD clinical categories (see Table D.1.1). Acute SCD 
patients had a significant difference in their white blood cell counts (p<0.05) when 
compared to Entry and SSS SCD patients. Controls were significantly different from 
all SCD clinical category patient groups for all three hematological variables 
(p<0.001).  
D.1.4 β-SCD Haplotypes  
 
It is possible that SCD severity would be influenced by β-SCD haplotypes. In 
order to ensure that SCD clinical severity was not driven by a β-SCD haplotype in the 
study, clinical category and β-SCD haplotypes were tested for association. A 61,345 
base pair (bp) region on chromosome 11 that spanned the β-globin locus was 
genotyped using 21 additional SNPs that were not included on the Illumina array and 
β-SCD haplotypes were constructed. In the Appendix V, marker properties of the 21 
genotyped SNPs are shown. One hundred nineteen (119) out of 169 SCD patients 
that were successfully genotyped were homozygous for the causal rs334 SNP 
genotype, confirming their HbSS genotype (Table D.1.3). Out of the 119 homozygous 
HbSS SCD patients, 109 (92%) had the Benin haplotype and 10 had other minor, 
atypical haplotypes. Fifty SCD patients were heterozygous for the rs334 genotype 
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and were presumed to have the HbSC genotype. Out of the 50 controls, 34 were 
HbAS carriers based on their heterozygous status for the rs334 mutation, and 16 
were HbAA homozygous for the normal rs334 genotype. No β-SCD haplotype was 
significantly associated with a SCD clinical category. 
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Table D.1.3 β-SCD haplotypes.  
Characterisation was performed in 237 genotyped participants were not significantly associated with clinical categories. 
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D.1.5 Relatedness of SCD participants, genetic ethnicity and population 
structure 
Identity by descent (IBD) and Pi-hat, estimates of relatedness, were calculated 
for SCD patients using Jmp/SAS and PLINK, respectively. The distribution of IBD 
and pi-hat in the genotyped individuals are plotted below in Figure D.1.4 and D.1.5. 
The Relationship matrix for the SCD patients was constructed using the IBD values 
across all marker variables (Figure D.1.6). Overall, there was marginal relatedness 
among the samples. Ten (10) pairs of participants had a pi-hat greater than 0.04 and 
were excluded from the Principal Component Analysis (PCA) that was performed 
using Eigenstrat in order to identify SCD participants’ genetic ethnicity. In this 
analysis, individuals from HapMap were included and 518,000 shared genome-wide 
genotyped SNPs were used. After filtering by minor allele frequency and removal of 
outliers, the first 2 genotypic principal components (gPCs) were significant. In Figure 
D.1.7, these two gPCs are shown. The first gPC separates European CEPH (green) 
from Africans, and the second gPC separates Benin SCD participants (red) from 
Nigerian Yorubans (YRI: black). Additional PCAs were run in order to evaluate the 
population structure within the SCD population (Figure D.1.8). No significant gPCs 
were identified, indicating that population structure is not substantial in this sample. 
Also, no correlation was observed between gPCs and clinical status, clinical 
category, sex, or Hb genotype (Figure D.1.8). 
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Figure D.1.4 IBD distribution  
IBD distribution of pairs of genotyped SCD participants identified few related 
participants. 
 
 
 
Figure D.1.5 Pi-hat distribution  
Pi-hat distribution of pairs of genotyped SCD participants identifies related 
participants. 
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Figure D.1.6 Relationship matrix  
Relationship matrix for 263 participants was calculated using IBD estimates 
computed across genome-wide marker variables. 
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Figure D.1.7 gPCA.  
Principal Component Analysis using 518,000 shared genome-wide genotyped SNPs 
from SCD patients, YRI Yoruban Africans and CEPH European HapMap individuals 
identifies SCD participants to be ethnically similar to YRI individuals. 
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Figure D.1.8 Plot of gPC1-2 of SCD patients.  
Ancestry analyses of 119, 104 and 235 unrelated individuals from the discovery phase, replication phase and the combined dataset 
I using 485,000 genotypes. No obvious population structure was observed with all genotypic principal components (gPCs) 
explaining 1% or less of the total variance. The plots show the first two gPCs for the discovery, replication, and the combined 
dataset I. No correlation was observed between gPCs and clinical status, sex (males, squares; females, triangles), or Hb genotype 
(blue, HbSS; green, HbSC; red, controls).  
 
 
 110 
  
 
 
 
 
 
D.2 GENE EXPRESSION PROFILES AND BIOLOGICAL PATHWAYS IMPLICATED IN 
SCD 
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D.2.1 Unsupervised gene expression analysis – discovery phase 
Analysis of gene expression shows that SCD has substantial influence on the 
transcriptome. One-way unsupervised hierarchical clustering analysis of the genome-
wide gene expression correlation matrix revealed that individual gene expression 
profiles cluster largely according to Hb genotype, SCD severity score (SV), and 
clinical status (ClinStatus; Figure D.2.1). Principal Component Analysis (PCA) 
revealed the presence of strong correlation structure in the data (Figure D.2.2) such 
that the first three expression principal components (ePC1-3) explain over a third of 
the total variance (Table D.2.1 and D.2.2). Variance component analysis of the first 
three ePCs further confirms the substantial effect of Hb genotype (explaining 45.6% 
of the variance) followed by clinical status and clinical category (explaining 7% of the 
variance) (Figure D.2.3 and D.2.4). Variance of ePC1 was explained primarily by Hb 
genotype (>70%) while ePC2 and 3 were dominated by the effect of clinical status, 
explaining 20% of the variance of each ePC, or clinical category, explaining 15% and 
20% of the variance, respectively. Sex and interaction effects had negligible effects 
on the variance (Figure D.2.3 and D.2.4). Repeating this analysis with only SCD 
patients (n=126) revealed that a third of the variance (31%) was captured by the first 
three ePCs, with Hb genotype and the follow-up effect explaining 19.5% and 8.6% of 
the variance, respectively (Figure D.2.3, Table D.2.1), or Hb genotype and clinical 
category explaining 20% and 6% of the variance, respectively (Figure D.2.4, Table 
D.2.2).  
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Figure D.2.1 Hierarchical clustering of gene expression data. 
One-way hierarchical clustering of the genome-wide gene expression correlation 
matrix for the combined dataset I (n=311). The heat map shows the clustering of 
individual expression profiles based on similarity. The highest level of clustering is 
observed for the Hb genotype (HB) effect followed by SCD severity score (SV) and 
clinical status (ClinStatus). The color coded heat-map displays the largest expression 
values in red (hot) and the smallest values in blue (cool). Intermediate values are 
displayed in different shades of red and blue.  
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Figure D.2.2 Principal component analysis using gene expression data. 
Principal componant analysis using genome-wide gene expression data. The first two 
expression principal components (ePC) from PC analysis of the discovery and 
replication phase samples, and in the combined dataset are plotted. Individuals are 
coloured according to Hb genotype (HbSS, blue; HbSC, green; and Controls, red), 
SCD severity score (SV, red to blue indicates high to low severity) and Clinical Status 
effect (FU, yellow; E, purple, Ctls, red).  
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Figure D.2.3 Histogram of the proportion of variance explained by expression  
principle componenets (ePC) 1 to 3 for each modeled variable (ClinStatus). 
 
Variance component analysis of ePC1-3. The proportion of variance explained (y-
axis) by each of the main variables (x-axis) is shown for the variance component 
analysis (VCA) of the first three expression principal components (ePC1-3). These 
first 3 ePCs explain 36%, 37% and 37% of the total variance in the discovery, 
replication, and in the combined dataset (See Appendix VI). The two main variables 
that explain this variance are Hb genotype and follow-up effect. The proportion of the 
variance explained by each variable is similar in the discovery, replication and 
combined datasets. VCA of SCD patients alone shows that the proportion of the 
variance explained by clinical category was similar to that when the controls were 
included but the proportion of the variance explained by Hb genotype dropped by 25-
50%. 
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Figure D.2.4 Histogram of the proportion of variance explained by expression 
principle componenets (ePC) 1 to 3 for each modeled variable (ClinCategory).  
 
Variance component analysis of ePC1-3. The proportion of variance explained (y-
axis) by each of the main variables (x-axis) is shown for the variance component 
analysis (VCA) of the first three expression principal components (ePC1-3). These 
ePCs explain 36%, 37% and 35% of the total variance in the discovery, replication, 
and in the combined dataset (see Appendix VII). The two main variables that explain 
this variance are Hb genotype and clinical category. The proportion of the variance 
explained by each variable is similar in the discovery, replication and combined 
datasets. VCA of SCD patients alone shows that the proportion of the variance 
explained by clinical category was similar to that when the controls were included but 
the proportion of the variance explained by Hb genotype dropped by 25-50%. 
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Table D.2.1 Table of the proportion of variance explained by expression principle components (ePC) 1 to 3 for each modelled  
variable (ClinStatus). 
Variance component analysis on the first three expression principal components (ePC1-3) explains over a third of the total variance 
in the discovery phase, the replication phase, and in the combined data set. This total variance that is explained by the first ePCs is 
reduced slightly when only SCD patients were included in the analysis. The variance explained by each variable in the model are 
indicated (ClinStatus: SCD clinical status, Hb genotype, Sex, and (*) interaction effects). The proportion of variance explained by 
each variable is similar in the discovery, replication and combined data set. Here, the SCD patients are categorised by Clinical 
Status (ClinStatus). 
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Table D.2.2 Table of the proportion of variance explained by expression principle components (ePC) 1 to 3 for each modelled 
variable (ClinCat). 
Variance component analysis on the first three expression principal components (ePC1-3) explains over a third of the total variance 
in the discovery phase, the replication phase, and in the combined data set. This total variance that is explained by the first ePCs is 
reduced slightly when only SCD patients were included in the analysis. The variance explained by each variable in the model are 
indicated (ClinicalCat: SCD clinical category, Hb genotype, Sex, and (*) interaction effects). The proportion of variance explained by 
each variable is similar in the discovery, replication and combined data set. Here, the SCD patients are categorised by Clinical 
Category (ClinicalCat).  
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D.2.2 Supervised gene expression analysis – discovery phase 
The magnitude and significance of differentially expressed genes between 
SCD clinical status, SCD clinical categories and controls were evaluated. Given that 
a fraction of the variation in expression PCs is likely due to differences in the 
proportion of cell types between SCD patients, we performed a probe-by-probe 
analysis of covariance (ANCOVA) of the discovery sample that accounts for total 
blood cell counts (red and white blood cell counts), in addition to sex, and genetic 
ethnicity using individuals’ scores at significant genotypic PC axes. This analysis 
revealed significant differences between SCD patients (E and FU) and controls (Ctls) 
and between clinical categories and controls. A quarter or more of the transcriptome 
was differentially expressed for the follow-up effect and for the clinical category effect 
at 1% False Discovery Rate (FDR) (Table D.2.3). Thousands of genes were also 
significantly differentially expressed between Hb genotypes (HbSS, HbSC, controls) 
while minor differences were observed between sexes and no effect of the genome-
wide genotypic ethnicity effect (gPCs) was detected. Since meaningful population 
structure in the sample was not observed (Figure D.1.10) and since no probes were 
significant for the gPC effect (FDR 1%), genetic ancestry is unlikely to significantly 
contribute to the observed gene expression differences in our sample.  
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Table D.2.3 ANCOVA 
Number of differentially expressed probes for the following effects: SCD Clinical 
Status (ClinStatus: E=Entry, FU=Follow-up and Ctls=Controls, Acute=A), SCD 
Clinical Category (ClinCategory: Acute=A. E=Entry, SSS=Steady-state satisfactory, 
SSU=Steady-state unsatisfactory, Ctls=Controls), Hb genotypes (HbSS, HbSC, Ctls), 
sexes (M=males, F= females), gPCs (genotypic principal components), and cell 
counts (RBCs=red blood cell counts, WBCs=white blood cell counts). The 3way-FU 
effect is between EvsFUvsCtls, and the 6-wasy ClinCategory comparison is between 
SCD patients: AvsEvsSSSvsSSU. These results were obtained from an analysis of 
covariance (ANCOVA, FDR 1%) of the discovery, replication and combined datasets 
I and II and accounts for sex and total blood cell counts (RBC and WBC). 
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D.2.3 Replication of differential gene expression among SCD participants 
 
 To evaluate if we could replicate the patterns of differential gene expression 
observed in the discovery phase, we performed the analyses described above on the 
replication group (n=154) and the combined datasets (combined dataset I and II). We 
observed similar results, with high correlation between discovery and replication 
phase principal component scores of all genes (Figure D.2.5). Unsupervised analysis 
identified similar clustering by Hb genotype and SCD severity score (SV). Forty five 
percent (45.2%) and 6.9% of the variance in the first three ePCs was explained by 
Hb genotype and clinical status (Table D.2.1), respectively. Thirty one percent (31%) 
and 10% of the variance in the first three ePCs was explained by Hb genotype and 
clinical category (Table D.2.2), respectively. When only SCD patients were included, 
Hb genotype and the follow-up effect explained 28.8% and 12.1% of the variance in 
the first three ePCs, respectively; while Hb genotype and clinical category explained 
31% and 10% of the variance in the first three ePCs, respectively (Table D.2.1 and 
D.2.2). The magnitude and significance of differentially expressed probes for the 
clinical status, clinical category and Hb genotype effects were highly consistent in 
both replication and discovery phases (Figure D.2.6 and Figure D.2.7).  
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Figure D.2.5 Correlation PCA between phases. 
Pearson correlation of Principal Components (PC) scores for each gene in the discovery (set 1), and replication phases (set 2). 
PCA of the gene expression data was performed for the discovery and replication. Principal component scores of all genes for each 
phase were contrasted. This analysis shows high correlation between discovery and replication phases. The correlations are shown 
for the first three ePCs; in G) ePC1, H) ePC2, and I) ePC3. Set 1= discovery phase, while set2 = replication phase.  
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Figure D.2.6. Volcano plots for ClinStauts effect. 
Volcano plots of differentially expressed probes from ANCOVA (FDR 1%) in 
discovery, replication, and combined data sets for the clinical status effect (E vs FU 
vs Ctls). Volcano plots showing significance (y-axis, -log10 p-value) vs log2 fold 
change (x-axis) of all probes analyzed in the contrasts between SCD follow-up and 
controls using the discovery (A-C), replication (D-F), and combined I dataset (G-I). 
Probes that are differentially expressed at FDR 1% are above the dotted red line. 
Correlation of gene expression fold change differences in the discovery and 
replication phases for all probes that are differentially expressed in the contrasts 
CvsE (J), CvsFU (K), and EvsFU (L) are shown. Correlations between the discovery 
and replication phases are significant (p<0.001). 
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Figure D.2.7. Volcano plots for ClinCat effect. 
A) Volcano plots showing significance (y-axis, -log10 p-value) vs log2 fold change (x-
axis) of all probes analyzed in the contrasts between SCD clinical categories and 
controls using the combined dataset. Probes that are differentially expressed at 
Bonferroni significance (p <1.75x 10-6) and at FDR 1% are colored in red and blue, 
respectively. B) Correlation between fold change differences in the discovery and 
replication phases for the set of differentially expressed probes between each of the 
SCD clinical categories (A, E, SSS, SSU) and the controls (Ctls). In red are probes 
that are differentially expressed only in the discovery phase; in blue are probes that 
are differentially expressed only in the replication phase; in purple are probes that are 
differentially expressed for both phases; in black are probes that are not differentially 
expressed in either phase. All correlations between the discovery and replication 
phases are significant (p<0.001). 
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D.2.3.1 Gene expression signatures associated with SCD clinical status 
 
Next, we focused on 160 SCD HbSS patients and 56 controls (combined data 
set II, n=216) to characterize the transcriptional signatures associated with SCD 
clinical status and follow-up considering only the HbSS group and the controls. HbSC 
individuals were excluded from this analysis given their small sample size relative to 
the HbSS group. SCD patients undergoing an acute event were also excluded to 
focus on the steady state of the disease. An ANCOVA (FDR 1%) of this dataset 
accounting for sex and cell counts revealed that over seven thousand probes were 
significantly differentially expressed (1% FDR) for the  clinical status effect 
(EvsFUvsCtls) and 739 probes were differentially expressed between SCD patients 
for the follow-up effect (EvsFU; Table D.2.3). The effect of clinical status is visually 
shown in a heat map generated using a 2-way hierarchical clustering of per-group 
mean expression levels of differentially expressed probes (Figure D.2.8).  
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Figure D.2.8 Gene expression signatures associated with ClinStatus.  
A) Venn diagram of the 7002 differentially expressed probes for the 3-way clinical status effect in the combined data set II. 739 
probes are uniquely differentially expressed for the follow-up effect (EvsFU) for SCD patients. B) Two-way hierarchical clustering of 
the mean expression levels for the 7002 differentially expressed probes in the combined data set II for each group of patients (E, 
FU, Ctls) is shown. Mean expression from this class of genes cluster controls from SCD entry and follow-up patients. 
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D.2.4 Identification of biologically relevant pathways in SCD  
In order to identify biological pathways subject to the effects of differential 
expression associated with SCD clinical status and clinical categories, Gene Set 
Enrichment Analysis (GSEA) [137] was performed using the differentially expressed 
genes in the discovery, replication and combined datasets (I, II).  
In order to identify sets of genes that differentiated SCD patients who took part 
in the follow-up program from SCD patients at entry and from controls, GSEA for the 
clinical status effect was performed using combined data set II, where we focused on 
the follow-up effect in HbSS patients. The results are shown in Figure D.2.9. A strong 
activation of biological pathways previously reported to be associated with SCD [43], 
pathways associated with lymphocyte development, stress (glucocorticoid and 
hypoxia related therapies), and uncontrolled cell growth is observed for the CvsE and 
CvsFU contrasts. Many of these pathways are also activated in the clinical course of 
SCD follow-up (EvsFU contrast).  
The 739 probes that uniquely differentiate the E from FU patients (the follow-
up effect; Figure D.2.8) were tested for significant overlap with genes belonging to 
pathways in the GSEA. A significant overlap was found in genes that were up-
regulated in B-lymphocytes expressing phosphotylated CD5 
(Gary_CD5_Targets_UP). This pathway most likely also plays a role in the clinical 
course of SCD follow-up. 
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Figure D.2.9 GSEA for ClinStatus effect. 
Gene Set Enrichment Analysis (GSEA) was performed for each contrast clinical 
status effect using the combined dataset II. This analysis identified biological 
pathways and sets of individual genes that are significantly enriched (Benjamini-
Hochberg-adjusted P < 0.05) in each contrast. Selection of the most distinctive 
significantly enriched pathways between entry and follow-up groups is shown. Cells 
are coloured by their respective Normalized Enrichment Scores for a given contrast. 
 
 131 
The GSEA results for the clinical category effect (Figure D.2.10) show a strong 
inflammatory response signature in the Acute patients driven by an enrichment in 
myeloid lineage, complement and coagulation cascade, interferon-inducible and 
inflammation pathways. The signature observed in SSU patients highlights a strong 
activation of platelets. Pathways associated with B- and T-cell stimulation, as well as 
metabolism-related pathways are upregulated in E and SSS patients.  
GSEA results for the discovery and replication phases are shown in Appendix 
VIII. The GSEA results in the discovery and replication phases are correlated (Figure 
D.2.11) and are similar to those in the combined data sets.  
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Figure D.2.10 GSEA for ClinCat effect. 
Gene Set Enrichment Analysis (GSEA) was performed for each clinical category 
versus controls contrast using the combined dataset I. This analysis identified 
biological pathways and sets of individual genes that are significantly enriched in 
each contrast. Only pathways and modules significantly enriched (Benjamini-
Hochberg-adjusted P < 0.05) from at least one contrast are shown. Colours in the 
heat map indicate the enrichment score relative to the controls. 
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Figure D.2.11. Correlation of GSEA between phases. 
Spearman correlations of NES for significant GSEA pathways (FDR =0.05) for the 
discovery and replication phases in at least one clinical category contrast. Gene set 
enrichment analysis (GSEA) was performed for contrasts of differentially expressed 
probes between SCD clinical categories (A, E, SSS, SSU) versus controls (C) for the 
discovery (phase 1) and replication (phase 2) phases. All pairwise clinical category 
comparisons from both phases are contrasted to each other in the following way: for 
each contrast, correlation of normalized enrichment scores (NES) of the genes from 
the pathways that are enriched in at least one comparison is tested.  These plots 
show a high degree of correlation observed for these contrasts with the majority of 
the genes showing the trend of direction in gene expression differentiation.       
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D.3. TRANSCRIPTIONAL BIOMARKERS OF SCD CLINICAL SEVERITY 
 136 
D.3.1 Identification of transcriptional biomarkers of SCD clinical categories 
Patients with SCD suffer a wide variety of disease complications [10]. The 
incidence of most clinical complications in SCD varies markedly both with time in the 
same individual and between different individuals. Meaningful biomarkers for SCD 
would be useful in the management of SCD complications. Recently, blood 
transcriptional profiling has been successfully used to predict disease pathogenesis 
in tuberculosis, infections, and tumour progression [58,59,60]. Through the 
identification of aberrant gene expression, it is possible to identify individuals who are 
susceptible to disease and to predict their outcome.  
To identify transcriptional biomarkers for clinical categories, discriminant analysis 
was performed using the full gene expression dataset (28,595 probes).  Individuals in 
the discovery phase were used as a “training set”. This analysis revealed 14 probes 
that differentiate clinical category with 97% accuracy (p<0.0001, Figure D.3.1). Since 
these 14 genes discriminated SSU patients with only 89% accuracy and since the 
canonical values for each SSS and SSU patients overlapped (Appendix IX), an 
additional discriminant analysis was performed on a sub-set of the discovery phase 
that included only SSS and SSU patients (n=37). Five additional probes that 
differentiated these two clinical categories with 100% accuracy were included (Figure 
D.3.1). Using the 5 additional probes and the original 14 probes made a final set of 
19 probes to be tested in the replication phase individuals (“test set”) for accuracy in 
predicting clinical category. Overall, these 19 biomarkers predicted clinical category 
with 80.1% accuracy (p<0.0001, Figure D.3.1) in the replication phase. “Leave-one-
out“ cross validation of the 19 biomarkers was performed using combined dataset I 
(n=311). Since a quantitative outcome variable is required, we used the severity 
score of each participant. In Figure D.3.2, the linear regression of this prediction is 
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shown to be significant (p<0.0001) and explained 70% of the variance. The mean 
and standard deviation of each clinical category’s severity score is also shown in 
Figure D.3.2.  
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Figure D.3.1 Transcriptional biomarkers for SCD clinical categories.  
A) Discriminant analysis performed on individuals in the discovery phase using 
28,595 expressed probes identified 14 probes that distinguish clinical categories with 
97% accuracy (p<0.0001). An additional discriminant analysis including only SSS 
and SSU SCD patients (n=37) from the discovery phase identified 5 extra probes that 
distinguished between SSS and SSU clinical categories with 100% accuracy. Using 
these 19 probes, we were able to predict clinical category in the replication phase 
individuals with 80% accuracy (p<0.0001).  B) Two way hierarchical clustering 
analysis of the 311 SCD patients and controls using the nineteen biomarkers 
clustered individuals by clinical category.   
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Figure D.3.2 Leave-one-out cross validation for 19 biomarkers 
A) Leave-one-out cross validation was performed in the combined dataset I using 
gene expression levels for the 19 transcriptional biomarkers to predict the severity 
score for each patient. A plot of the 311 individuals’ predicted (y-axis) vs true (x-axis) 
severity score values is shown. The linear regression was estimated (red line) and 
shown to be significant (p<0.0001) and explains 70% of the variation. The 95% 
intervals are shown in green. B) The mean and standard deviation values for the 
severity score for each clinical category show a progressively higher (worse) severity 
score for Entry, SSS, SSU, and A SCD patients. 
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 D.3.2 Identification of transcriptional biomarkers for SCD patient progression  
 
Since we are ultimately interested in identifying patients who are 
unsatisfactory even after follow-up, an additional discriminant anaysis was performed 
including only SSS and SSU SCD patients. This resulted in 38 SCD patients in the 
training set (20 SSS patients and 18 SSU patients), and 42 SCD patients in the test 
set (22 SSS patients and 20 SSU patients). A discriminant analysis on the training 
set, using the entire gene expression data (28,628 expressed probes), identified 3 
probes for genes GCAT, CD79A, NUCKS1 that discriminated SSS from SSU patients 
with 100% accuracy (Figure D.3.3 below). These probes were 74% accurate in 
discriminating patients in the test set (Figure D.3.3). Leave-one-out cross validation 
was performed to predict each patients severity score based on the 3 gene 
expression levels. The linear regression was significant (p=0.0001), but explained a 
small proportion of the variance (R2=0.17)  (Figure D.3.4).  
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Figure D.3.3 Discriminant analysis for SSS and SSU patients. 
Discriminant analysis performed on training set (n=38) identified 3 probes that 
discriminate between SCD patients that were in SSS or SSU condition with 100% 
accuracy. These 3 probes discriminated SSS from SSU patients with 74% accuracy 
in the test set (n=42). The receiver operating curve (ROC), illustrates that the results 
are perfect in the training set and above the diagonal in the test set, which represents 
good classification (better than random).  
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 Figure D.3.4 Leave-one-out cross validation using 3 biomarkers. 
Leave-one-out cross validation using the 3 probe gene expression level’s predicted 
the severity score for the 42 SCD patients. The actual severity score (x axis) is 
plotted against the predicted severity score (y axis) and a regression line was fit 
(p=0.0001), although the variance explained is negligible (r2= 0.17). The mean 
severity score for the SSS and SSU patients was calculated.    
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D.4. THE GENETIC REGULATION OF GENE EXPRESSION VARIATION IN SCD 
PATIENTS 
 145 
D.4.1 The genetic architecture of transcript abundance in SCD 
 The genetic architecture of transcript abundance in SCD was investigated 
through genome-wide association analysis of gene expression traits in SCD patients 
and controls. Two models tested for association between SNP genotype and gene 
expression traits: model 1 accounted for SCD Clinical Status and model 2 accounted 
for SCD Clinical Category. Both models also accounted for blood cell counts (RBC 
and WBC), and sex (see Table D.4.1 and the Methods). 
 Given the high degrees of correlation in the results of gene expression analyses 
for the discovery and replication phases, and to increase mapping power, we 
performed the analysis by combining the datasets. Subsets of the combined 
datasets, for which both gene expression and genotypic data were available, were 
used. Model 1 (that accounted for Clinical status) used a subset of combined data set 
II and had a sample size of n=173 (120 not acute HbSS SCD patients and 53 
controls). Model 2 (that accounted for Clinical category) used a subset of combined 
data set I and had a sample size of n=263 (205 SCD patients and 58 controls).  
 The expression data for the combined datasets were re-normalized in order to 
minimize potential batch effects. This resulted in a final set of 19,431 probes tested in 
model 1 and 18,890 probes tested in model 2. Marker properties were also re-
calculated for the combined data sets and quality control checks were applied. After 
filtering by marker properties, 560,675 SNP genotypes were used in model 1 and 
568,921 SNP genotypes in model 2. Multiple regression analyses were run and 
Bonferroni correction for multiple testing was applied.  
Since 560,675 SNPs were tested for association with 19,431 probes in model 
1, a genome-wide Bonferroni threshold for distal-associations corresponds to 
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0.05/(19,431 probes x 560,675 SNP) = 4.59 × 10-12. For local associations, a 
Bonferroni threshold corresponds to 0.05/(19,431 probes x 200 SNPs) = 1.28 x 10-08 
considering an average number of 200 SNPs tested against each probe.  
Since 568,921 SNPs were tested for association with 18,890 probes in model 
2, a genome-wide Bonferroni threshold for distal-associations corresponds to 
0.05/(18,890 probes x 568,921  SNP) = 4.65 × 10-12. For local associations, a 
Bonferroni threshold corresponds to 0.05/(18,890 probes x 200 SNPs) = 1.32 x 10-08 
considering an average number of 200 SNPs tested against each probe.  
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Table D.4.1 eSNP models and results. 
Description of eSNP models and their results. For each model, different data sets were included, as well as different variables: 
(SNP, ClinStatus = SCD Clinical Status, Blood counts (RBC, WBC), Sex, ClinCat=SCD Clinical Category), and interaction effects). 
The thresholds needed to reach a significant p value for local and distal eSNP associations were calculated using a Bonferonni 
threshold. The final number of significant peak associations (Assoc) are indicated for each model, with the corresponding number of 
local and distal eSNP associations.  
 
 
* For each eSNP model (Model), a specific data set (Data set), number of individuals (n), and variables (Variables) were included. 
The number of SNPs and probes that were tested in each of the corresponding models are indicated, with the corresponding 
Bonferroni corrected p-value thresholds for local (pval local) and distal (pval distal) associations. Based on these thresholds, the 
final number of significant associations are indicated (Assoc), broken down by the number of local and distal associations. 
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 Model 1 identified three hundred and ninety genome-wide significant peak SNP-
probe (eSNP) associations. This corresponded to 371 local and 19 distal effects. See 
Figure D.4.1 for an illustration of Model 1 eSNP associations.  
 Model 2 identified five hundred and eighty-eight genome-wide significant peak 
SNP-probe associations, corresponding to 579 local and 9 distal effects. See Figure 
D.4.2 for an illustration of Model 2 eSNP associations.  
 Seventy five percent of the local associations implicate SNPs located within 1 Mb 
from the probe coordinates. These associations explain on average 20% of the 
variance of transcript abundance (Figure D.4.3).   
 Of the genes that are differentially regulated among SCD clinical severities, many 
are also under genetic control. One hundred of the 390 significant eSNP associations 
in model 1 implicated genes that are differentially expressed for the 3-way SCD 
Clinical status effect. Eighty-nine out of the 588 significant eSNP associations in 
model 2 implicated genes that are differentially expressed for the 6-way SCD-clinical 
category effect. 
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Figure D.4.1 Model 1 eSNP results.  
a) Manhattan plot of 390 peak eSNP associations identified in Model 1. Each 
association is plotted by SNP chromosomal location on x-axis and by significance 
(negative –log10 p-values (NLP)) on the y-axis. The colour code refers to the SNP 
chromosomal location. Local associations are circled and were significant at a NLP 
value of 7.89 or more. Distal associations are in triangles and were significant at a 
NLP of 11.34 or more.   
b) Plot of eSNP associations based on their SNP (x-axis) and probe (y-axis) 
chromosomal location. Associations along the diagonal are local (the SNP- probe 
pair are located on same chromosome) and those off the diagonal are distal (the 
SNP-probe pair are located on different chromosomes). Out of the 390 peak 
associations, 371 are local, and 19 are distal.  
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Figure D.4.2 Model 2 eSNP results.  
Manhattan plot of peak 588 associations identified in Model 2. a) Each association is 
plotted by SNP chromosomal location on the x-axis and by significance (negative –
log10 p-values (NLP)) on the y-axis. The colour code refers to the SNP chromosomal 
location. Local associations are circled and were significant at a NLP value of 7.88 or 
more. Distal associations are in triangles and were significant at a NLP of 11.34 or 
more. 
b) Plot of eSNP associations based on their SNP (x-axis) and Probe (y-axis) 
chromosomal location. Those associations along the diagonal are local (the SNP-
probe pair are located on same chromosome) and those off the diagonal are distal 
(the SNP-probe pair are located on different chromosomes). Out of the 588 peak 
associations, 579 are local and 9 are distal.  
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Figure D.4.3 Variance explained by eSNP associations.  
Histogram of variance explained by each significant eSNP association in the basic 
model of the combined data set. The mean proportion of the variation (R2) that was 
explained by each eSNP association in the basic model for the combined data set 
was 0.1967 +/- 0.0494 s.d. The range was from 0.104–0.847.  
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 In model 1, five eSNP genes, GSTM1, GSTT1, HLA.DQB1, HLA.DRB1, and 
SLC14.A1, were associated with SCD phenotypes in previously reported association 
studies (Table D.4.2).  Model 2 identified eight genes, FCGR3B, GSTM1, GSTT1, 
HLA-DQB1, HLA-DRB1, HLA-G, HP, and SLC4A1 that are associated with an eSNP 
and which were previously associated with SCD phenotypes (Table D.4.3). 
 Almost half of the eSNP genes (150/390 eSNP genes in model 1; 229/527 eSNP 
genes in model 2) overlapped with previously reported significant eQTL associations 
(Table D.4.2 and D.4.3). Out of these, 58 in model 1 and 21 in model 2 were exact 
SNP-gene eSNP pairs. (Table D.4.2 and D.4.2.3).  
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Table D.4.2. Comparison of Model 1 eSNP results with literature. 
A) In model 1, 6 eSNP genes were also previously associated with SCD in candidate 
gene studies, with one of them being associated with an interaction. The list of 
candidate genes previously associated with SCD was obtained from the PhenoPedia  
database [39]. The overlap between genes that had previously been associated with 
SCD phenotypes and with genes under eSNP control identified in our study was 
obtained. The six genes’ and their respective references are shown in the table 
below, along with the probe-SNP pair that we identified. B) Overlap between genes 
associated with eSNPs in the present study and genes in previous eQTL studies that 
was obtained through the eQTL database (http://eqtl.uchicago.edu/cgi-
bin/gbrowse/eqtl/). The table shows the number of genes that were identified in our 
study to be associated with a SNP (detected at genome-wide significance) that 
overlap with genes reported in the twelve published studies. The comparison 
includes all genes reported in these studies that are significant at negaltive log10 p-
value (NLP) greater than 7 (the genome wide threshold for local eSNP associations). 
The total number of genes that overlapped is two hundred eighteen, one hundred 
and fifty of which are significant at NLP > 7. Sixty eight are exact gene-SNP pairs, 
with fifty eight being significant at NLP > 7. 
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A 
 
B 
 
* Ref: Dimas09_Tcell, Dimas09_Fibro, Dimas09_Lympho, Montgomery10_exo, Montgomery10_trans, 
Myers, Pickrell10_eQTL, Pickrell10_sQTL, Schadt, Stranger, Vayrieras, Zellers10 
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Table D.4.3 Comparison of Model 2 eSNP results with literature.  
A) In model 2, 8 eSNP genes were previously associated with SCD in candidate 
gene studies. The list of candidate genes associated with SCD was obtained from 
the PhenoPedia  database [39]. The eight genes’ and their respective references are 
shown in the table below, along with the probe-SNP pair that we identiifed. B) 
Overlap between genes associated with eSNPs in the present study and previous 
eQTL studies available through the eQTL database (http://eqtl.uchicago.edu/cgi-
bin/gbrowse/eqtl/). The table shows the number of genes in our study (detected at 
genome-wide significance) that overlap with genes reported in the twelve published 
studies indicated. The comparison was limited to genes reported in these studies at 
negative 10log p-value (NLP) greater than 7. The total number of genes that 
overlapped is two hundred twenty nine, twenty one of which are exact gene-SNP 
pairs. 
A 
eSNP Genes # Probes # Publications Reference 
FCGR3B 1 2 Taylor et al. 2002; 
Kuwano et al. 2000 
GSTM1 3 1 Silva et al. 2011 
GSTT1 1 1 Silva et al. 2011 
HLA-DQB1 1 4 Mahdi et al. 2009; Mahdi et al. 2008; 
Al-Ola et al. 2008; Tamouza et al. 2002 
HLA-DRB1 1 4 Mahdi et al. 2009; Mahdi et al. 2008; 
Al-Ola et al. 2008; Tamouza et al. 2002 
HLA-G 1 1 Cordero et al. 2009 
HP 1 3 Fowkes et al. 2006; Savy et al. 2010; Adekile et 
al. 2010 
SLC4A1 1 1 Ware et al. 2011 
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B 
Study Genes (eSNP association with NLP>7) 
Dimas09_Tcell 
Dimas09_Fibro 
Dimas09_Lympho 
Montgomery10_exon 
Montgomery10_transcript 
Myers 
Pickrell10_eQTL 
Pickrell10_sQTL 
Schadt 
Stranger 
Veyrieras_Pvalue 
Zeller10 
29 
20 
26 
27 
18 
9 
31 
12 
29 
91 
78 
283 
Total # unique overlapping eSNP genes  229 
Exact # of overlapping gene-SNP association 
pairs  
21 
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D.4.2 SNP-by-clinical severity interactions explain gene expression variability 
Differential expression analysis revealed thousands of genes differentially 
expressed between clinical severities: 7,002 probes were differentially expressed for 
the 3-way clinical status effect (EvsFuvsCtls); and 4,220 probes were differentially 
expressed for the 6-way clinical category effect (EvsSSSvsSSUvsA). In order to 
identify regulatory effects that are dependent on clinical severity for these genes, we 
tested for SNP-by-Clinical Status interaction effects and SNP-by-Clinical category 
interaction effects in Models 3 and 4 (See Table D.4.1 and the Methods for details). 
D.4.3 SNP-by-Clinical Status interactions  
Because testing for interaction effects between the control and SCD follow-up groups 
might be sensitive to differences in the representation of each group within each genotypic 
class, we applied an additional filter to the list of SNPs in these models and excluded all 
SNPs not in HWE in the clinical groups (FU, Entry, Controls). This resulted in a final number 
of 455,750 SNPs that were retained for eSNP analyses. Bonferroni correction for multiple 
testing in this analysis resulted in a genome-wide significance threshold of p = 0.05/(7,002 
probes x 200 SNPs) = 3.57 x 10-8 for local associations and p = 0.05/(7,002 probes x 
455,750 SNP) = 1.27 × 10-11 for distal-associations.  
Model 3 identified 13 significant interaction effects, eight of which remained genome-
wide significant after accounting for relatedness in the entire sample using a Q-K mixed 
model ([143], see Methods for details): ZSCAN12L1 (p-value = 4.26 x 10-10), C9ORF173 (p-
value = 8.94 x 10-9), CAPZA1 (p-value = 1.33 x 10-8), SVIL (p-value = 2.41 x 10-8), MEF2A 
(p-value = 1.69 x 10-8), and C1ORF88 (p-value = 5.42 x 10-9). These interactions are 
illustrated in Figures D.4.4 and in Appendix X. The significance of the associations before 
and after the QK-mixed model is shown in Table D.4. Figure D.4.3a-c shows three local 
eSNP interaction effects where higher expression levels of the corresponding gene in the 
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follow-up group relative to both the Entry group and the controls is driven by the minor allele 
of the eSNP in question. Figure D.4.3d-e shows two associations where the higher 
expression levels in the controls relative to SCD patients is observed only in the presence 
of the minor allele for the corresponding eSNP. A comprehensive circos plot illustrating the 
genome-wide significant SNP-probe associations from model 1 and the SNP-by-Clinical 
Status interaction effects from model 3 is shown in Figure D.4.5.  
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Figure D.4.4 Examples of significant SNP-by-clinical status interaction effects.  
Five SNP-by-clinical status interaction effects are shown. All are local eSNP 
interactions. Expression levels are shown on the y-axis, and SNP genotype on the x-
axis. The eSNP interaction involving gene zinc finger and SCAN domain containing 
12 pseudogene 1 (ZSCAN12L1) is shown in (A); chromosome 9 open reading frame 
173 (C9ORF173) is shown in (B); capping protein (actin filament) muscle Z-line, 
alpha 1 (CAPZA1) is shown in (C); supervillin (SVIL) is shown in (D); and myocyte 
enhancer factor 2A (MEF2A) is shown in (E). Linear regression for each group is 
plotted and colored: yellow for follow-up (FU), purple for entry (E), and red for 
controls (Ctls).  
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Table D.4.4 ClinStat interactions before and after accounting for relatedness. 
Significance (–log(10) p-values (NLP)) for eSNP interactions effects between 
SNPxclinical status associated with gene expression levels.  Using combined data 
set II, a multiple linear regression analysis was performed that accounted for Hb 
genotype, clinical status, sex and cell counts and tested for significant 
GenotypexClinical status interaction effects. 13 peak genome-wide significant 
SNPxClinical category interaction effects were identified all of which were local 
(Local_Distal column: local=0, distal =1). The negative log p values (NLP) for the 
interaction effects are shown before and after accounting for relatedness 
(NLP_before_QK; NLP_after_QK). 
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Figure D.4.5 Genetic regulation of gene expression in SCD patients.  
Circularised Manhattan plot showing genome-wide significant SNP-probe 
associations from the analysis of the combined II dataset. Bonferroni correction for 
multiple testing was applied to all of our analyses with a genome-wide significance 
threshold of p < 0.05/(19,431 probes x 200 SNPs) = 1.28 x 10-08 (NLP=7.89) for local 
associations in model 1 and p < 0.05/(19,431 probes x 560,675 SNP) = 4.59 × 10-12 
(NLP=11.34) for distal-associations in model 1; while model 3 thresholds were p < 
0.05/(7,002 probes x 200 SNPs) = 3.57. x 10-08 (NLP = 7.45) for local associations 
and p < 0.05/(7,002 probes x 455,750 SNP) = 1.57 × 10-11 (NLP=10.80) for distal-
associations. Distal associations are shown in the center of the plot. All genes 
involved in an interaction effect are differentially expressed and shown in red. eSNP 
genes from model 1 that are differentially expressed for the clinical status effect are 
shown in blue. The y-axis of the Manhattan plot indicates significance values (-log10 
p-values) for the local-associations. Genes under eSNP control that are not 
differentially expressed for the clinical status effect (in the ANCOVA analysis at FDR 
1%) are shown in black. 
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D.4.4 SNP-by-Clinical Category interactions  
Because testing for interaction effects between the SCD clinical categories might 
also be sensitive to differences in the representation of each group within each genotype 
class, we applied the additional filter to the list of SNPs in this model and excluded all SNPs 
not in HWE in each clinical category group (Entry, SSS, SSU, Acute). A final number of 
399,821 SNP were retained for eSNP analyses. Bonferroni correction for multiple testing in 
this analysis resulted in a genome-wide significance threshold of p = 0.05/(4,220 probes x 
200 SNPs) = 5.92 x 10-08 for local associations and p = 0.05/(4,220 probes x 399,821 SNP) 
= 2.96 × 10-11 for distal-associations. This analysis revealed 11 SNP-by-clinical category 
interaction effects (shown in Figure D.4.6 and Appendix XI), 2 of which remained genome-
wide significant after accounting for relatedness in the entire sample using a Q-K mixed 
model ([143], see Methods for details, Table D.4.5): HP and ZNF16). A comprehensive 
circos plot illustrates the genome-wide significant SNP-probe associations from model 2 
and the SNP-by-Clinical Category interaction effects from model 4 are shown in Figure 
D.4.7.  
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Table D.4.5 ClinCat interactions before and after accounting for relatedness. 
Significance (–log(10) p-values (NLP)) for eSNP interactions effects between 
SNPxclinical category associated with gene expression levels.  Using combined data 
set I, a multiple linear regression analysis was performed that accounted for Hb 
genotype, clinical category, sex and cell counts and tested for significant 
GenotypexClinical category interaction effects. 10 peak genome-wide significant 
SNPxClinical category interaction effects were identified: 8 local and 2 distal 
(Local_Distal column: local=0, distal =1). The negative log p values (NLP) for the 
interaction effects are shown before and after accounting for relatedness 
(NLP_before_QK; NLP_after_QK). 
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Figure D.4.6. Examples of significant SNP-by-clinical category interactions.  
Four eSNP interaction effects involve the genes PIK3CG, associated with SNP 
rs10224307 (NLP = 7.2, Figure D.4.6a), HP, associated with SNP rs742898 (NLP = 
13.6, Figure D.4.6b), AZIN1, associated with the SNP rs2460221 (NLP = 7.3, Figure 
D.4.6c), and OBFC1, associated with the SNP rs7080456 (NLP = 7.3, Figure D.4.6d). 
These examples show how the eSNP effect is dependent on SCD clinical category 
being most significant mainly in the the Acutes and in SSU patients relative to other 
categories. 
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Figure D.4.6 Genetic regulation of gene expression in SCD patients.  
Circularised Manhattan plot showing genome-wide significant SNP-probe 
associations from the analysis of the combined dataset. Bonferroni correction for 
multiple testing was applied to all of our analyses with a genome-wide significance 
threshold of p < 0.05/(18,890 probes x 200 SNPs) = 1.32 x 10-08 (NLP=7.89) for local 
associations in model 2 and p < 0.05/(18,890 probes x 568,921 SNP) = 4.65 × 10-12 
(NLP=11.33) for distal-associations in model 2; while model 4 thresholds were p < 
0.05/(4,220 probes x 200 SNPs) = 5.92. x 10-08 (NLP = 7.2) for local associations and 
p < 0.05/(4,220 probes x 399,821 SNP) = 2.96 × 10-11 (NLP=10.5) for distal-
associations. Distal associations are shown in the center of the plot. All genes 
involved in an interaction effect are differentially expressed and shown in red. eSNP 
genes from model 2 that are differentially expressed for the clinical category effect 
are shown in blue. The y-axis of the Manhattan plot indicates significance values (-
log10 p-values) for the local-associations. Genes under eSNP control that are not 
differentially expressed for the clinical category effect (in the ANCOVA analysis at 
FDR 1%) are shown in black.  
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D.5 POTENTIAL SCD DRUG TARGETS 
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 D.5.1 Drug target genes identified for SCD patients  
Methods of translating our genomic results into improved clinical care can be 
accomplished by identifying overlaps between genes that are important in the 
pathobiology of SCD and genes that are known drug targets. These lists provide 
candidate drugs that can be evaluated for their effectiveness in improving SCD 
outcome.  
In order to identify drug targets that are specific to the disease, we identified 
genes that control differential expression between SCD patients and controls. Basic 
eSNP analyses were run separately for 205 SCD patients and 58 controls which 
identified significant associations between SNP genotype and probe expression 
levels for each group. After stringent filtering based on quality control and marker 
properties (see Methods) and using Bonferroni thresholds, 368 eSNP associations 
remained for the SCD patients and 96 eSNP associations for the control group. This 
gave a final number of 303 eSNP associations unique to the SCD group (Figure 
D.5.1).  
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Figure D.5.1 Venn diagram for eSNP associations. 
The overlap of eSNP associations between SCD patients and controls. 
 
Thirty four out of the 368 eSNP genes in the SCD group were drug targets 
identified in the CTD database, whereas eleven out of the 96 eSNP genes in the 
control group were drug targets identified in the CTD database. Since we were 
interested in identifying genes that were potential drug targets for SCD patients, we 
restricted further investigations to the genes that were unique to the SCD group. Of 
the 34 drug targets in the SCD group, twenty five (25) were unique to the SCD group. 
Table D.5.1 gives a list of these 25 genes that are drug targets along with the 
corresponding drug. In Appendix XII, illustrations of the 25 eSNP associations are 
shown.   
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Table D.5.1 Twenty-five drug targets for SCD. 
The twenty five drug targets were significant eSNPs uniquely in the SCD patient 
group and not significant in the control group. The eSNP genes and corresponding 
drugs are listed in the table.  
 
 
Of the 25 eSNP drug targets, seven eSNP associations were dependent on 
clinical category (Figure D.5.2). This would suggest that SCD patients may not 
respond equally to medications that target these genes. 
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Figure D.5.2 Drug targets by ClinCat. 
Seven examples of eSNP associations plotted by clinical category. The linear 
regression for the associations are coloured by clinical category.  
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D.5.2 Drug target genes identified for SCD patients after follow-up 
 
We were particularly interested in identifying treatments to improve patients 
who do not improve in their condition even after follow-up. Gene expression analysis 
identified 824 probes (775 genes) that were differentially expressed between SSS 
and SSU patients after accounting for Hb genotype, clinical category, and sex 
(FDR=5%; see Appendix XIII). Of these differentially expressed genes, 86 were drug 
targets identified in the CTD database. Enrichment analysis for these 86 gene targets 
that are differentially expressed between SSS and SSU patients was performed 
using ToppFun (http://toppgene.cchmc.org/enrichment.jsp). Significant enrichment in 
the vitamin binding category for the GO Molecular Function category was identified 
(Appendix XIV). Enrichment in this pathway may suggest potential therapies that 
should be investigated for clinical use in improving SCD patients who are 
unsatisfactory.  
Examining which of the differentially expressed genes were under genetic 
control identified six of the 84 differentially expressed drug targets to be under 
genetic control (Table D.5.3). Of particular interest, 2 were involved in vitamin 
binding: peptidylglycine alpha-amidating mono-oxygenase (PAM) and glycine 
acetyltransferase (GCAT). In Figure D.5.4, the eSNP association for the 6 genes are 
illustrated. As can be seen, the eSNP association is dependent on the SCD clinical 
category.  
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 Table D.5.2 Six potential drug targets identified for SSS and SSU patients.  
The six potential drug targets are also eSNP genes that are differentially expressed 
between SSS and SSU patients. All associations are local eSNP associations (the 
SNP-probe pair are on the same chromosome). Significance for all associations were 
genome-wide after Bonferonni correction (negative log10 pvalue (NLP)). 
 
DrugTarget SNP SNP Chr Probe Probe Chr Local Distal NLP 
GCAT rs1894644 22 ILMN_1724437 22 Local 17.07 
NMNAT3 rs16849307 3 ILMN_1665123 3 Local 9.55 
PAM rs461605 5 ILMN_2313901 5 Local 13.44 
PARP3 rs323865 3 ILMN_2397954 3 Local 11.55 
PTGS2 rs689470 1 ILMN_2054297 1 Local 25.21 
PVALB rs4821544 22 ILMN_2069224 22 Local 30.62 
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Figure D.5.3. Six drug targets. 
The 6 eSNP associations that are drug targets are shown below and colored by 
clinical category (SSS in orange and SSU in purple). On the y-axis, gene expression 
levels are plotted, and SNP genotype is plotted on the x-axis.  
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E. DISCUSSION 
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E.1 Discussion of key results  
In 2008, SCD was recognised as a global health priority by the United Nations 
who urged African countries to adopt a national strategy to reduce under-5 mortality 
by improving care and treatment of this disorder. In order to improve treatment, basic 
research is required to increase our knowledge of the factors that contribute to the 
clinical heterogeneity of SCD. Characterising the sources of the clinical variation in 
SCD patients is important to improve therapies and follow-up programs, lessening 
the burden of the disease on the public health system. Despite many candidate gene 
and genome-wide association studies having been performed, the majority of the 
underlying genetic factors that contribute to the phenotypic variation in SCD remain 
unknown. In this study, we used the joint power of genotyping and gene expression 
analysis [96] to characterise the genomic architecture of SCD. Utilising this approach 
increased our chance of success. A summary of our key findings and their relavence 
is explained below. 
E.1.1 Discussion of General Results 
A total of 311 children from Cotonou, Benin, West Africa, were recruited for 
this study, including 250 pediatric SCD patients with either the HbSS or HbSC 
genotype sampled in two phases. A two-phase approach allowed us to replicate our 
findings. The distribution of SCD severity, clinical status, clinical categories, Hb 
genotypes, and sex were proportionate in both phases. Sixty one healthy siblings of 
SCD patients at the CPMI-NFED, with at least one normal hemoglobin allele, and of 
roughly equal age and proportions of sex were also recruited. Participants were 
distantly or not related with each other. Since cases and controls were not 
significantly related, the assumption of independent observations that is needed in 
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most association test statistics was not violated. Ethnicity analyses revealed that the 
sample was of similar ethnic background (based on gPCA), thus eliminating the 
possibility of population stratification.  
Three quarters of our controls were heterozygous HbAS and one quarter were 
homozygous HbAA. Few probes were differentially expressed between HbAA and 
HbAS individuals and none of the variance in the controls was explained by the 
genotype effect. For these reasons, we grouped HbAA and HbAS individuals and 
used them as a control sample. 
In addition to nucleic acids and clinical phenotypes, we obtained hematological 
samples from each participant in this study. In order to maximise relevancy and 
minimize redundancy, we only retained red blood cells (RBCs) and white blood cells 
(WBCs) in our analyses. Low RBC count can indicate anemia, an important 
determinant of SCD severity, and elevated WBC count can be an indication of 
infection and an acute event in SCD patients. Since cell count differences might 
confound differential expression, variability in RBCs and WBCs were included as 
covariates in the analyses. 
Although the Hb genotype is the primary determinant of SCD severity, we did 
not detect evidence for association between Hb genotype and clinical severity as 
measured by SCD clinical categories. Nor did we detect significant associations 
between β-SCD haplotypes and SCD clinical categories. Thus, other genetic factors, 
located in other genomic regions, or environmental factors must influence the clinical 
heterogeneity observed in our SCD sample.   
Previous studies identified that men with sickle cell disease experience more 
sickle cell crises than do women, but this was documented after puberty [12]. We did 
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not detect evidence for association between sex and clinical category, which is most 
likely explained by fact that the SCD patients in our sample are young and pre-
pubescent.  
E.1.2 The influence of SCD on the human transcriptome  
 
We first identified the extent of gene expression variation in SCD patients that 
is explained by clinical phenotypes and measured the magnitude and significance of 
gene expression differences between SCD patients in an initial discovery phase. The 
unsupervised analysis of gene expression profiles shows that SCD has substantial 
influence on the human transcriptome, explaining over a third of the total variance. 
Hb genotype, SCD clinical status and SCD clinical category are the main variables 
that influence this gene expression variation. The Hb genotype had the strongest 
effect on gene expression. However, significant differences in gene expression 
profiles between SCD patients (grouped according to clinical status or clinical 
category) and controls were also observed, with over a quarter of the transcriptome 
being differentially expressed. We replicated these findings in a replication cohort. 
The only other documented work on differential expression in SCD patients 
examined differences between HbSS patients and controls [43]. When we compare 
our results with the previously published results from this study by Jison et al. [43], 
we found an overlap of 207 genes that were differentially expressed. One-hundred 
and twelve (112) of these genes were differentially expressed in the discovery, the 
replication, and in Jison’s published data set (see Figure E.1.1). Differences in the 
number of differentially expressed genes identified in our study and in the one 
documented by Jison et al. may be due to the differences in sample size (17 
untreated SCD patients and 13 controls in the Jison study, as compared to our 
sample of 250 SCD patients and 61 controls). Furthermore, the analysis was 
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performed using different blood types (we used whole blood, while Jison restricted 
their analysis to peripheral blood mononuclear cells without platelets and 
neutrophils). Most likely some of the gene expression variation observed in our study 
is driven by the differences in the subsets of cell types that are present in whole 
blood. By using whole blood, we capture more variation; however, we haven’t 
measured cell specific effects. It is possible to infer cell specific effects by using the 
genomic signature of flow-cytometry-sorted immune cell types reported by Nakaya et 
al. [139] where cell type-specific modules are constructed based on the level of 
expression levels of each gene relative to each other cell type in the PBMC 
mixture[139]. We identified significant associations between SCD clinical category 
contrasts and the six cell type-specific expression profiles investigated (Appendix 
XV). Finally, the differences in technologies that were used in our study and Jison’s 
study (we used Illumina HT12v4 chips that captured over 47,000 probes while Jison 
used the HU95Av2 gene chip from Affymetrix containing only 12,626 sequenced 
genes) probably also played a role in differences in the results. However, in both our 
study and in Jison’s study, metabolism, cell-cycle regulation, angiogenesis, 
inflammation, antioxidant and stress response pathways were enriched from the 
genes that were differentially expressed.  
Other studies have examined gene expression differences in SCD, but these 
are not comparable to ours for various reasons. One study used gene expression to 
validate a protocol and did not analyse their data beyond the validation step [44]. The 
second study performed their analysis on microarray chips that captured miRNAs 
and not genes [45]. 
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Figure E.1.1 Comparison of gene expression results with literature. 
A) Venn diagram of the gene that were differentially expressed between HbSS SCD 
patients and controls in the discovery, replication and combined data set I. B) Venn 
diagram of the genes that were differentially expressed between HbSS SCD patients 
and controls in the discovery and replication data sets and in the published results 
from Jison et al [43].  
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E.1.3 Biological pathways implicated in SCD 
 
Gene Set Enrichment Analysis (GSEA) [137] procedures allowed us to identify 
and replicate biological pathways involved in the clinical course of SCD. Strong 
modulation of the transcriptome implicates pathways affecting core hematological cell 
functions.  
Enrichment of genes that were uniquely differentiated between the entry and 
follow-up patients identified a significant up-regulation in B-lymphocytes expressing 
phosphorylated CD5, B-cell Receptor Signalling and upstream regulation of B-cells 
by PAX5. PAX5 expression has been shown to increase the quantity and the 
commitment of B cells [145]. These observations reflect perturbed cellular profiles in 
the entry groups and more stable profiles after clinical follow-up. Furthermore, 
markers of mitosis, cell cycle and DNA synthesis were identified in the analysis on 
combined data set II and likely suggest a more stable state of blood cells in the 
follow-up group in general. The strong interferon related signature also suggests a 
more perturbed and potentially more pathogenic state of blood cells prior to clinical 
follow-up. The over expression of activated B lymphocyte markers in the entry group 
tends to point in that same direction. Previous studies have shown that changes in B 
cell function occurs during vaso-occlusive crisis (VOC) in patients with SCD [146]. 
Thus, follow-up of SCD patients may act on these pathways.  
The results of the GSEA that was performed on differentially expressed genes 
between clinical categories identified a strong inflammatory response signature in 
acute patients, which is consistent with the processes induced during SCD crises 
events such as vaso-occlusive crisis (VOC) [147]. Activation of platelets in SSU 
patients suggests their implication in SCD complications that contribute to the 
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unsatisfactory clinical state, including SCD vasculopathy [148] and hemolysis-
associated pulmonary hypertension [149]. Pathways associated with B- and T-cell 
stimulation, as well as metabolism-related pathways that are up-regulated in entry 
patients and SSS patients suggest an induction of these processes and a role in 
driving a clinically satisfactory state. Several of these pathways were previously 
shown to be differentially regulated between SCD steady-state patients and controls 
[43].  
E.1.4 Genetic control of gene expression in SCD  
 
To the best of my knowledge, this is the first study to characterize the genetic 
architecture of transcript abundance in SCD patients and controls. Hundreds of peak 
eSNP associations were identified. Three hundred and ninety genome-wide 
significant peak SNP-probe associations were identified in model 1 (which includes 
the Clinical Status effect) and five hundred and eighty-eight in model 2 (which 
includes the clinical category effect). This corresponds to 371 local and 19 distal 
effects in model 1, and 579 local and 9 distal effects in model 2. These associations 
explain on average 20% of the variance in transcript abundance in either model. 
Seventy five percent of the local associations implicate SNPs located within 1 Mb 
from the probe coordinates.  
Of the genes that are differentially regulated among SCD clinical severities, 
many are also under genetic control. One hundred (100) of the 390 significant eSNP 
associations in model 1 implicated genes that are differentially expressed for the 3-
way SCD clinical status effect. Eighty-nine out of the 588 significant eSNP 
associations implicated genes that are differentially expressed for the 6-way SCD-
clinical category effect. We identified an overlap between eSNP genes identified in 
this study and with genes previously identified to be associated with SCD severity. 
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Five genes that are associated with an eSNP in model 1 were previously associated 
with SCD phenotypes in reported association studies, and eight genes which are 
associated with an eSNP in model 2 were previously associated with SCD 
phenotypes. We observed significant overlap between the eSNP associations for 
SCD and those reported in 12 published eQTL studies of various tissues including 
peripheral blood and its derivatives. Almost half of the eSNP genes in model 1 
(150/390 eSNP genes) are replicated. Of these, 58 were exact SNP-gene eSNP 
pairs.  Almost half of the eSNP genes in model 2 (229/527 eSNP genes) were also 
replicated. Of these, 21 were exact SNP-gene eSNP pairs (21/229). The other 
associations in our datasets are either novel, of weaker strength in the 12 eQTL 
studies or might be reported in other published studies.  
E.1.5 Identification of interaction effects  
 
Using the joint analysis of gene expression and genotyping, we identified 
statistical SNP-by-clinical severity interaction effects that were associated with log-
transformed gene expression levels. The regression coefficients for the interaction 
terms represent the change in the genotypic differences in mean log-transformed 
expression levels. 
Differential gene expression analyses identified thousands of genes 
differentially expressed between SCD patients with different clinical severities 
(Clinical Status or Clinical Category). We restricted the eSNP interaction analyses to 
this class of genes: for the SNP-by-Clinical status effect (model 3) we tested for 
significant interactions with 7002 genes; for the SNP-by-Clinical category effect 
(model 4) we tested for significant interactions with 4220 genes. In doing so, we 
identified regulatory eSNP effects that are dependent on clinical status or clinical 
category for genes that are differentially expressed.  
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Model 3, which included the SNP-by-Clinical status effect, identified 13 
significant statistical interaction effects, eight of which remained genome-wide 
significant after accounting for relatedness in the entire sample using a Q-K mixed 
model [143]. The genes that are associated with these 8 interactions are 
ZSCAN12L1 (p-value = 4.26 x 10-10), C9ORF173 (p-value = 8.94 x 10-9), CAPZA1 (p-
value = 1.33 x 10-8), SVIL (p-value = 2.41 x 10-8), MEF2A (p-value = 1.69 x 10-8), and 
C1ORF88 (p-value = 5.42 x 10-9). Three of these eSNP interaction effects have 
higher expression levels of the corresponding gene (ZSCAN12L1, C9ORF173, and 
CAPZA1)  in the follow-up group relative to both the Entry group and the controls, 
and this is driven by the minor allele of the eSNP in question. These interactions may 
help explain why certain SCD patients do not improve even after following a rigorous 
clinical care program. Two of the remaining eSNP interactions have higher 
expression levels in the controls relative to SCD patients being observed only in the 
presence of the minor allele for the corresponding eSNP (SVIL, and MEF2A). The 
genes associated with the clinical status interactions have not been documented to 
have a link with SCD, and thus the biological mechanism of how they would affect the 
clinical progression of the disease is not known. Nonetheless, it remains of interest to 
identify if these interactions can provide a basis for targeted interventions for SCD 
patients with a worse clinical phenotype.  
In model 4, 11 significant SNP-by-Clinical category effects were identified that 
are dependent on clinical category, 2 of which remained genome-wide significant 
after accounting for relatedness in the entire sample using a Q-K mixed model [143]. 
The genes that are associated with the 11 interactions are ATP6VOA2, AZIN1, 
NOP56, OBFC1, PBX1, PIK3CG, PREPL, PTPRA, TMEM180, ZNF716 (NLP = 
11.60) , HP (NLP =12.2). Seven of these interaction effects involve genes that have 
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been associated with disease, with three local and one distal effect implicating genes 
known to be involved in biological processes implicated in the pathobiology of SCD. 
A description of these effects and how they may impact SCD is given below.  
 A local eQTL interaction involved the PIK3CG gene. This gene has recently 
been associated with platelet aggregation [150], and in another GWAS, a SNP 
associated with PIK3CG transcript levels and protein function was associated with 
mean platelet volume and platelet count [151]. Furthermore, mice lacking the 
PIK3CG gene have profound defects in platelet aggregation [152]. Our finding 
suggests that SSU and acute patients that are homozygote for the major allele at 
SNP rs10224307 would have a higher risk of platelet aggregation given the higher 
level of expression.  
 A distal eSNP interaction effect implicates expression of the haptoglobin (HP) 
gene, which is responsible for binding free hemoglobin during intravascular 
hemolysis [153]. Transcription of this gene is elevated in SCD acute patients, and 
this pattern is dependent on the genotype of the rs742898 SNP located in a predicted 
enhancer region of the SERPINA3 gene. Clustering analysis of gene expression 
profiles have previously shown that HP and SERPINA3 cluster together with other 
acute phase response genes, suggesting shared regulatory mechanisms [154]. We 
do not detect a local eSNP association between rs742898 SNP and SERPINA3 gene 
expression. This is perhaps not surprising, however, since SERPINA3 is expressed 
predominantly in hepatocytes [155], and not in the tissue (blood) that was sampled. 
Another explanation for not detecting a significant local eSNP association is that the 
SERPINA3 gene is alternatively spliced, and the probe used in this study captured 
the effects from the non-differentially expressed transcript [156].  
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Interestingly, a common polymorphism in the HP gene, characterized by 
alleles Hp-1 and Hp-2, gives rise to structurally and functionally distinct haptoglobin 
protein phenotypes, with Hp-2 previously associated with the prevalence of 
infections, autoimmune diseases, and other disorders [153]. A model described by 
Quaye [153] proposed a  role of HP in the inflammatory response (Figure E.1.2) with 
the different Hp alleles activating different immune responses (TH1 and TH2). We 
characterized the HP haplotypic structure in the Acute patients (see the Appendix 
XVI for more details on the method) and demonstrated that the interaction effect is 
driven by the association of the Hp-2 heterozygote patients with higher levels of HP 
expression resulting in the eSNP association being significant in the Acute patients 
who have the Hp-2 allele, but not in those with the Hp-1 allele.  
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Figure E.1.2 Model of the role of HP in the inflammatory response.  
Signals from stressed cells induce expression of IL-6/8 which in turn induce 
expression of Hp. The strong haemoglobin (Hb) binding, antioxidant, and anti-
inflammatory activity of Hp-1 lead to a TH2 dominant cytokine expression. The 
corollary holds for the Hp-2 phenotype. ROS: reactive oxygen species.   
 
*Adapted from Quaye, 2008 [153]. 
 The AZIN1 gene was previously associated with risk of liver fibrosis 
progression in patients with chronic hepatitis C virus (HCV) infection at the 
polymorphic site rs62522600 [157,158,159]. This AZIN1 SNP leads to enhanced 
generation of a novel alternative splice form of AZIN1, causing differences in gene 
expression and progression of liver fibrosis [160]. Interestingly, SCD patients have a 
higher risk of HCV morbidity [161,162]. Here we show that Acute and SSU SCD 
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patients with the major allele for SNP rs2460221 have higher gene expression levels 
for the AZIN1 gene.  
 In a recent GWAS [163], SNP rs4387287, located close to the OBFC1 gene, 
was associated with leukocyte telomere length (LTL). In another GWAS, a key gene 
involved in telomere length (TNKS) was associated with sickle cell anemia severity 
[164]. Here we give supportive evidence of regulation of OBFC1 gene expression, in 
Acute SCD patients, as being dependent on genotypic class for the SNP rs7080456. 
 Three additional genes associated with an interaction effect have been 
associated with other diseases: NOP56 has been associated with spinocerebellar 
ataxia [165], PBX1, pre-b cell leukemia homeobox 1, is associated with cancer [166], 
type 2 diabetes [167,168,169], and congenital heart defects [170], and PTPRA has 
been associated with Alzheimer disease [171] and schizophrenia [172].  
Using eQTL approaches, transcriptional genotype-by-environment interactions 
have previously been reported in humans [173,174,175,176] but mostly using in vitro 
systems. Here we report a demonstration of the existence of these effects in vivo in 
SCD. The genes implicated in these interactions show differential eSNP effects 
depending on SCD follow-up status or clinical category. These interactions show how 
the genetic control of gene expression through allelic variation is likely to impact 
processes modulating SCD severity, as well as in clinical follow-up programs.   
E.2 Implications for public health 
 
The genomic results generated for this project can be applied to potentially 
improve public health programs and care for SCD patients. Using the gene 
expression data, we provide candidate biomarkers for clinical progression. Examining 
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genes that control differential gene expression led to identification of potential drug 
targets. 
E.2.1 Identification of transcriptional biomarkers of SCD severity 
  
 Up till now, efforts to identify biomarkers of clinical progression in SCD has 
had limited success [57,61,62,63,64,177]. Although more than 100 different blood 
and urine biomarkers have been described in SCD, the clinical value of these 
biomarkers has not been assessed for clinical validity and utility. Ultimately, the goal 
is to identify biomarkers that are specific, independent indicators of future risk. New 
technologies, such as transcriptomics and proteomics, has lead to the discovery of 
more useful molecules [178] in other diseases. While mRNAs do not play as 
important a role in cellular functions as proteins, there are a number of reasons why 
one might prefer doing mRNA expression profiling. The principal reason is that 
nucleic acids (such as mRNAs) are much easier to separate, purify, detect and 
quantify than proteins for the purpose of biomarkers. Also since protein 
concentrations can be considered to be integrals of mRNA concentrations, the 
variability at the mRNA level is usually larger than the variability at the protein level. 
Nonetheless, mRNA and protein expression measurements complement each other 
and thus both types of biomarkers are useful.  
Here, using discriminant analysis, we identify transcriptional biomarkers of 
SCD clinical categories. We identified 19 transcriptional biomarkers of SCD clinical 
categories in a discovery phase. Using these 19 biomarkers, we were able to classify 
SCD patients with 80.1% accuracy in the replication phase.  
Identifying patients who do not improve in their clinical state even after 
intensive clinical follow-up is of clinical importance. We performed an additional 
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discriminant analysis to identify transcriptional biomarkers for SCD patients who were 
steady-state satisfactory (SSS) or unsatisfactory (SSU). These patients are followed 
for at least one year before a diagnosis is made on their condition. Predicting which 
SCD patients will follow an unsatisfactory clinical course could help in order to tailor 
follow-up programs by providing a pro-active treatment plan for these patients who 
would be expected to otherwise be unsatisfactory. We identified 3 additional 
transcriptional biomarkers for this group of patients. These biomarkers warrant 
further investigation for their diagnostic and prognostic utility in SCD.  
E.2.2 Potential drug targets for SCD  
 
Finding a widely available cure for SCD remains a challenge. Bone marrow 
transplant offers the only potential cure for SCD. But finding a donor is difficult and 
the procedure has serious risks associated with it, including death. As a result, 
treatment for SCD is usually aimed at avoiding crises, relieving symptoms and 
preventing complications. Even under the best of conditions, an individual afflicted 
with SCD can only expect to live to their mid-forties or early fifties. SCD patients need 
to visit their physician regularly to check their red blood cell count and monitor their 
health. Treatments may include medications to reduce pain and prevent 
complications, blood transfusions and supplemental oxygen.  
The only disease-modifying drug that is presently available and that is 
approved by the FDA is hydroxyurea (HU). When taken daily, HU reduces the 
frequency of painful crises and may reduce the need for blood transfusions. HU 
stimulates production of fetal hemoglobin, which helps prevent the formation of sickle 
cells. However, HU reduces white blood cell counts, red blood cell counts, and 
platelets, thus increasing the risk of infections, anemia, and hemorhage. Also, there 
is some concern that long-term use of this drug may cause tumours or leukemia. 
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Other side effects include nausea, gastro-intestinal upset, skin, nail and hair 
modifications, infertility, and teratogenic effects. The drug is not beneficial for 
everyone and is not FDA approved for young children or pregnant woman. Hence, 
there is an urgent need for more specific and effective treatments for SCD.  
 The standard approach to developing therapeutics involves testing many 
thousands of compounds against a known target in order to identify a lead 
compound. The lead compound can then be further refined in silico and in vitro 
before heading into the lengthy and costly clinical trials pipeline. This process, which 
consists of phases I, II, III and IV before final drug approval, involves 10-17 years of 
drug development from target identification until FDA approval, with only a 10% 
probability of success [179]. As a result, the pharmaceutical industry spends an 
average of about 1.2 billion US dollars to bring each new drug to market [180]. There 
is also a high risk associated with de novo drugs due to unforeseen adverse side 
effects, as seen in the case of Thalidomide, a drug used to treat morning sickness 
which resulted in devastating birth defects [181].  
A novel approach to therapeutic development is to identify new applications for 
drugs that have already been approved, or have successfully completed phase I 
clinical trials [182]. This process of “drug repositioning” aims not to develop drugs de 
novo, but associate existing therapeutics with new phenotypes. Using our genomics 
results, we attempted to identify candidate drug targets that could be investigated for 
repurposing in SCD. Of course, due diligence must be used in all instances of drugs 
repositioning hypotheses. As pointed out by Wang and Zhang [183], the lack of 
knowledge on directionality could lead to potential side effects rather than therapeutic 
benefits. Our eSNP data allowed us to identify genes that are modulated by known 
drugs, and identify if they are modulated in the correct direction with respect to the 
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pathology of SCD. In this study, we identify twenty-five drug target genes that are 
genetically controlled uniquely in the SCD patient group. Among these drug target 
genes, some have differential gene expression levels between SCD clinical 
categories that are dependent on SNP genotype. This suggests that not all SCD 
patients would react in the same way to these medications. Nonetheless, these 
genes are interesting candidates for drug repurposing in SCD.  
For example, CASP4, which we identified as a drug target, is an interesting 
candidate for SCD because of its link with folic acid. Folic acid is a form of the water-
soluble vitamin B9. Its biologically active forms (tetrahydrofolate and others) are 
essential for nucleotide biosynthesis and homocysteine remethylation. Studies 
performed by Novakovic et al. [184] showed that when folic acid was restricted, 
CASP4 had increased gene expression levels. We showed that SCD patients in an 
acute or steady-state unsatisfactory condition and who have the minor allele for SNP 
rs1712840 have higher gene expression levels of CASP4 mRNA. Our results 
suggest that acute and SSU SCD patients with the minor allele for SNP rs1712840 
would potentially benefit from folic acid supplementation. By supplementing them 
with folic acid, these patients might have their CASP4 gene expression levels 
reduced to similar, “normal”, values as non-acute SCD patients and controls. Of 
course, before exposing any patient to a drug, further analysis in vitro and in animal 
models would be required to test the effects of folic acid on SCD clinical 
improvement. Also, protein levels should be examined since post-translational 
modification might influence the results.   
Identifying improved therapies for SCD patients who are not experiencing an 
acute event yet remain unsatisfactory over the course of a follow-up program 
(steady-state unsatisfactory patients) is a major concern. By comparing the genes 
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that are differentially expressed between steady-state satisfactory and unsatisfactory 
patients with genes in a public pharmacogenetic database, and evaluating which 
ones are under genetic control, we suggest candidate drug target genes that control 
differential expression between steady-state satisfactory and unsatisfactory SCD 
patients. One of the candidate drug target genes is prostaglandin-endoperoxide 
synthase (PTGS), also known as cyclooxygenase. PTGS is the key enzyme in 
prostaglandin biosynthesis, and acts both as a dioxygenase and as a peroxidase 
[185]. There are two isozymes of PTGS: a constitutive PTGS1 and an inducible 
PTGS2, which differ in their regulation of expression and tissue distribution. This 
gene encodes the inducible isozyme. It is regulated by specific stimulatory events, 
suggesting that it is responsible for the prostanoid biosynthesis involved in 
inflammation and mitogenesis. PTGS2 is targeted by many drugs, including 
nonsteroidal anti-inflammatory drugs such as acetaminophen and ibuprofen, and 
morphine. We see in our analysis that SSU patients with the minor allele for 
rs689470 have increased expression of PTGS2. If any of the potential drugs that 
target PTGS2 could decrease its expression in patients with the minor allele for 
rs689470 and who are in SSU condition, it may improve their clinical outcome.  
 Interestingly, genes that are differentially expressed between SSS and SSU 
patients and that are drug targets are enriched in vitamin binding properties. Since 
the late 1980’s, under-nutrition has been considered as a serious complication of 
SCD that should be treated as part of standard clinical care of SCD patients. Growing 
interest in the nutritional problems of SCD has created a body of literature from 
researchers seeking nutritional alternatives as a means of decreasing morbidity and 
improving quality of life among SCD patients. In general, SCD patients are lacking in 
nutrients for adequate growth and development, despite apparently sufficient dietary 
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intakes. Although there is still a paucity of data supporting the efficacy of 
macronutrient supplementation, it is becoming clearer that recommended dietary 
allowances (RDAs) for the general population are insufficient for sickle cell patients. 
A similar shortage is likely to be true for micronutrient deficiencies, including recent 
findings of vitamin D deficiency that may be associated with incomplete ossification 
and bone disease, which are known complications of SCD. By identifying drug target 
genes enriched in vitamin binding properties, our results suggest that nutrient 
supplementation should be investigated for use in SCD clinical care prgrams.  
There are many pharmacogenetic databases, each with different 
characteristics. CTD promotes understanding about the effects of chemicals on 
human health by integrating data from curated scientific literature to describe 
chemical interactions with genes and proteins, and associations between diseases 
and chemicals, and diseases and genes. We compared the drug target genes that 
we identified in CTD database with drug target genes in another open source 
database: DrugBank (http://www.drugbank.ca/extractor). The DrugBank database is 
a unique bioinformatics and cheminformatics resource that combines detailed drug 
data with comprehensive drug target information. The database contains 6825 drug 
entries including 1541 FDA-approved small molecule drugs, 150 FDA-approved 
biotech (protein/peptide) drugs, 86 nutraceuticals and 5082 experimental drugs. In 
this study, we identified that 13 of the 30 eSNP genes that were drug targets 
identified in CTD, were also drug targets in DrugBank. Interestingly, the drug target 
genes we identified in DrugBank have multiple drugs that are associated with them 
(Appendix XIX). These additional drugs need to also be investigated in their 
repurposing use in SCD.  
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E.3 Strengths and Limitations 
  
 A two-phase genome-wide study was performed employing a case-control 
design to examine the association of gene expression profiles with SCD clinical 
severity and its genetic control. Using the joint power of genotyping and gene 
expression analysis to characterise the genomic architecture of SCD, we increased 
our chance of successfully capturing associated variants, since genotypes have 
effects on transcript abundance, on average, one order of magnitude stronger than 
disease phenotypes [92]. Genome-wide thresholds were used for all analyses to 
control for false positives. By using gPCA, the cases and controls were confirmed to 
be of similar ethnic backgrounds, making the problem of population stratification 
inherent in the case-control design irrelevant. Using a two phase design in our study 
enabled us to replicate our findings. In the replication phase, all analyses were with 
(i) the same phenotype, (ii) and the same markers/variables to assess the 
associations in a second sample. Replication studies generally require investigations 
in separate populations that are independent of the original study. We recruited 
individuals that were part of the same large cohort for which the discovery sample 
was obtained, but stratified by date of sampling. Since selection factors that might 
have influenced any disparities between the two sample phases were similar and not 
under the influence of the exposure in this study (i.e. genotypes), it is believed that it 
is unlikely that any selection factor would significantly influence the validity of these 
findings. Other biases, if any, are likely to be minimal since (i) the clinical 
demographic features and characteristics of the patients in either sample were 
similar; and (ii) the allele frequencies of the SNPs were similar for the control 
samples in the discovery and in the replication phase. This suggests that both 
samples were generated from the same source population.  
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 We performed our experiments in vivo. Using in vitro experiments, 
environmental factors can be controlled; however, in vivo experiments capture the 
complexity of intercellular signaling and interactions that are present in real life. By 
sampling diseased and healthy individuals in vivo, we captured the complexity of 
SCD and were able to characterise biological pathways involved in the development 
of the disease.    
 Non-genetic exposures that are known risk factors for the disease may 
confound genetic associations, if: (i) the genotype influences the exposure, or (ii) if 
the gene being studied is in LD (or in association) with another gene that influences 
the exposure. Although environmental factors are unlikely to confound genetic 
associations, it is possible for this to happen if they are associated with disease and 
genotype. If any of the environmental factors that are associated with SCD severity 
are also associated with allele frequencies for the SNPs associated with gene 
expression, then confounding would be a problem. In order to examine the possibility 
of confounding due to malaria (a possible environmental source of confounding), we 
compared the list of genes that were under genetic control in both SCD and in 
malaria [115]. More than 50% of the genes were significant in only the SCD 
analyses, and not significant in the malaria analyses (Appendix XVII). Importantly, 
when we examined the parasitemia levels in our SCD sample, only 11 patients had 
detectable parasitemia levels. Thus, exposure to malaria is not likely to confound our 
association results. Other non-genetic factors may possibly confound the SNP 
associations we detected in SCD; however, this is unlikely.  
 Gene expression data can be influenced by many in vivo and in vitro factors 
and counfound results. Multiple environmental and biological factors, such as age, 
sex, cell count differences, life style, geography, and place of residence, nutrition, 
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time of sampling, treatment type, and disease status are known to influence 
differential expression between individuals. In SCD, all of these factors likely impact 
gene expression since they are risk factors for clinical severity. Gene expression 
heterogeneity is also caused by systematic bias from sources such as technical 
variation in microarray manufacturing [186]. We attempted to reduce the differences 
due to technical variation to the best of our capabilities. Using TEMPUS tubes, blood 
samples are lysed and stabilised instantly, reducing heterogeneity due to RNA 
degradation. Sample collection was done in a standardised manner following pre-
established protocols. The time of sampling was performed within a 3 hours window 
(between 9am and noon). Shipment of samples was done on dry ice to ensure 
limited degradation and a reliable company that allowed us to track the samples was 
employed. RNA was extracted from samples in a systematic manner and an attempt 
to randomize the order that this was done was made so as not to create batch 
effects. We also randomised our cDNA synthesis step, the order the samples were 
put on the microarray chips, and the scanning procedure. All of these steps were 
performed to limit the technical variation that can cause confounding in gene 
expression studies.  
We measured the impact of age, sex, genetic principal components (a proxy to 
ethnicity), cell count differences (RBCs and WBCs), and SCD clinical severity in the 
gene expression analysis. Nonetheless, many other non-measured variables could 
influence our results. It is possible to identify these hidden expression artifacts that 
arise from technical, demographic, genetic and environmental factors through 
surrogate variable analysis [187]. We used surrogate variable (SV) analysis to 
identify and estimate the amount of expression heterogeneity in our data and 
identified 11 significant SVs. However, these SVs did not substantially alter the level 
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of gene expression differentiation for the clinical status effect after including them in 
the ANCOVA model. Based on the high correlation (Appendix XX) between the 
significance levels in ANCOVA models before and after accounting for SVs, the 
results from the gene expression analysis are believed to be robust and are not 
significantly influenced by non-accounted for variables.  
Although we did not match cases with controls, we did sample cases and 
controls with similar sex and age distributions. Furthermore, we accounted for age 
and sex in our models. Cell count differences can also confound gene expression 
studies if they are associated with both the disease outcome and with gene 
expression differences. Much debate exists on whether cell count differences should 
be accounted for in gene expression studies. By including RBC and WBC counts in 
our regression models, we accounted for cell count differences in this study. Thus, 
gene expression differences and genetic associations that are independent of the 
differences in cell counts were identified.  
 
 The possibility of selection bias influencing the results was considered. In 
particular, prevalence-incidence bias, which can occur in studies where 
asymptomatic, mild, clinically resolved, or fatal cases are inadvertently excluded from 
the case group because the selected cases were examined some time after the 
disease process has already begun (i.e. looking at prevalent versus incident cases) 
[188], was considered. It is possible that some patients who had SCD were missed, 
either because they died from the disease before being sampled, or because they 
were mild cases and not followed at the Center. If the distribution of the alleles in 
these cases were different from those that took part in the study, selection bias would 
influence the results. Since there is still no newborn screening for SCD in Benin, it is 
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possible that very severe cases were missed. However, since individuals suspected 
of having SCD are referred to the Center due to it being the only SCD Center in the 
country, and since clinical symptoms do not generally appear until about 2 years of 
age because infants are protected by the production of HbF, severe SCD are not 
believed to be missing from our sample. Since all SCD patients eventually undergo 
crises, even those with mild clinical symptoms will eventually require treatment or be 
seen in clinic. Thus, these mild patients are most likely included in our sample as 
well.  
 Information bias, i.e. genotyping and transcription profiling accuracy, needs to 
be considered for all genetic and genomic studies, including this one. In using 
Illumina’s chip assays, only high quality data was retained. The accuracy for 
Illumina’s OmniExpress and HT-12 Bead Chips are very high (>99.8% [189], >99.6 
[125], respectively). As genotyping was carried out blinded to the case/control status 
of the subject, misclassification bias if any, was also likely to be minimal.  
 There is a possibility that misclassification occurred when SCD patients were 
assigned a clinical category. Patients were assigned a clinical category by an 
experienced hematologist who based his decision on a patient’s clinical course, 
complete blood counts and hematological analysis, weight gain, and overall well-
being after several months of follow-up. It is possible that misclassification occurred if 
any of the methods used to generate the data used for the clinician’s decision were 
inaccurate. If this were to happen, bias would be introduced in our results. If the 
extent of the misclassification were different between the cases and controls, or if it 
occurred more often in one clinical category as compared to another, than differential 
misclassification would occur, and could lead to under- or over-estimation of the true 
magnitude of the measure of association. If the degree of misclassification was 
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uniform between groups, then non-differential misclassification would occur. The 
non-differential misclassification would result in a dilution of the measure of 
association and bias the results toward the null value of no association. Since all 
patients followed the same protocol, if there was misclassification, it was probably 
non-differential. Also, if other variables that were not taken into account by the 
clinician affected a patient’s clinical category assignment, than error would be 
introduced into our results.  
 
 Genetic factors that are known to influence hemoglobin, such as HbF, might 
influence our results. However, this is not believed to be an issue since we performed 
a globin reduction step, removing expressed globin genes, thereby ensuring that 
signal from other genetic factors that might influence severity beyond the known 
effects of globin genes could be detected. Also, insignificant population structure and 
limited genetic differentiation was observed when 541 genotypes from a subset of 
genes known to influence hemoglobin levels (alpha-globin, G6PD, BCL11A, MYB 
and HBS1L) were used in PCA and gene-wise Fst analysis performed to estimate the 
magnitude of genetic differentiation among the SCD clinical categories, or between 
SCD patients and controls. Thus, confounding due to these genes is unlikely or 
limited.  
Other genetic factors or processes not captured by the Illumina chip might 
account for variability in gene expression, including, but not limited to SNPs not 
captured by the chip, gene methylation, alternative splicing, or protein modification. If 
any of these factors are involved in the clinical heterogeneity observed in SCD 
patients, our study would not have captured these effects.  
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Gene-environment interactions are a fundamental component of the genetic 
architecture of complex traits and disease susceptibility. Interaction effects have 
been recognized for many years to play an important part in disease etiology. Gene-
environment interactions add sources of complexity in the mapping relationship 
between genotype and phenotype. As such, a need for research strategies that 
embrace, rather than ignore, this complexity are needed. In the current study, we 
addressed this necessity by implementing SNP-by-SCD clinical severity terms in our 
linear regression models to identify statistical transcriptional interaction effects. One 
of the major limitations for traditional GWAS in identifying interaction effects has been 
a lack of power. Sample size requirements for GWA GxE studies can be enormous. 
A useful rule-of-thumb is that detection of an interaction requires at least four times 
the sample size than for detecting a main effect of comparable magnitude [190]. By 
using an integrative approach that capitalizes on the advantage of using of gene 
expression as an endophenotype, we gain sufficient power to identify significant 
statistical transcriptional interaction effects.  
It has been argued that formal statistical tests for GxE interactions are less 
useful than biological or public health interactions [191]. Statistical tests depend on 
the trait measurement scale, and may yield little insight even after formal rejection or 
retention of the statistical model, since multiple (potentially contradictory) biological 
models can be consistent with the same statistical model for interaction [191]. This 
may be true, however, as some of the interactions we identified involve genes 
previously reported to be linked to SCD, it is conceivable that they contribute to the 
clinical heterogeneity observed in SCD. This needs to be confirmed. These 
interaction effects should be tested in other SCD populations to validate their 
contribution to the clinical heterogeneity. For example, the PIK3CG gene should be 
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evaluated for its contribution in platelet aggregation in unsatisfactory SCD patients 
who have the minor allele at SNP rs10224307. Acute inflammation should be 
demonstrated to occur in patients who have elevated HP gene expression, who have 
the Hp-2 allele, and who have the minor allele of rs742898 SNP in the SERPINA3 
gene. Furthermore, the mechanism of HP gene expression regulation by rs742898 
SNP in SERPINA3 gene should also be evaluated. SCD patients with liver cirhosis 
and chronic Hepatitis C infection should be tested for association with AZIN1 gene 
expression conditional on SNP rs2460221. And finally, telomere lengths should be 
tested for association with OBFC1 gene expression conditional on SNP rs7080456 
alleles in SCD patients with different clinical severities. All of the interactions we have 
identified should be further investigated as potential markers for identifying targeted 
programs or treatments for SCD patients.  
We suggest potential transcriptional biomarkers of SCD clinical categories. 
One of the limitations of our analysis is that we do not test these biomarkers at 
predicting clinical category in patients after follow-up. Ultimately, these biomarkers 
need to be tested for their accuracy in predicting a patient’s clinical category in 
longitudinal studies. The potential misclassification of a patient’s clinical category 
may limit our results. A more precise method of measuring clinical severity might 
improve the accuracy in identifying clinically useful biomarkers.   
Since we have not included information on patient treatment and nutritional 
status in the drug target analysis, it is possible that our results are biased. In order to 
better evaluate the usefulness of these drugs, additional medical information, 
including patients’ medications and their nutritional intake would be needed. 
Furthermore, and as explained above, in vitro and in vivo testing on animal models 
would be needed to validate the proper modulation and evaluate the clinical 
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usefulness, as well as potential side effects, of a candidate drug before exposing 
SCD patients to it.  
E.4 Public Health Relevance: importance, recommendations, and 
generalisability.  
 
Our study has provided valuable genomic information to the scientific 
community on SCD. In order to meet the United Nations goal of reducing under five 
mortality caused by SCD, newborn screening programs are being integrated into 
many countries, followed by the need to improve clinical care. By studying the 
underlying genomic factors associated with SCD severity, we contribute to this effort. 
Additional studies will need to confirm our results and test the applications of these 
findings for SCD treatment and care.  
 Here, we have identified gene expression profiles associated with SCD 
severity. Utilizing transcriptomic information has improved our understanding of the 
molecular basis of this disease and has provided candidate transcriptional 
biomarkers of SCD progression. We have also identified many novel genetic loci that 
control gene expression traits in SCD, as well as interaction effects. Gene-by-
environment (GxE) interactions are worth studying in public health for several 
reasons [109]. They can shed light on fundamental biological mechanisms. They can 
also be important for risk prediction and for evaluating the benefit of changes in 
modifiable environmental exposures or environmental regulations. From a public 
health perspective, the idea of personalized recommendations and targeted 
interventions has been questioned, as the overall benefit of small changes at a 
population level may be larger than that of large changes in high-risk individual [192]. 
Personalised recommendations, however, may be considered reasonable for cases 
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when an exposure has a null or negative effect in one genotype group and a 
protective effect in another genotype group [193]. Personalised recommendations 
can also be applied in pharmacogenetics, where different patients will react 
differently to drugs depending on their genetic “make-up”. Thus interactions can help 
in choosing the best treatment for an individual to optimize therapy based on genetic 
predisposition [109]. The interactions we have identified should be considered when 
prescribing medications for SCD patients. Further investigation in novel treatments 
that take into consideration the drug targets we identified should be performed. 
Before being put into general practice, there is a need for additional studies to 
validate our findings, including clinical trials to test the suggested drugs on SCD 
clinical improvement, as previously stated.  
The SCD patients recruited for this study were sampled in order to obtain a 
representative sample of the clinical heterogeneity of SCD observed at the National 
SCD Center. Since there is only one SCD Center in Benin, and it is believed that all 
Benin SCD patients are referred to it (personal communications with MC Rahimy), 
our findings can be generalised to the pediatric SCD population of Benin. In order to 
generalise our findings to all SCD patients, additional studies are needed to validate 
our results in other populations (including adults SCD patients), environmental 
settings and contexts.  
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F. CONCLUSIONS AND FUTURE DIRECTIONS 
Using a two-stage case-control sampling design, we identified and replicated a 
strong transcriptional signature for clinical state in SCD patients that implicates core 
biological pathways involved in the pathobiology of the disease. Identifying specific 
biological pathways involved in SCD will help make more personalized strategies for 
diagnosing, treating and preventing SCD possible. By improving our understanding of 
these pathways, we can open the door to new improvements.  We have provided a 
genome-wide picture of regulatory variation in vivo in SCD patients and highlighted 
genotype-by-clinical severity interaction effects that likely contribute to the clinical 
heterogeneity observed in SCD patients. Using gene expression data, we suggest 
potential transcriptional biomarkers for SCD patients. These results further our 
understanding of the transcriptional events occurring in SCD patients and their 
genetic regulatory control and may guide future treatment strategies and biomarker 
development. The genetic and transcriptional markers reported in this study can 
potentially guide follow-up programs. Furthermore, the markers detected in whole 
blood, a readily and ethically accessible source of biological material in children, will 
particularly be useful in populations where the disease is most prevalent.  
F.1 Validation of results in different environments and cohorts 
 
It remains important to validate our results in different environments using 
other SCD cohorts. However, since there is no universal method of measuring SCD 
severity, a major challenge will be in comparing our results based on SCD clinical 
categories with other methods of measuring clinical severity.  
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Recently, we have obtained ethics approval to examine the genomics of SCD 
in pediatric patients in Montreal. Of particular interest will be cell specific gene 
expression analyses, which will allow the dissection of specific gene expression 
profiles according to the isolated cell type. We also propose to use even deeper 
transcription profiling based on NextGen sequencing of RNA to complement the 
microarray-based transcription profiling. This Montreal cohort will allow us to test for 
replication of the results we identified in the African study, but it will also allow us to 
investigate environmental and geographical factors that impact SCD severity.  
F.2 Application of  SCD genomics to other disease: malaria 
 
Sickle cell disease carriers (HbAS) are protected against clinical malaria 
caused by infection with the most virulent species, Plasmodium falciparum [194]. Our 
current knowledge of the molecular mechanisms for this protection is not completely 
understood. However, a recent in vitro study [195] showed that human microRNAs 
were found to be more abundant in SCD patients and carriers than in individuals with 
normal HbAA. It was demonstrated that these microRNAs translocate and 
incorporate into the P.falciparum parasite mRNAs, thereby inhibiting translation of 
mRNA and reducing the parasite’s growth [195]. These results warrant further 
investigation in vivo and offer exciting possibilities for a novel malaria treatment. 
Applying genomic information identified in SCD to other diseases, such as malaria, 
may offer novel treatments beyond SCD patients.  
F.3 Challenges of integrating genomics into African SCD public health 
programs  
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The effective development and application of genomics-based interventions to 
improve public health in developing countries has become a priority that is 
recognised by the World Health Organization (WHO) [196]. The current trend is for 
countries in the developing world to collaborate with more developed nations (north-
south collaborations). Nonetheless, there is also an increase in the trend toward 
south-south collaborations, in which developing countries pool their limited 
resources, help each other and learn from each other’s experience. Integrating 
results from genomic research in SCD public health practice remains challenging. In 
2010, the WHO issued a report on SCD that provided specific targets and goals for 
sub-Saharan African countries to adopt a national strategy for comprehensive care 
and treatment of this disorder [3]. By 2015, 25% of countries should have a plan, and 
by 2020, 50% of countries should have a plan to reduce under-5 mortality by 30%. 
Such bold targets will not be met easily, however. Active north-south and south-south 
partnerships that prioritize research will be required to help sub-Saharan African 
countries develop robust sickle cell strategies that can provide diagnosis, 
management, and treatment of SCD [197]. Active research partnerships can begin 
with networking, as supported by the new Global Sickle Cell Disease Network [198]. 
Recent initiatives by the National Institutes of Health, the UK’s Medical Research 
Council, and other academic and non-profit organizations in drug repurposing has 
great possibilities of translating genomic information in order to find new indications 
for old drugs and/or failed candidates [199]. Applying drug repurposing to SCD could 
identify novel treatments at a fraction of the cost than traditional drug discovery 
studies can offer. Through similar novel initiatives, research projects that investigate 
and translate genomics studies will help improve the survival and quality of life of 
disadvantaged children with SCD wherever they live.  
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Appendix I: Genes associated with SCD 
 
Genes associated with Sickle Cell Anemia that are reported in Human genome 
epidemiology (HUGE). Genes are ranked by the evidence strength that was 
calculated based on the volume of different types of published literature in human 
genome epidemiology (data source: HUGE Literature Finder). The number of 
publications, genetic associations, and GWAS that were identified for each gene is 
indicated. 
Rank Gene Publications 
Genetic 
Associations GWAS 
1 HBB 55 33 0 
2 G6PD 11 9 0 
3 BCL11A 9 9 3 
4 UGT1A1 12 12 1 
5 MTHFR 12 9 1 
6 F5 9 8 1 
7 F2 9 7 1 
8 HBA1 9 9 0 
9 TNF 5 5 1 
10 ITGB3 4 4 1 
11 HBS1L 5 5 0 
12 HLA-DRB1 5 5 0 
13 MYB 5 5 0 
14 NOS3 5 5 0 
15 GP1BA 3 3 1 
16 APOE 3 3 1 
17 ITGA2 3 3 1 
18 VCAM1 3 3 1 
19 HLA-DQB1 4 4 0 
20 ACE 2 2 1 
21 FGB 2 2 1 
22 ITGA2B 2 2 1 
23 SERPINE1 2 2 1 
24 MBL2 4 3 0 
25 ANXA2 3 3 0 
26 HFE 3 3 0 
27 HP 3 3 0 
28 TGFBR3 3 3 0 
29 F7 1 1 1 
30 F8 1 1 1 
31 FGA 1 1 1 
32 GOLGB1 1 1 1 
33 OR51B5 1 1 1 
34 APOA1 1 1 1 
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35 ICAM1 1 1 1 
36 OR51B6 1 1 1 
37 ENPP1 1 1 1 
38 UGT1A10 1 1 1 
39 UGT1A8 1 1 1 
40 UGT1A6 1 1 1 
41 UGT1A3 1 1 1 
42 SELE 1 1 1 
43 SELL 1 1 1 
44 SELP 1 1 1 
45 THBD 1 1 1 
46 NPRL3 1 1 1 
47 KCNK6 1 1 1 
48 CCR5 2 2 0 
49 ADRB2 2 2 0 
50 CYP2D6 2 2 0 
51 F13A1 2 2 0 
52 ABO 2 2 0 
53 GSTM1 2 2 0 
54 GSTT1 2 2 0 
55 HBG2 2 2 0 
56 HLA-G 2 2 0 
57 HMOX1 2 2 0 
58 IL4R 2 2 0 
59 MYH9 2 2 0 
60 NOS2A 2 2 0 
61 BMP6 2 2 0 
62 APOL1 2 2 0 
63 FCGR2A 2 1 0 
64 FCGR3B 2 1 0 
65 KLF1 1 1 0 
66 ADCY9 1 1 0 
67 CCR2 1 1 0 
68 CYBA 1 1 0 
69 CYP2C19 1 1 0 
70 AGT 1 1 0 
71 EDN1 1 1 0 
72 FCGR3A 1 1 0 
73 DARC 1 1 0 
74 GPM6B 1 1 0 
75 GSTP1 1 1 0 
76 HBBP1 1 1 0 
77 HLA-A 1 1 0 
78 HLA-E 1 1 0 
79 APOB 1 1 0 
80 IFNG 1 1 0 
81 IGF1R 1 1 0 
82 IL8 1 1 0 
83 AQP1 1 1 0 
84 ITGAV 1 1 0 
85 ARG1 1 1 0 
86 ARG2 1 1 0 
87 LDLR 1 1 0 
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88 SMAD3 1 1 0 
89 SMAD6 1 1 0 
90 NOS1 1 1 0 
91 SAR1A 1 1 0 
92 RHCE 1 1 0 
93 CCL5 1 1 0 
94 BMP4 1 1 0 
95 SLC4A1 1 1 0 
96 SLC14A1 1 1 0 
97 BMPR1A 1 1 0 
98 BMPR2 1 1 0 
99 SOD2 1 1 0 
100 TRIM21 1 1 0 
101 TEK 1 1 0 
102 KLF10 1 1 0 
103 UGT2B7 1 1 0 
104 VEGFA 1 1 0 
105 SLC14A2 1 1 0 
106 SELI 1 1 0 
107 KL 1 1 0 
108 ACVRL1 1 1 0 
109 CD40LG 1 1 0 
110 TOX 1 1 0 
111 TNFRSF1A 1 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 227 
  
 
 
 
 
 
 
 
 
Appendix II : Copy of the Consent Form  
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FORMULAIRE DE CONSENTEMENT 
 
Titre de l'étude:  Intercations Génomiques et Environmentales de l’Anémie 
     Falciforme et du Paludisme en Afrique de l’Ouest. 
 
Personnes responsables: Philip Awadalla, PhD, U. of Montreal, CHU 
Sainte-Justine 
 Greg Gibson, PhD, U. of Queensland 
Chérif Rahimy, MD, PhD, l’Université d’Abomey-Calavi (UAC) au Bénin. 
Ambaliou Sanni, MD, l’Université d’Abomey-Calavi (UAC) au  Bénin 
 Michel Duval, MD, U. of Montreal, CHU 
Sainte-Justine  
 Nancy Robitaille, MD,U. of Montreal, CHU 
Sainte-Justine   
 
 
Source de financement: Cette recherche est financée par le Centre 
de recherche du CHU Sainte-Justine, Fonds de la recherche en sante de Quebec 
(FRSQ), The National Academies of Science and the Keck Foundation, The Human 
Frontiers in Science Program. 
 
Nom du patient:   
 
Votre enfant ou vous-même est atteint d’anémie falciforme (drépanocytose) et /ou 
malaria. Nous vous proposons de participer à une étude de recherche. 
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 L’éthique médicale et la loi exigent d’obtenir un consentement écrit avant 
d’entreprendre un procédé de recherche. 
 
L'étude ci-haut mentionnée est proposée par le CHU Sainte-Justine et l’Université 
d’Abomey-Calavi (UAC) au Bénin. Elle vous a été expliquée par le Dr ___________. 
 
Nous vous offrons de participer à un projet de recherche. La participation à l’étude 
implique un prélèvement de sang réalisé lors d’une visite au centre d’anémie 
falciforme. Ces projets de recherche sont menés seulement auprès de personnes qui 
acceptent d’y participer. Prenez le temps nécessaire pour évaluer ce document. Si 
vous le souhaitez, parlez-en avec votre famille et vos amis avant de prendre votre 
décision. 
 
Par souci de simplicité, dans le reste du document, le terme "vous" doit être compris 
comme « vous-même ou votre enfant », et le terme "je" doit être compris comme 
« moi-même ou mon enfant ».  
 
 
 
1. QUELLE EST LA NATURE DE L'ÉTUDE ? 
 
Pertinence de la recherche 
 
La drépanocytose, ou anémie falciforme, est due à la présence de différentes 
formes du gène de l’hémoglobine, notamment la forme  « S ».  
 
Toutes les personnes atteintes d’anémie falciforme ou drépanocytose, 
partageant la même forme S, ne sont pas malades de la même façon. Certaines 
sont très malades, d’autres beaucoup moins. Ces différences sont dues ; 
 
• Soit à d’autres gènes hérités des parents 
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• Soit à des facteurs d’environnement : lieu de vie, habitudes de vie, etc.  
 
Si on pouvait connaitre la cause de ces différences entres les personnes 
atteintes d’anémie falciforme ou drépanocytose, on pourrait adapter le 
traitement à chaque personne et même prévenir certaines complications.  
 
Il est bien connu que le gène de l’anémie falciforme ou drépanocytose confère 
une résistance au paludisme. Le paludisme est une maladie sévère, très 
fréquente en Afrique de l’Ouest. Il est causé par un parasite appelé Plasmodium 
falciparum, transmis par une piqûre de moustique.  
 
Objectifs de la recherche 
 
Notre premier objectif est de comprendre pourquoi il y a des différences de 
gravité entre deux personnes atteintes de drépanocytose ou anémie falciforme. 
Nous voulons identifier les déterminants génétiques et les facteurs 
environnementaux expliquant ces différences. 
 
Notre second objectif est de comprendre les liens entre les symptômes du 
paludisme, la quantité de parasites dans le sang et les facteurs génétiques et 
d’environnement. 
 
 
 
2. COMMENT SE DÉROULERA L'ÉTUDE ? 
 
Lors de votre visite au Centre d’anémie falciforme à Cotonou, Bénin, il vous 
sera prélevé 5 ml de sang. Ce prélèvement servira aux études génétiques. Les 
parents devront répondre à des questions sur l`histoire médicale de l`enfant. 
Cela nécessitera environ 15 minutes et se fera lors de la même visite au Centre. 
 
Identification des échantillons: La confidentialité des échantillons sera 
assurée en leur assignant un code spécifique. Ce code permettra de vous lier à 
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l'échantillon mais le décodage ne pourra se faire que par Chérif Rahimy, 
l’investigateur principal au Bénin, ou par une personne déléguée par ce dernier. 
Votre échantillon ne portera pas de nom et ne permettra pas de vous identifier 
directement. 
 
Autres recherches: En  signant ce formulaire, vous nous autorisez à conserver 
les échantillons non utilisés dans cette étude pour d'autres recherches sur la 
drépanocytose ou anémie falciforme ainsi que toutes autres maladies 
associées. Ces recherches seront approuvés par un comité d’éthique et 
pourraient impliquer l’envoi des échantillons à d’autres chercheurs, même à 
l’extérieur de notre institution. Les échantillons demeureront codés. Les 
échantillons seront conservés au Service d'hématologie-oncologie du CHU 
Sainte-Justine et gardés tout le temps que le service pourra en assurer la bonne 
gestion. 
 
Confidentialité et communication des résultats: Les résultats personnels 
des études ne vous seront pas divulgués directement, ni à votre médecin 
traitant à moins que ceux-ci aient une importance significative pour votre santé. 
Dans ce cas, les résultats seront communiqués à votre médecin qui vous 
informera et seront ensuite enregistrés dans votre dossier médical afin 
d’assurer un meilleur suivi médical. Vous pourrez communiquer avec l'équipe 
de recherche afin d'obtenir de l'information sur l'avancement des travaux ou les 
résultats généraux du projet de recherche. Par ailleurs, les résultats de cette 
étude pourront être publiés ou communiqués dans des congrès ou dans des 
articles scientifiques mais aucune information pouvant vous identifier ne sera 
dévoilée. L’équipe de recherche du CHU Sainte-Justine consultera le dossier 
médical de votre enfant pour obtenir les informations pertinentes à ce projet de 
recherche. Tous les renseignements obtenus dans le cadre de ce projet de 
recherche seront confidentiels, à moins d’une autorisation de votre part ou 
d’une exception de la loi. Les dossiers sous étude seront conservés au CHU 
Sainte-Justine sous la responsabilité du Dr. Philip Awadalla. La confidentialité 
de l’ordinateur est soigneusement gardée. Cependant, aux fins de vérifier la 
saine gestion de la recherche, il est possible qu’un délégué du Comité d’éthique 
de la recherche du CHU Sainte-Justine  ou un représentant des organismes 
subventionnaires consulte vos données de recherche et votre dossier médical. 
 
3. QUELS SONT LES AVANTAGES ET BÉNÉFICES ? 
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Il est difficile  de prédire si des bénéfices directs résulteront de ce programme 
de recherche.  Nous espérons que les connaissances acquises grâce à cette 
étude seront utiles dans l'avenir à l’amélioration du diagnostic et du traitement 
de la drépanocytose ou anémie falciforme et de la malaria. 
 
 
4. QUELS SONT LES INCONVÉNIENTS ET RISQUES ? 
 
Toute personne donnant de son sang encoure un risque de douleur, de 
saignement et d’ecchymose (bleu) au site d'introduction de l'aiguille ou un 
épisode d’étourdissement et d`évanouissement. Les soins appropriés seront 
pris pour éviter ces complications.  
 
5. QUELS SONT MES DROITS EN TANT QUE PARTICIPANT ? 
 
En signant ce formulaire de consentement, vous ne renoncez à aucun de vos 
droits prévus par la loi.  De plus, vous ne libérez pas les investigateurs de leur 
responsabilité légale et professionnelle advenant une situation qui vous 
causerait préjudice. 
 
Pour plus d'information concernant cette recherche, vous pouvez contacter M 
Chérif Rahimy, l’investigateur responsable au Bénin, au +229 21 30 72 42. 
Pour des informations regardant les droits des patients sous programme de 
recherche, vous pouvez contacter le commissaire local aux plaintes et à la 
qualité des services du CHU Sainte-Justine au 514-345-4749. 
 
6. Y A-T-IL UNE COMPENSATION PRÉVUE ? 
 
Aucune compensation n'est accordée pour votre participation à cette étude.   
 
Cette étude pourrait contribuer à la création de produits commerciaux, ou à la 
commercialisation plus large de produits existants, dont vous ne pourrez retirer 
aucun avantage financier. 
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 7. SUIS-JE LIBRE DE PARTICIPER À CETTE ÉTUDE ? 
 
Vous êtes totalement libre de participer ou non à cette étude.  Toute nouvelle 
connaissance susceptible de remettre en question votre participation vous sera 
communiquée.  Vous êtes  libre de vous retirer de ce programme de recherche, 
à tout moment, sans qu'aucun préjudice ne soit porté aux traitements 
subséquents.  Si vous vous retirez du programme de recherche, vos 
échantillons sanguins seront détruits. 
 
Un refus de participation n'implique aucune pénalité ou perte de certains 
bénéfices.  Vous êtes libre de recevoir les soins du médecin de votre choix à 
tout moment.  Si vous ne participez pas à l'étude ou si vous vous retirez, cela 
n'affectera pas la qualité des soins qui vous seront offerts. 
 
 
8. RENSEIGNEMENTS COMPLÉMENTAIRES  
 
Pour des renseignements plus complets sur la drépanocytose ou anémie 
falciforme, le Service d’hématologie-oncologie du CHU Sainte-Justine ou de 
l’Université d’Abomey-Calavi (UAC) au Bénin vous a remis un document 
d’information et reste à votre disposition pour répondre à toutes vos questions. 
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FORMULAIRE D'ADHÉSION ET SIGNATURES 
 
Protocole:  
 
On m’a expliqué la nature et le déroulement du projet de recherche. J’ai pris connaissance du 
formulaire de consentement et on m’en a remis un exemplaire. J’ai eu l’occasion de poser des 
questions auxquelles on a répondu. Après réflexion, j’accepte que mon enfant participe à ce 
projet de recherche. J’autorise l’équipe de recherche à consulter le dossier médical de mon 
enfant pour obtenir les informations pertinentes à ce projet.  
 
             
  
Nom du participant    Assentiment du participant capable de  
 Date 
(Lettres moulées)    comprendre la nature du projet 
      (signature) 
 
             
  
Nom du parent, tuteur pour  
participant de moins de 18 ans   Consentement  (signature)  
 Date 
(Lettres moulées) 
 
Assentiment verbal d’un participant incapable de signer mais capable de comprendre la nature 
de ce  
projet :  oui  non  
 
J’ai expliqué au participant et/ou à son parent/tuteur tous les aspects pertinents de la 
recherche et j’ai répondu aux questions qu’ils m’ont posées. Je leur ai indiqué que la 
participation au projet de recherche est libre et volontaire et que la participation peut être 
cessée en tout temps. 
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Nom de la personne qui a obtenu  (signature)     Date 
  
le consentement (Lettres moulées) 
     
Le projet de recherche doit être décrit au participant et/ou à son parent/tuteur ainsi que les 
modalités de la participation. Un membre de l’équipe de recherche doit répondre à leurs 
questions et doit leur expliquer que la participation au projet de recherche est libre et 
volontaire. L’équipe de recherche s’engage à respecter ce qui a été convenu dans le 
formulaire de consentement.  
       
             
  
Nom du chercheur responsable   (signature)    
 Date   
(Lettres moulées) 
  
 
Personnes ressources: 
- Dr Philip Awadalla 
- Dr Chérif Rahimy 
- Dr Nancy Robitaille 
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Appendix III : Blood collection procedure 
 
Protocol de Collecte d’Échantillons de Sang pour le Centre de Drépanocytose 
 
Matériel : 
Fiche de l’échantillon 
Formulaire de consentement 
Fiche de données cliniques 
Matériel de collecte de sang 
Marqueur indélébile 
Tube Tempus (Bleu) 
Tube EDTA (Violet) 
Porte-tubes 
Congélateur 
 
Procédure : 
 
1- Remplir le Formulaire de Consentement  
 
2- Remplir la Fiche de l’Échantillon 
 
3- Marquer le Numéro de l’Échantillon ainsi que la date et l’heure sur les tubes 
Tempus (Bleu) et EDTA (Violet). 
 
4- Procédez à la collecte d’échantillon de sang 
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 4- Collectez environ 3 ml de sang dans le tube Tempus 
(Bleu).  
 
Le tiret noir sur le tube indique le niveau 3 ml 
 
Mélangez bien le tube en l’inversant 25 fois 
 
Mettez le tube dans le porte-tubes. 
 
 
 
 
5- Collectez 1 ml de sang additionnel dans le tube EDTA 
(Violet).  
 
Mélangez bien le tube en l’inversant 5-10 fois 
 
Mettez le tube dans le porte-tubes EDTA. 
 
 
 
 
6- Conserver les 2 tubes dans un congélateur à température -20C ou 
inferieure 
 
7- Préparer 3 lames pour faire le test de parasitémie (goutte épaisse et frotti pour 
chaque lame) à partir du sang d’un tube EDTA avec un capillaire 
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Appendix IV: Correlation of relatedness estimates using different numbers of 
SNPs 
Relatedness estimates generated using 1,986 SNPs (2k) were compared to 
estiamtes generated using 327,554 SNPs (400k). Removing unrelated individuals 
with pi hat values of 0.125 or less (which corresponds to first cousins), gave a 
correlation of 0.98 between the two estimates. Thus, to infer closely individuals (with 
a pi-hat of at least 0.125),  1986 genome-wide SNPs is sufficient and can be used in 
the analyses we performed.  
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 Appendix V: Marker properties of SNPs genotyped using Sequenom 
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Appendix VI: Additonal VCA results (ClinStatus) 
 
Variance component analysis on the first three expression principal components 
(ePC1-3) explains over a third of the total variance in the discovery phase (A and B), 
the replication phase (C and D), and in the combined data set (E and F). ePC1 is 
primarily explained by Hb genotype (phenotype), while ePC2 and ePC3 are driven by 
clinical status (EvsFUvsC)  and follow-up (EvsFU) in all three datasets.  
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Appendix VII: Additional VCA results (ClinCat) 
Variance component analysis on the first three expression principal components 
(ePC1-3) explains over a third of the total variance in the discovery phase (A and B), 
the replication phase (C and D), and in the combined data set (E and F). ePC1 is 
primarily explained by Hb genotype (phenotype), while ePC2 and ePC3 are driven by 
the clinical category effect in all three datasets. 
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Appendix VIII: GSEA Discovery and Replication phases 
 
Gene Set Enrichment Analysis for the discovery and replication phases for SCD 
patients grouped accordng to Clinical Categories. Clustered scaled normalized 
enrichment scores from the GSEA for the discovery and replication phases are 
shown. Only pathways and modules significantly enriched (Benjamini Hochberg P < 
0.05) from at least one contrast are shown. Colors in the heat map indicate the 
enrichment score relative to the controls. 
Discovery Phase 
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Replication phase  
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Appendix IX: Canonical values from discriminant analysis  
 
Canonical values for each individual in discovery phase was calculated based on the 
discriminant analysis.The first 2 canonical values are plotted against each other. 
Controls (C) are colored in green, entry (E) are blue, acute (A) are red, steady-state 
satisfactory (SSS) are orange, and steady-state unsatisfactory (SSU) are turquoise. 
As can be seen, the canonical values for the SSS and SSU patients overlap.  
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 Appendix X : Remaining SNP-by-ClinStatus interactions 
 
Eight remaining SNP-by-ClinStatus interaction effects of genes differentially 
expressed between SCD clinical status. Using the combined dataset II, a multiple 
linear regression analysis was performed that accounted for clinical status, sex and 
cell counts and tested for significant interaction effects for 7002 genes that are 
differentially expressed between the Clinical Status effect (EvsFUvsCtls). Thirteen 
peak genome-wide significant interaction effects were identified; eight of which 
remained significant after running a Q-K mixed model that accounts for relatedness. 
Five of the 8 interactions are plotted in Fig. D.4.5, and the remainder of interactions 
are plotted below (A-C are those that remain significant for the Q-K mixed model; D-
H the remainder of the 13 interactions). These interaction effects show how the 
eSNP effect is modulated by clinical status. All interactions are local. The color code 
for the clinical status is indicated on the right hand side. Expression levels are shown 
on the y-axis and SNP genotypic class on the x-axis.  
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Appendix XI: Remaining SNP-by-ClinCat interactions 
 
Remaining SNP-by-ClinCategory interaction effects of genes differentially expressed 
between SCD clinical categories. Using the combined dataset, a multiple linear 
regression analysis was performed that accounted for Hb genotype, clinical category, 
sex and cell counts and tested for significant SNPxClinical category interaction 
effects for 4220 genes that are differentially expressed between clinical categories. 
Eleven peak genome-wide significant SNPxClinical category interaction effects were 
identified: nine of which are local and two are distal. Four of the 11 interactions are 
plotted in Fig. D.4.7, and the other seven interactions are plotted below. These seven 
interaction effects show how the eSNP effect is modulated by SCD clinical state. Six 
out of the seven interactions plotted here are local, and one (TMEM180 and 
rs6573755) is distal. The color code for the clinical category is indicated on the left 
hand side. Expression levels are shown on the y-axis and SNP genotypic class on 
the x-axis.  
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 Appendix XII: Plots of 25 eSNP associations that are drug targets  
Twenty-five eSNP associations significant in SCD patients and not in controls. The 
genes for these associations are drug target.  
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Appendix XIII : Volcano plot of genes differentially expressed b/t SSS and SSU 
Volcano plot of the differentially expressed genes between SSS and SSU SCD 
patients. 824 probes (which corresponds to 775 genes) were differentially expressed 
(FDR= 5%) between SSS and SSU SCD patients when an ANCOVA was performed 
that accounted for Hb genotype, clinical category, and sex. The dotted red line 
indicates the threshold of significance, with all dark dots above this line indicating a  
probe that was significant. NLP (-log(pvalue)) is plotted on the y-axis, and the fold 
change value between SSS and SSU patients is plotted on the x-axis.  
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Appendix XIV : Toppfun results 
ToppFun results for enriched GO categories. The 86 drug targets that were 
differentially expressed between SSS and SSU patients were included in the 
ToppFun enrichment analysis, with all 28,000 expressed probes being the reference. 
The significant GO categories, pathway name, and p-values are shown below.   
Category Name P-value 
GO: Molecular Function vitamin binding 0.0001 
GO: Molecular Function oxidoreductase activity 0.000361 
GO: Molecular Function ligase activity, forming carbon-sulfur bonds 0.004258 
GO: Molecular Function IgG receptor activity 0.008838 
GO: Molecular Function protein-methionine-R-oxide reductase activity 0.026435 
GO: Molecular Function acetate-CoA ligase activity 0.026435 
GO: Molecular Function transferase activity, transferring pentosyl groups 0.028416 
GO: Molecular Function acid-thiol ligase activity 0.042045 
GO: Molecular Function L-ascorbic acid binding 0.048893 
GO: Biological Process coenzyme biosynthetic process 0 
GO: Biological Process carboxylic acid metabolic process 0 
GO: Biological Process oxoacid metabolic process 0 
GO: Biological Process coenzyme metabolic process 0 
GO: Biological Process organic acid metabolic process 0.000001 
GO: Biological Process cellular ketone metabolic process 0.000001 
GO: Biological Process response to bacterium 0.000001 
GO: Biological Process cofactor biosynthetic process 0.000002 
GO: Biological Process oxidation-reduction process 0.000002 
GO: Biological Process cofactor metabolic process 0.000006 
GO: Biological Process response to organic substance 0.000006 
GO: Biological Process positive regulation of inflammatory response 0.000026 
GO: Biological Process response to lipopolysaccharide 0.000043 
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GO: Biological Process response to endogenous stimulus 0.000044 
GO: Biological Process small molecule biosynthetic process 0.000047 
GO: Biological Process response to molecule of bacterial origin 0.000107 
GO: Biological Process cellular nitrogen compound biosynthetic process 0.000108 
GO: Biological Process positive regulation of response to external stimulus 0.000112 
GO: Biological Process acetyl-CoA metabolic process 0.0002 
GO: Biological Process cellular response to chemical stimulus 0.000321 
GO: Biological Process response to other organism 0.000385 
GO: Biological Process response to hormone stimulus 0.000447 
GO: Biological Process regulation of inflammatory response 0.000466 
GO: Biological Process positive regulation of nitric-oxide synthase biosynthetic process 0.000801 
GO: Biological Process inflammatory response 0.000854 
GO: Biological Process response to peptide hormone stimulus 0.001334 
GO: Biological Process defense response 0.00135 
GO: Biological Process response to wounding 0.001562 
GO: Biological Process monocarboxylic acid metabolic process 0.001833 
GO: Biological Process multi-organism process 0.001967 
GO: Biological Process nitric-oxide synthase biosynthetic process 0.001996 
GO: Biological Process regulation of nitric-oxide synthase biosynthetic process 0.001996 
GO: Biological Process acetyl-CoA biosynthetic process 0.002021 
GO: Biological Process response to hypoxia 0.002208 
GO: Biological Process response to oxygen levels 0.003271 
GO: Biological Process homeostatic process 0.003534 
GO: Biological Process response to biotic stimulus 0.003857 
GO: Biological Process positive regulation of defense response 0.003868 
GO: Biological Process response to external stimulus 0.005684 
GO: Biological Process regulation of response to external stimulus 0.007488 
GO: Biological Process xenobiotic metabolic process 0.007853 
GO: Biological Process cellular response to xenobiotic stimulus 0.007853 
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GO: Biological Process positive regulation of immune effector process 0.008185 
GO: Biological Process response to xenobiotic stimulus 0.008628 
GO: Biological Process positive regulation of acute inflammatory response 0.012303 
GO: Biological Process lipid biosynthetic process 0.015471 
GO: Biological Process positive regulation of cytokine biosynthetic process 0.016006 
GO: Biological Process positive regulation of tumor necrosis factor biosynthetic process 0.016549 
GO: Biological Process regulation of lipid metabolic process 0.019728 
GO: Biological Process response to steroid hormone stimulus 0.022107 
GO: Biological Process regulation of defense response 0.024549 
GO: Biological Process positive regulation of response to stimulus 0.024586 
GO: Biological Process regulation of chemokine production 0.025446 
GO: Biological Process alcohol metabolic process 0.027733 
GO: Biological Process chemokine production 0.02898 
GO: Biological Process positive regulation of nitric oxide biosynthetic process 0.037114 
GO: Biological Process phosphorylation 0.040278 
GO: Biological Process response to insulin stimulus 0.040292 
GO: Biological Process response to interleukin-15 0.044903 
GO: Biological Process acetate biosynthetic process 0.044903 
GO: Biological Process propionate biosynthetic process 0.044903 
GO: Biological Process cell activation 0.049536 
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Appendix XV: Cell type specific expression profiles  
We inferred differences in the proportions of subtypes of peripheral blood 
mononuclear cells (PBMCs)[200] by obtaining cell type specific expression 
modules[139] that are constructed based on genomic signatures of flow-cytometry-
sorted immune cell types. We calculated the average transcript abundance across all 
individuals for each module and compared the means in each SCD clinical category 
to see if they were significantly different. This analysis showed significant differences 
between SCD clinical categories for all six cell type-specific expression profiles 
investigated. 
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Appendix XVI: Characterisation of HP alleles.  
Characterisation of Hp alleles in acute SCD patients and testing for association with 
gene expression. Specific primers that differentiate between Hp1 and 2 alleles [201] 
were used to genotype acute SCD patients in PCR reactions. A multiple linear 
regression analysis to test for the association between HP gene expression and 
rs742898 SNP genotype conditioning on Hp allele was performed using JMP 
Genomics v5.0 (SAS). 
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  Appendix XVII: Venn diagram SCD and Malaria 
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Appendix XVIII: GEO Accession Numbers  
 
All expression data are available at NCBI Gene Expression Ominbus (GEO) 
under the series number GSE35007. The individual expression arrays are listed as 
GSM860207 through GSM860517. 
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Appendix XIX: Drugs identified in DrugBank that target 14 eSNP genes 
 
Drug Generic Name 
Partner 
Gene 
Name 
3,4-Dichloroisocoumarin CFD 
Isatoic Anhydride CFD 
Aminoglutethimide CYP19A1 
Anastrozole CYP19A1 
Exemestane CYP19A1 
Letrozole CYP19A1 
Testolactone CYP19A1 
Guanosine-5'-Diphosphate EEF1A1 
4-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}BUTANOIC ACID EPHX2 
6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID EPHX2 
7-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEPTANOIC ACID EPHX2 
N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE EPHX2 
N-Cyclohexyl-N'-(4-Iodophenyl)Urea EPHX2 
N-Cyclohexyl-N'-(Propyl)Phenyl Urea EPHX2 
N-Cyclohexyl-N'-Decylurea EPHX2 
(11S)-8-CHLORO-11-[1-(METHYLSULFONYL)PIPERIDIN-4-YL]-6-
PIPERAZIN-1-YL-11H-BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE FNTB 
(20S)-19,20,21,22-TETRAHYDRO-19-OXO-5H-18,20-ETHANO-12,14-
ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-
K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9-CARBONITRILE FNTB 
(20S)-19,20,22,23-TETRAHYDRO-19-OXO-5H,21H-18,20-ETHANO-
12,14-ETHENO-6,10-METHENOBENZ[D]IMIDAZO[4,3-
L][1,6,9,13]OXATRIAZACYCLONOADECOSINE-9-CARBONITRILE FNTB 
[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-
METHYL]-PHOSPHONIC ACID FNTB 
2-CHLORO-5-(3-CHLORO-PHENYL)-6-[(4-CYANO-PHENYL)-(3-METHYL-
3H-IMIDAZOL-4-YL)- METHOXYMETHYL]-NICOTINONITRILE FNTB 
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4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-
IMIDAZOL-1-YL)METHYL]BENZONITRILE FNTB 
ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID FNTB 
FARNESYL FNTB 
FARNESYL DIPHOSPHATE FNTB 
GERANYLGERANYL DIPHOSPHATE FNTB 
Glycine GCAT 
Pyridoxal Phosphate GCAT 
Glutathione GPX4 
Glutathione GSTA5 
(9r,10r)-9-(S-Glutathionyl)-10-Hydroxy-9,10-Dihydrophenanthrene GSTM1 
(9s,10s)-9-(S-Glutathionyl)-10-Hydroxy-9,10-Dihydrophenanthrene GSTM1 
Fluorotryptophane GSTM1 
Glutathione GSTM1 
Glutathione S-(2,4 Dinitrobenzene) GSTM1 
Zinc Trihydroxide GSTM1 
Glutathione GSTT1 
Cyanocobalamin MTRR 
Hydroxocobalamin MTRR 
L-Methionine MTRR 
Alpha,Beta-Methyleneadenosine-5'-Triphosphate NMNAT3 
Deamido-Nad+ NMNAT3 
Nicotinamide Mononucleotide NMNAT3 
Nicotinamide-Adenine-Dinucleotide NMNAT3 
Chymostatin PAM 
N-Alpha-Acetyl-3,5-Diiodotyrosylglycine PAM 
Threonine Derivative PAM 
Vitamin C PAM 
2-methyl-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one PARP3 
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4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one PARP3 
N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-
DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE PARP3 
1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole PTGS2 
1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole PTGS2 
Acetaminophen PTGS2 
Acetylsalicylic acid PTGS2 
Aminosalicylic Acid PTGS2 
Antipyrine PTGS2 
Antrafenine PTGS2 
Balsalazide PTGS2 
Bromfenac PTGS2 
Carprofen PTGS2 
Celecoxib PTGS2 
Diclofenac PTGS2 
Diflunisal PTGS2 
Etodolac PTGS2 
Etoricoxib PTGS2 
Fenoprofen PTGS2 
Flufenamic Acid PTGS2 
Flurbiprofen PTGS2 
gamma-Homolinolenic acid PTGS2 
Ginseng PTGS2 
Heme PTGS2 
Ibuprofen PTGS2 
Icosapent PTGS2 
Indomethacin PTGS2 
Ketoprofen PTGS2 
Ketorolac PTGS2 
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Lenalidomide PTGS2 
Lornoxicam PTGS2 
Lumiracoxib PTGS2 
Magnesium salicylate PTGS2 
Meclofenamic acid PTGS2 
Mefenamic acid PTGS2 
Meloxicam PTGS2 
Mesalazine PTGS2 
Nabumetone PTGS2 
Naproxen PTGS2 
Nepafenac PTGS2 
Niflumic Acid PTGS2 
Nimesulide PTGS2 
Oxaprozin PTGS2 
Phenylbutazone PTGS2 
Piroxicam PTGS2 
Pomalidomide PTGS2 
Prostaglandin G2 PTGS2 
Resveratrol PTGS2 
Rofecoxib PTGS2 
Salicyclic acid PTGS2 
Salicylate-sodium PTGS2 
Salsalate PTGS2 
Sulfasalazine PTGS2 
Sulindac PTGS2 
Suprofen PTGS2 
Tenoxicam PTGS2 
Thalidomide PTGS2 
Tiaprofenic acid PTGS2 
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Tolmetin PTGS2 
Trisalicylate-choline PTGS2 
Valdecoxib PTGS2 
Formic Acid PVALB 
   
 
 265 
Appendix XX Correlation between ANCOVA results before and after 
accounting for surrogate variables.  
 
Correlation plot of the significance level (NLP= -log10 (p-value)) for 
differentially expressed probes for the clinical status effect before and after 
accounting for 11 surrogate variables. The full ANCOVA model was run (sex, clinical 
status, RBC, WBC) for the Combined data set II (HbSS non-acutes SCD + controls) 
with and without the 11 surrogate variables. For each model, the NLP values were 
extracted for each probe for the clinical status effect and correlated with each other, 
as seen below. Based on the high correlation, the gene expression analysis is 
believed to be robust and not significantly influenced by non-accounted for variables.  
 
0
4
8
12
16
20
24
28
32
N
LP
0 1 2 3 4 5 6 7 8 9 11 13 15 17 19 21 23 25 27 29
NLP_sv11
 
 
 
 266 
Appendix XXI Relative power and sample size requirements  
 
Genotype-gene expression association power analysis using SPSS (linear trend). 
R2(T) are regression coefficients. N is sample size. A sample size of 200 individuals 
was calculated to be sufficient to identify eSNPs that explain 20% of the variation 
across the genome with 80% power.  
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Appendix XXII Contribution, source of funding, and publications 
 
Contribution: 
The present study was a collaborative effort. The PhD candidate was involved in all 
stages of the study, from design, ethics approval, sampling, genomic experiments, 
analysis, interpretation of results, and publication. The samples were collected in 
Benin by Elias Gbeha, Selma Gomez, Mohamed Cherif Rahimy, Youssef Idaghdour, 
and Jacklyn Quinlan. Mohamed Cherif Rahimy followed the SCD patients and 
oversaw characterisation of SCD patient clinical categories. All haematological 
analysis was performed at the National Sickle Cell Disease Centrer under Mohamed 
Cherif Rahimy’s direction. Elias Gbeha, Youssef Idaghdour, and Jacklyn Quinlan 
processed the samples and performed the genomic experiments in Montreal. 
Vanessa Bruat, Thibault de Malliard, and Jean-Christophe Grenier provided 
bioinformatics support for statistical analysis of the data by Jacklyn Quinlan. Jean-
Philippe Goulet and Jacklyn Quinlan performed enrichment analysis. Interpretation of 
the results was performed by Jacklyn Quinlan with help from Philip Awadalla and 
Youssef Idaghdour. Philip Awadalla, Youssef Idaghdour and Jacklyn Quinlan wrote 
the paper (accepted Feb. 14, 2014 by Frontiers in Genetics).  
Source of funding:  
The research study operations were funded by a Human Frontiers in Science 
Program Grant RGP0054/2006-C awarded to Philip Awadalla. Jacklyn Quinlan was 
supported by doctoral Fellowships from the Fonds de la Recherche en Santé du 
Québec, the Réseau de médecine génétique appliquée (the Louis-Dallaire 
fellowship) and by the “Bourse de Fins d’Études” from the Département de Médecine 
Sociale et Préventive from Université de Montréal. 
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